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ABSTRACT 
 
 Gene transfer represents an important advance in the treatment of both genetic 
and acquired diseases. Topical gene therapy involves administration of the genetic 
material onto the surface of skin and mucosal membranes. Cationic gemini surfactants 
(m-s-m, where m represents the carbon atoms in the alkyl tail and s represents the carbon 
atoms in the spacer) are a novel category of delivery agents with especially high 
potential for polynucleotides. This is due to their structural versatility, ability to bind and 
condense DNA, and relatively low toxicity.  
 The objectives were to design, construct and characterize a cationic, non-viral 
gemini surfactant-based delivery system for an IFN-γ coding plasmid suitable for 
cutaneous gene therapy and to evaluate this novel therapeutic approach in a Tsk (tight-
skin scleroderma) mouse model to determine its clinical feasibility. 
 The delivery systems were characterized by microscopy, dynamic light scattering 
(DLS), circular dichroism (CD) and small angle X-ray scattering (SAXS). In vitro gene 
expression was evaluated in PAM 212 keratinocyte culture. The extent of topical 
delivery of the plasmid using nanoparticle and nanoemulsion formulations was 
evaluated by measuring IFN-γ levels in CD1, IFN-γ-deficient and Tsk mice. The effect 
of transgene expression on collagen synthesis was evaluated in Tsk animals by real-time 
PCR. 
 The in vitro plasmid–gemini–lipid (PGL) system showed heterogeneous particle 
size (100-200 nm small particles and 300-600 nm aggregates). Electrostatic interactions 
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between the DNA and PGL systems shifted the negative ζ-potential of the DNA (-47 
mV) to positive values (30-50 mV). At the same time, condensation of the DNA, and 
formation of Ψ– DNA was indicated by the increase of the overall negative signal in the 
CD spectra, due to the flattening of the 290 nm peak and shift of the 260 nm peak into 
the negative region in a structure-dependent manner. Lipid organization of the DNA–
DOPE system, in the absence of gemini surfactants, shows hexagonal structure, while 
addition of gemini surfactant at +/- charge ratio of 10 caused lamellar phase 
organization. For short spacers (n=3-6), additional Pn3m cubic phase also appear to be 
present.  
 In vitro transfection efficiency in the 12-n-12 series was found to be dependent 
on the length of the spacer between the two positively charged head groups, with the 
n=3 spacer showing the highest activity. The PGL systems with 12-3-12 and 12-4-12 led 
to significantly higher transgene expression compared to the other surfactants of the 
series. The transfection efficiency significantly correlated with the surface area occupied 
by one molecule (a). The effect of the tail length influenced the transfection efficiency, 
with longer tails being associated with higher protein expression. The highest in vitro 
transfection efficiency was recorded with the 18:1-3-18:1 surfactant (1.4±0.3 ng/5x104 
cells). 
In vivo, high levels of IFN-γ expression were detected in the skin of animals 
treated with both nanoparticle (359±239 pg/cm2) and nanoemulsion (607±411 pg/cm2) 
formulations compared to topical naked DNA (136±125 pg/cm2). IFN-γ levels in the 
skin of animals injected with 5 µg DNA were 256±130 pg/cm2. IFN-γ levels in the 
lymph nodes were higher for the nanoparticle formulation (433±456 pg/animal) 
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compared to nanoemulsion (131±136 pg/animal) suggesting different delivery pathway 
of the two formulations. 
 IFN-γ expression was at high levels in the skin of Tsk mice after 4-day and 20-
day treatments (472±171 and 345±276 pg/cm2). Both 4-day and 20-day treatments 
reduced the procollagen type I α1 mRNA levels for the topical treatment (64 and 70% 
reduction) and intradermal injection (58 and 72% reduction). Intercellular adhesion 
molecule-1 (ICAM-1) was upregulated by 50% in both topically treated and injected 
animals after 20-day treatment.   
 Here, it has been demonstrated that cationic gemini surfactant-based delivery 
systems are able to transfect epidermal cells in vivo, and the transgene IFN-γ expression 
is sufficient to cause significant reduction of collagen in an animal model of 
scleroderma. It has been shown for the first time that topical gene therapy is a feasible 
approach for the modulation of excessive collagen synthesis in scleroderma-affected 
skin.  
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I. INTRODUCTION 
I.1. General view on gene therapy 
Gene transfer represents an important advance in the treatment of both genetic 
and acquired diseases. Gene therapy relies on the efficient transfer of DNA, RNA 
fragments or chimeric DNA-RNA molecules into cells. The goal is to correct a genetic 
mutation, create a new function by inserting a gene, or block gene overexpression. The 
modification can be permanent (best achieved by chromosomal insertion) or transient in 
the targeted cell or tissue. Genetic immunization is based on the delivery of DNA 
encoding for a foreign protein and its expression in cells. The in situ generated protein 
has the potential to induce both cell-mediated and humoral immune responses [1, 2]. The 
recombinant genetic material is carried by vectors of viral or non-viral type. Viral 
vectors include adenoviruses, adeno-associated virus or retroviruses. The efficiency of 
delivery of viral vectors is higher than non-viral systems, and this method can integrate 
the genes into chromosomes, causing permanent modification in the cell. Unfortunately, 
the immunogenicity of these carriers restricts their use. Moreover, the size of the 
inserted gene is limited (low packaging capacity), and large-scale production is difficult 
and costly. The non-viral vectors, plasmids and oligonucleotides, are transferred into 
cells via physical methods or chemical delivery agents. These vectors do not pose the 
safety issues of the viruses and are easy to prepare, but their efficiency is low, and can 
induce only transient gene expression. The successful introduction of recombinant 
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genetic material into mammalian cells and expression of these genes modifying cellular 
phenotypes in the1970s led to the recognition of the potential of this technique as a 
therapeutic tool. The early methods included chromosome transfer (cell fusion, 
chromosome-and microcell-mediated gene transfer), viral vectors (DNA and RNA 
viruses), physical methods (microinjection and electroporation) and chemical agents 
(calcium phosphate precipitation, polyethylene glycol and liposomes) [3]. The first 
successful treatment was reported in 1990 at the National Institute of Health. The patient 
was treated for adenosine deaminase deficiency causing severe immunodeficiency.  In 
past decades, research has focused on genetic diseases such as cystic fibrosis [4], 
hemophilia [5, 6], sickle cell anemia, and Gaucher’s disease. Important achievements 
can be mentioned in the treatment of acquired diseases (cancer, neurological disorders, 
cardiological disorders) as well [7]. Genodermatoses such as epidermal fragility, 
keratinization, hair, pigmentation disorders and cancer are candidates for topical gene 
therapy [8, 9]. 
A major setback for gene therapy occurred in 1999, when a patient suffering 
from ornithine transcarboxylase deficiency died from multiple organ failure in a clinical 
trial involving gene therapy. Moreover, in 2002 two children treated for X-linked severe 
combined immunodeficiency disease developed leukemia-like syndrome 
(http://ornl.gov/sci/techresources/). Due to these events, the question was posed: Is gene 
therapy a feasible approach? Recent advances such as mapping of human and animal 
genomes, development of new therapeutic tools such as small interfering RNAs, 
improved delivery systems, better designed in vitro and in vivo experiments, use of new 
analytical tools, such as synchrotron radiation, RNA and DNA microarrays and 
combination of these with advanced computational systems, will provide the answer.  
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Currently, 520 ongoing clinical trials in the US (http://www.clinicaltrials.gov/) 
are focusing on both gene therapy and genetic immunization. Although most are 
oriented towards cancer therapy, some trials are exploring treatment options for other 
genetic or acquired diseases. Some of the trials involve ex vivo methods. For example, 
genetically modified fibroblasts producing human nerve growth factor are 
intracerebrally injected in Alzheimer’s patients in order to reduce neuronal atrophy 
(Clinical Trials.gov ID: NCT00017940). Patients with homozygous familial 
hypercholesterolemia can be treated with autologous hepatocytes transduced with a 
normal low-density lipoprotein receptor gene (Clinical Trials.gov ID: NCT00004809). 
Gaucher's disease is caused by the absence of glucocerebrosidase due to a genetic 
deficiency inducing glycocerebroside accumulation in macrophages. Ex vivo 
transduction of bone marrow stem cells with retroviruses containing the human 
glucocerebrosidase gene and transplantation in patients could provide the necessary 
enzyme levels (Clinical Trials.gov ID: NCT00001234). Systemic administration of DNA 
is involved in several clinical trials. Duchenne muscular dystrophy (DMD) is a fatal 
muscle degenerative disorder, caused by mutations in the dystrophin gene. Antisense 
oligonucleotides can be used to restore the production of dystrophin by exon skipping 
and improve muscle survival and function (Clinical Trials.gov ID: NCT00159250). 
Patients with diabetic neuropathy and macrovascular disease can be treated by 
intramuscular administration of a plasmid containing the cDNA for vascular endothelial 
growth factor (Clinical Trials.gov ID: NCT00056290). In another study, human clotting 
factor IX (inserted in adeno-associated virus vector) will be injected into the liver of 
patients suffering from severe hemophilia B (Clinical Trials.gov ID: NCT00076557).  
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Topical gene therapy involves administration of the genetic material onto mucosal 
membranes (lungs, conjunctiva, oral and rectal cavities) and the surface of the skin. 
Cystic fibrosis transmembrane conductance regulator gene (CFTR) can be delivered to 
the cells lining the nose of cystic fibrosis patients using cationic liposome mediated gene 
transfer (Clinical Trials.gov ID: NCT00004471) or adenovirus vector (Clinical 
Trials.gov ID: NCT00004779).  Platelet-derived growth factor-B (PDGF-B) gene can 
improve the healing of chronic wounds especially frequent in diabetic patients. Injection 
of the genetic material into the wound can generate PDGF-β, improving the clinical 
appearance of chronic wounds compared to previous methods of direct application of 
wound-healing substances (Clinical Trials.gov ID: NCT00065663 and NCT00000431). 
Particle bombardment of unaffected skin with DNA (gp100 and granulocyte 
macrophage colony stimulating factor (GM-CSF) cDNA) coated gold beads is a 
therapeutic option for malignant melanoma patients. The two proteins, gp100 and GM-
CSF, can help the body build immune response and kill the tumour cells (Clinical 
Trials.gov ID: NCT00003897).  
Presently, no clinical trials use gene delivery to intact skin for treatment of skin 
disorders. However, research in the last decade is progressing towards improvement of 
the delivery systems and extension of gene therapy to genodermatoses.   
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I.2. DNA delivery systems 
I.2.1. Naked DNA 
There are many advantages of using DNA-based drugs (therapeutic genes) 
compared to the delivery of proteins. Proteins are relatively unstable molecules and 
require intact tertiary and quaternary structure for their activity, whereas DNA is more 
stable and only chemical alterations can cause loss of potency, as nucleic acid sequence 
is most important for its function [10]. Using plasmid DNA for delivery of the 
therapeutic genes could yield sustained protein expression at the site of application. 
Although biologically active interferon (IFN)-γ in a liposomal system could be delivered 
through skin [11], the short half life of the cytokine might require frequent 
administration, whereas DNA application could generate proteins for a longer period of 
time. Since the size of the gene is not a limiting factor in plasmid vectors, several 
therapeutic genes could be inserted in the same backbone, and expressed concomitantly 
at the target site.  
The discovery of plasmid vector systems as a tool in molecular biology was an 
important breakthrough in gene therapy. Potentially infectious polyoma virus DNA was 
inserted into plasmids and the recombinant DNA was tested in mouse cells and mice. 
The injected plasmid did not cause infection in mice. Moreover, live E.coli containing 
the recombinant polyoma virus plasmid DNA were also unable to induce infection by 
either ingestion in a food source or parenteral injection [12].  
The capability of plasmids to generate proteins was tested by microinjection into 
Xenopus laevis oocyte nuclei [13-15]. The ability of the transgene to integrate into the 
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host genome of mouse eggs [16] and cultured mammalian cells [17, 18] was also 
demonstrated. Although, early studies show that gene expression can only be achieved 
by nuclear injection [19], it was later demonstrated that plasmid injected into the 
cytoplasm could also be expressed [20].  Further studies demonstrated transfection with 
circular plasmids led to transient gene expression, and only a few copies integrated into 
the chromosomal DNA. The reference gene, chloramphenicol acetyltransferase (CAT), 
expression declined from 10 units/g tissue at 24 hours to 4.6 units at 72 hours. No CAT 
activity could be detected after 96 hours [21]. 
Subsequently, the use of DNA-based drugs for therapeutic purposes emerged and 
studies demonstrated that proteins could be generated in vivo. Studies with non-fasting 
male Wistar rats injected intravenously with liposome-encapsulated plasmid containing 
the gene for rat insulin I showed that the gene penetrates mainly the liver and spleen, 
causing significant reduction of the glucose level and a simultaneous increase in the 
blood insulin level. The effect lasted for about 10 hours [22]. Integration and even 
longer expression can be achieved by the use of viral vectors (up to 48 hours) [23, 24] or 
use of linear double stranded DNA [25]. 
DNA molecules are negatively charged, high molecular weight compounds, an 
impediment in the spontaneous transfection procedure. Poor expression is due to 
membrane barriers and enzymatic processes. In a recent review, several barriers were 
identified in the efficient delivery of DNA-based drugs after intravenous 
administration:(1) physicochemical properties, such as the size of the DNA–cationic 
lipid complexes and the strength of the interaction; (2) interaction with blood 
components such as albumin; (3) recognition by the immune system and phagocytosis; 
(4) permeation through blood vessels; (5) slow uptake by target cells; (6) endosomal 
 6
release; (7) cytoplasmic stability; and (8) nuclear localization [26, 27] and immune 
response triggered by the foreign genetic material [28, 29]. A detailed description of 
transfection barriers is offered by Varga et al. [30]. Researchers recognized that due to 
these drawbacks delivery issues would arise when the genetic material was used as a 
therapeutic drug. 
Structural characteristics of DNA could be the starting point in the design of 
delivery systems. There are three known conformations of DNA: A-, B- and Z-DNA. B-
DNA is considered the native form of DNA, since its X-ray diffraction pattern is similar 
to the DNA found in intact sperm heads. A- and Z-DNA have been found only in certain 
biological contexts such as sporulation, protein binding, salt concentration, or 
environmental conditions such as salt concentration and relative humidity. Parameters 
such as the diameter of the DNA double strand, helical sense, the shape of major and 
minor grooves, helix pitch and rise (Figure I.1) are specific for each conformation (Table 
I.1) [31].  These parameters are essential for modeling purposes. In order to design 
cationic delivery agents, knowing the sterical arrangement of the phosphate groups is 
important. Di- and polycationic agents could bind adjacent phosphates of the helix rise 
(at a distance of 3.32Å for the B-DNA) or helix pitch (at 33.2 Å) depending on the 
distances between the positively charged moieties. The width and depth of the minor and 
major grooves could determine the properties of the groove-binding agents. The major 
groove of the B-DNA is wide and deep, and the minor groove is narrow and shallow. 
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Figure I.1.  The structure of B-DNA represented by stick-and-ball model.  
The view on the left is perpendicular to the axis, and on the right is down the axis. 
Carbon atoms are gray, oxygen atoms red, nitrogen atoms blue and phosphorus atoms 
pink, respectively. The structure is derived from PDB structure 264D 
(http://www.rcsb.org) 
 
Table I.1.  Properties of A-, B- and Z-DNA conformations. 
Property [31] A-Form B-Form Z-Form 
Helical sense Right-handed Right-handed Left-handed 
Repeating helix unit 1 base pair 1 base pair 2 base pairs 
Rotation/base pair (degrees) 33.6 35.9 +/- 4.2 -60/2 
Mean base pairs/turn 10.7 10.0 +/- 1.2 12 
Inclination of base normals to helix axis 
(degrees) 
+19 -1.2 +/- 4.1 -9 
Rise/base pair along helix axis (Å) 2.3 3.32 +/- 0.19 3.8 
Pitch/turn of helix (Å) 24.6 33.2 45.6 
Mean propeller twist (degrees) +18 +16 +/- 7 ~0 
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After intravenous injection, foreign DNA is destroyed by scavenger cells, with 
the half life of naked plasmid being less than 10 minutes [32]. One of the first delivery 
attempts involved direct injection of the plasmid into cells. In this case, the barriers to 
protein expression were the destruction of the DNA by the endonucleases and 
penetration through the nuclear pores into the nucleus. This method required specialized 
equipment and personnel, and was not feasible for clinical application.  
Injection of naked DNA into various tissues (muscle, skin, tumour) showed 
protein expression could be achieved at the site of injection. When the plasmid is 
injected into the tissue, some cells are pierced thereby facilitating the penetration of the 
plasmid leading to high protein levels around the injection sites. For example, recent 
studies demonstrate direct injection of naked plasmid containing genes of several 
cytokines such as interleukin (IL)-4, IL-6, IL-10, transforming growth factor (TGF)-β1, 
monocyte chemotactic and activating factor (MACAF), GM-CSF, tumour necrosis 
factor (TNF)-α and IFN-γ into the skin markedly increase levels of these cytokines at the 
site of injection. IL-4, IL-6 and IL-10 were also detected in the serum levels high enough 
to exert biological effect [33]. This demonstrates that direct injection can be used as a 
delivery tool for plasmid DNA into the tissue. Another example is the application of 
naked DNA onto damaged tissue. Platelet-derived growth factor A and B chain genes 
were inserted in plasmid vectors and used in lyophilized collagen pads to treat 
experimentally induced ischemic dermal ulcer in rabbit. By applying the pads on the 
wounds, the DNA can directly enter the cells of the damaged tissue. The volume of 
granulation tissue formation as well as epithelization and wound closure were evaluated 
after 10 days. A significant increase in new granulation tissue formation was observed 
when the collagen pads contained 1 mg plasmid versus empty collagen pads. 
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Application of pads loaded with 2 mg plasmid caused another 15% increase over the 1-
mg plasmid pads [34]. One of the practical applications of this study would be in chronic 
wound healing. Another study demonstrated that injection of naked DNA can result in 
delivery to the circulatory system, a useful feature for application in peripheral arterial 
occlusive disease [35]. Gene therapy can be employed as a potential treatment for 
myocardial and lower limb ischemia. Plasmid DNAs encoding for three isotypes of the 
angiogenic cytokine vascular endothelial growth factor were injected into ischemic skin 
flaps in rat. The flap survival and angiogenesis were assessed after 7 days. The results 
show significant flap survival in one of the isotypes, suggesting that plasmid transfection 
could be used as a supplementary tool in reconstructive surgery [36]. 
Increasing the ionic strength in the phosphate buffered saline (PBS) vehicle (1.5x 
and 3x PBS) used for injecting DNA led to higher transfection efficiency in mice after 
intradermal injections than using physiological buffer [37]. The physiological effect of 
the delivered DNA is dose dependent; inadequate concentrations are not able to generate 
enough protein, but very large doses also have a negative effect on protein expression. In 
a study using two plasmids coding for keratinocyte growth factor and insulin-like 
growth factor, three different doses of DNA (0.22 µg, 2.2 µg and 22 µg) were injected 
into the skin. Therapeutic parameters characteristic for wound healing were monitored, 
and the highest therapeutic effects for both plasmids were found at the 2.2 µg dose [38]. 
Although the direct injection method is not feasible for all candidates for gene 
therapy, it is the most frequently employed method in current clinical trials. For 
example, therapeutic protein is generated for treatment of angina (ClinicalTrials.gov 
identifier: NCT00090714) by cardiac injection of plasmid carrying the VEGF gene. 
Human clotting factor IX gene inserted into adeno-associated virus (AAV) vector 
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injected into the liver was approved for testing in hemophilia B patients 
(ClinicalTrials.gov identifier NCT00076557). Direct injection into tumour tissue of 
genes coding for cytokines (IL-2, IL-12), immunostimulatory proteins, and antigens was 
proposed for treatment of melanoma, breast, ovary, colorectal, liver and renal cancers.  
I.2.2 Lipid-based delivery systems for DNA 
In order to treat certain diseases where direct injection of the genetic material is 
not feasible (e.g., metastatic tumours, genodermatoses with extensive lesions, conditions 
affecting the brain) or non-invasive methods are preferred (pediatric and geriatric 
patients, mass vaccination), new delivery systems are necessary in order to efficiently 
deliver DNA to the site of action. The role of delivery systems is to overcome cellular 
and molecular obstacles without invasive intervention [39]. The cell membrane is a 
common barrier whether viral or non-viral carriers are used. Macromolecules penetrate 
the cell membrane by endocytosis. Targeted receptor-mediated uptake, achieved by 
conjugation of the delivery vectors with targeting moieties, could direct delivery to 
certain cells or tissues. Intracellular trafficking can also pose challenges. If not protected, 
the genetic material can be destroyed in the lysosomes. Polymers are used for their 
buffering capacity. They facilitate extravasation by increasing membrane 
permeabilization, allowing the DNA to pass into the cytoplasm. The endonucleases 
present inside the cell can also destroy the foreign DNA. Cationic agents can shield the 
DNA from the effect of DNase. In order to increase the penetration of the genes into the 
cell nucleus, nuclear localization peptides can be used to guide the transport of DNA in 
the cytoplasm. Transcription, translation and plasmid dilution can also hinder protein 
expression. Pharmacokinetic models can be utilized to evaluate which are the rate 
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limiting steps in protein expression. Factors such as complex internalization, endosomal 
escape, DNA unpacking, nuclear pore targeting, nuclear import, plasmid degradation, 
dilution, and protein production have been evaluated. Computational models of known 
agents can help to predict the effect of various compounds. Unfortunately, in vitro 
modeling does not always correlate with in vivo results. 
Liposomes, discovered by Alec Bangham, were used as membrane models [40], 
and later as drug delivery vehicles [41]. In the 1980s the potential of the liposomes as 
delivery agents for macromolecules, e.g., DNA, was also evaluated [42].  By liposomal 
encapsulation, the therapeutic index of the drugs can be increased and specific cells can 
be targeted [43]. Certain types of lipid-based delivery systems can efficiently deliver 
DNA into the cell in vivo. Liposomes having relatively low cellular toxicity can be used 
for the transfection of various cell types; the efficiency is based on physical and 
chemical characteristics of the building elements of the liposomes.  
By using cationic lipids, electrostatic interactions take place between the positive 
charges in the delivery agent and the negative charges on the phosphate backbone of the 
DNA. The phosphate groups of the DNA are neutralized by the positively charged lipids 
and the DNA is compacted thereby facilitating the transfer through cell membranes. 
Cationic lipids can also protect DNA against degradation by endonucleases. The cationic 
to anionic charge ratio (+/- ratio) plays an important role in the evaluation of delivery 
efficiency of various agents. A wide variety of cationic lipids has been described in the 
literature as macromolecular delivery agents. Several synthetic positively charged 2,3-
dialkyloxypropyl quaternary ammonium compounds have been described in the 
literature to increase transfection efficiency of plasmid DNA in vitro [44-48].  Plasmid 
DNA–alkylphospholipid (APL) lipoplexes containing DODAB (Table I.2) injected into 
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tumours significantly reduced tumour size compared to naked DNA and Lipofectin–
DNA complexes [49]. Moreover, intravenous preinjection of 3-tetradecylamino-N-tert-
butyl-N’-tetradecyl propionamidine cationic liposomes followed by intravenous 
injection of plasmid-liposome complexes increased transfection efficiency 40 times, due 
to the inhibitory effect of the liposomes on the TNFα, which plays a role in triggering 
immune responses [50]. In addition to the classical approach of the monovalent 
quaternary ammonium compounds, such as DODAP and DOTAP (Table I.2), and 
cationic derivatives of cholesterol, new compounds such as reducible cationic lipids, 
disulphide-bond bearing lipids, acid-labile cationic lipids and glycine betaine derivatives 
were also tested in order to overcome the barriers of DNA delivery.  Reducible cationic 
lipids bearing disulfide bonds improve the release of the DNA in the cytoplasm, where 
the bond is cleaved, the DNA is released and the transfection efficiency is improved 
1000 fold [51]. Cationic lipids with acid-labile vinyl ether linkage are stable at neutral 
pH, but degrade in the acidic environment of the endosomes, promoting the escape of 
the DNA into the cytosol and increasing transfection 2-3 fold compared to the DOTMA-
cholesterol system (Table I.2). The in vivo transfection efficiency of the two delivery 
systems in tumours was comparable [52]. Cationic cholesterol-derivative (Dc-chol), 
formulated in liposomes or emulsions was used to transfer DNA into the cells. The 
advantage of the compound lies in its high transfection efficiency and low cellular 
toxicity in vitro. The presence of serum reduced the transfection efficiency of the 
liposomal formulation, but had no effect on the emulsion-type formulations [53]. The 
transfection ability of the Dc-chol emulsion in the presence of serum makes these types 
of formulations suitable for parenteral administration. Another cationic sterol-derivative 
(dexamethasone–spermine) increased DNA delivery in vitro 10-fold at a +/- charge ratio 
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of 6, compared to Lipofectamine. The advantage of the system in vivo was the intrinsic 
anti-inflammatory property of the corticosteroid [54]. Ultradeformable cationic 
liposomes (UCL) prepared with DOTAP (Table I.2) showed in vitro transfection 
efficiency comparable with Lipofectamine, and were able to deliver plasmid DNA to the 
liver, kidney and lungs after transdermal application [55]. Some cationic lipids, 
especially monovalent lipids, present relatively high cytotoxicity and therefore their in 
vivo use is limited.  Natural glycine betaine compounds covalently linked to acyl chains 
by enzymatically hydrolysable peptide and ester bonds showed reduced cytotoxicity and 
also improved transfection efficiency by 40% compared to commercial agents in 
cultured hepatocytes [56].  
The efficiency of the cationic lipids as delivery systems can be augmented by 
incorporating neutral lipids in the delivery systems. Injected intramuscularly, DOTAP 
(Table I.2) containing liposomes (dehydration/rehydration vesicles) entrapping plasmid 
DNA encoding for hepatitis B surface antigen triggered IgG production at significantly 
higher levels than naked DNA. The magnitude of the immune response was dependent 
on the nature of the helper lipid, the highest being with phosphatidylcholine (PC)–
DOPE–DOTAP vesicles compared to dipalmitoyl phosphatidylcholine (DPPC) or 
cholesterol-containing liposomes [57].  
A helper lipid, added to the cationic lipid–DNA complexes, can increase both the 
stability of the delivery system and its in vitro and in vivo transfection efficiency. For 
example, solid nanoparticles having a cetylpalmitate core and containing positively 
charged lipids, such as cetylpyridimium chloride, CTAB, dimethyldodecyl ammonium 
bromide or DOTAP (Table I.2), transfected mammalian cells more efficiently than 
DNA–PEI (Table I.2) complexes. In vivo efficiency was not reported in this publication 
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[58]. Creating highly stable particles (no aggregation and polydispersity) under 100 nm 
in size can be achieved by template-driven assembly of the nanoparticles. For this 
purpose, detergents with an alkyl chain of 12-18 carbons and an isothiuronium head 
group are cleaved in controlled conditions to reveal a reactive thiol group. Accumulated 
on the DNA template, these groups form disulfide-linked lipids containing two alkyl 
chains. Complex formation was evaluated by fluorescence assay, particle size and ζ 
potential measurements, electron microscopy and thin layer chromatography. Fibroblasts 
from monkey kidney (CV-1 cells) transfected with the complexes showed high 
efficiency when combined with fractured dendrimers to increase cell association of the 
complexes [59].  
A comparison of several helper lipids (dilauroylphosphatidylethanolamine 
(DLPE, C12:0), dimiristoylphosphatidylethanolamine (DMPE, C14:0), dipalmitoyl-
phosphatidylethanolamine (DPPE, C16:0), diphytanoylphosphatidylethanolamine 
(DPyPE, C16:0 branched), distearoylphosphatidylethanolamine (DSPE, C18:0), and 
dioleylphosphatidylethanolamine (DOPE, C18:1)) showed that branched and 
unsaturated species combined with cationic lipids act in “physical synergism” to 
increase transfection efficiency [60].  
Co-lipids such as DOPE have been widely used for their membrane-active 
properties, namely the ability to induce hexagonal lipid conformation [61, 62]. DOPE 
has been associated with a variety of cationic compounds such as cationic lipids [63-72], 
cholesterol derivatives [71, 73, 74] and poly-L-lysine [75].   
The role of the cationic lipids, as presented here, is (1) compaction of the DNA 
molecule so it can penetrate through the cell membranes, (2) protection of the genetic 
material inside the cells from degradation by endonucleases, and (3) release of the free 
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DNA to cross the nuclear membrane. However, as mentioned above, the transfection 
efficiency of the cationic lipid-based delivery systems is much lower than the viral 
vectors.  Several ways can improve gene expression. In the literature, three areas are 
targeted: (1) compaction of the DNA and penetration of the cell membrane, including 
tissue-specific targeting, (2) escape from the endosomes and dissociation of the 
complexes, and (3) nuclear targeting. New delivery agents could target peptides to 
facilitate the uptake by certain cells, fusogenic peptides and lipids to increase membrane 
permeability, acid-labile compounds and polymers to facilitate lysosomal escape, 
biodegradable compacting agents to help DNA unpacking, and nuclear targeting 
sequences to direct the DNA towards the nucleus.    
The first step of efficient gene expression is the efficient transport of the 
macromolecule through the cell membrane. Peptides such as sequences of Tat protein 
from human immunodeficiency virus (HIV) and adenine nucleotide translocator (Ant) 
protein can promote cellular uptake of macromolecules. Poly(3-guanidinopropyl 
methacrylate), a polycationic agent that mimics the effect of these peptides, was able to 
deliver DNA into cells at higher efficiency compared to polyarginine-based agents. This 
compound can introduce the genetic material into the cells due to its penetration and 
DNA-compaction properties [76].  Another example of increased cellular uptake is 
fusogenic liposomes formulated with anionic 1,2-dioleyl-phosphoethanolamine-N-
dodecanoyl (N-C12-DOPE) and DOPC encapsulating spermine-compacted DNA. These 
complexes efficiently transfected OVCAR-3 cells in vitro and ovarian cancer cells in 
vivo after intraperitoneal injection. This agent also showed significantly lower toxicity 
than cationic delivery agents [77]. Another delivery approach is cross-linked delivery 
systems. Short peptides containing multiple cysteine residues are able to form disulfide 
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bonds after binding the DNA, and increase the condensation of the DNA molecule. The 
transfection efficiency of cross-linked peptides was 5-60 times higher than non-cross-
linked peptides in vitro [78, 79]. Monovalent surfactants can form multivalent cationic 
sheaths on a DNA template, using cysteine-based detergent to avoid aggregation [80]. 
Targeting naturally endocytosed receptors on the cell surface, such as integrin, is 
an attractive approach for enhanced gene delivery. PLL–molossin (Table I.2), a fusion 
peptide derived from American pit viper, coupled with a 16-lysine residue is one such 
ligand. For efficient delivery, exposing the cells to chloroquine (a buffering agent that 
inhibits lysosomal enzymes) to facilitate escape of the genetic material from the 
endosomes is necessary. Since efficient transfection of cells can be achieved after a 
fairly long contact time with the transfection agent, and additional chloroquine exposure 
of 8-10 hours, this method is suitable only for ex vivo delivery. The organs are exposed 
to the PLL–mollossin–DNA system followed by addition of chloroquine before 
transplantation [81].  One of the applications of this technique is in chronic allograft 
rejection whereby targeting vascular smooth muscle cells with non-viral vectors ex vivo 
could arrest or reverse the graft rejection [82]. 
Tissue-specific delivery can be achieved with TerplexDNA, created by 
complexation of plasmid DNA with stearyl-PLL and low-density lipoprotein (LDL). 
Increased cellular delivery into the heart and protein expression (elevated for up to 30 
days) were observed. Levels of protein were significantly lower with naked DNA and 
lasted for only 5 days [83]. Similarly, after systemic administration of TerplexDNA in 
mice, protein expression persisted in major organs for 35 days versus naked DNA for 
only 7 days [84]. Mannose receptor-mediated gene transfer, a liver-targeting method, 
was carried out by intravenously injecting plasmid DNA complexed with mannosylated 
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PLL. These complexes selectively accumulated in the liver, measured by the amount of  
32P-labelled DNA, and achieved the highest protein expression compared to all other 
major organs [85]. Galactose-modified polyornithine had a similar effect, with 60% of 
the radioactivity of the 32P-labelled DNA accumulating in the liver. Gene expression in 
the hepatocytes was higher with galactose-modified polyornithine compared to 
DOTMA–cholesterol liposome-encapsulated DNA [86]. Lipid-linked targeting peptides 
(RGD-DOPE), selected to deliver genes into epithelial cells, were able to increase 
transfection efficiency of the DOTMA-cholesterol-DNA complexes 10 fold. This 
improvement is important as it demonstrates that specifically designed peptides are able 
to target certain cell types (e.g., tumour cells) and increase the uptake of DNA, leading 
to higher transgene expression [87]. 
The release of DNA from endosomes and dissociation from the cationic 
components of the delivery system are important factors in efficient gene expression. 
Only free DNA can penetrate into the nucleus through the nuclear pores. Histidine-rich 
polylysine can complex DNA and facilitate DNA unpacking in the cytoplasm [88]. A 
similar effect can be achieved when poly-L-lysine (PLL) is coupled to nicotinic acid 
[89]. These compounds bind H+ ions at low pH in the endosome/lysosome, facilitating 
the escape of genetic material from the vesicles (sponge effect). Unfortunately, 
quantitative comparison is not feasible since all experiments used different vectors, 
conditions and assays to evaluate plasmid delivery and gene expression. Similar roles 
have been described for dendritic PLL (DPK) of 6th generation. DPK was able to 
transfect cells comparably to the commercial agent. The probable mechanism of uptake 
of the complexes was macropinocytotic engulfing, and the release from the endosomes 
was mediated by the sponge-effect (the protonable moieties confer buffering capacity to 
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the molecule, causing swelling and rupture of the endosome) of the DPK [90]. 
Polyethylenimine (PEI) (Table I.2), a cationic polymer, efficiently absorbs on the 
surface of DNA and protects against endonucleases [91]. It acts as a proton sponge, thus 
facilitating release of the DNA from the endosomes [92]. PEI mediated gene transfer 
into pancreatic tumour disseminated into the peritoneal cavity due to the permeability of 
the peritoneal tissue [93]. Increased expression was observed when the DNA was 
complexed with linear PEI compared to the branched counterparts [94, 95]. Moreover, 
association with anti-platelet endothelial cell adhesion molecule (PECAM-1 or CD31) of 
the PEI–DNA complexes increases targeting of the pulmonary endothelium, with 
minimal systemic toxicity after intravenous administration [95]. Incorporation of 
receptor-targeting ligand into PEI–DNA complexes shielded with polyethylene glycol 
(PEG) enhances delivery of the genetic material to the tumour cells [96]. Combinations 
of polycation-condensed DNA with liposomal encapsulation are believed to further 
increase the uptake and expression efficiency of the plasmid [77, 97].  
Fusogenic peptides (composed of short sequences of amino acids containing 
glutamates) derived from influenza virus hemagglutin increased 3-4 fold the transfection 
efficiency of Lipofectamine, a cationic lipid used for integrin receptor-targeted delivery 
of the PLL–mollossin–DNA vector. The mechanism of action probably relies on the 
more effective escape of the complexes from the endocytic vesicles [98]. 
 Efficient intracellular trafficking of the DNA released form the endosomes is 
necessary for increased gene expression. Intradermal injection of DNA, complexed with 
high-mobility group box 1 (HMGB1) protein (having a DNA binding domain and a 
nuclear localization signal) and encapsulated into liposomes, increased gene expression 
10 fold due to enhanced nuclear targeting [99]. 
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 Complex systems have been created to overcome cellular barriers and increase 
gene expression. New design approaches such as the “modular design” [100] combining 
different targeting strategies could be important in the future of non-viral gene therapy. 
For example, using cationic lipids such as DOPE to facilitate DNA uptake can be 
associated with targeting moieties such as transferrin to promote endocytosis [101]. 
Fusogenic peptides (influenza hemagglutin peptide) increase the escape of the DNA 
from endosomes/lysosomes [76, 102]. Combination with an integrin-targeted non-viral 
DNA vector (polylysine-molossin) can further improve gene expression [98]. In vivo, 
the delivery of genetic material can be further increased by preinjecting the animals with 
cloroquine, followed by the PLL–molosin–DNA system [103]. These examples illustrate 
that multicomponent systems including agents that condense and protect the genetic 
material, target specific cells, facilitate cellular uptake, enhance release from endosomes 
and mediate intracellular trafficking towards the nucleus are the future of non-viral gene 
delivery. The efficiency of these systems might approach that of viral delivery without 
the high toxicity.  
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Table I.2.  Cationic gene delivery agents and adjuvants  
Generic 
name Chemical name Chemical formula Characteristics Ref. 
Monovalent cationic lipids 
CTAB  Hexadecyltrimethylam
monium bromide 
 
cationic, single 
chained 
[104] 
DODAC Dioctadecyldimethyla
mmonium chloride 
N+X
cationic, double 
chained 
[105, 
106] 
DODAB Dioctadecyldimethyla
mmonium bromide 
N+X
cationic, double 
chained 
[105] 
DOTMA  N-[1-(2,3-
dioleyloxy)propyl]-
N,N,N-
trimethylammonium 
chloride 
R O
R O N(CH3)3 Cl
-
R = oleyl  
cationic, double 
chained, ether 
links, 
compaction and 
penetration of 
DNA 
[44] 
DOTAP  (2,3-bis-octadec-9- 
enoxyloxy-propyl)- 
trimethyl-ammonium 
chloride 
O
O Cl-
O
O
N
 
cationic, double 
chained, ester 
links, 
compaction and 
penetration of 
DNA 
[107] 
DMRIE 1,2-
dimyristyloxypropyl-
3-dimethyl-
hydroxyethyl 
ammonium bromide 
O
O N OH
Br cationic, double chained, 
compaction and 
penetration of 
DNA 
[47] 
GAP-
DLRIE 
N-(3-aminopropyl_-
N,N-dimethyl-2,3(bis-
dodecyloxy)-1-
propanimidium 
bromide 
H2N N
O
O
Br
cationic, 
compaction and 
penetration of 
DNA 
[48] 
RPRs reducible lipids 
N
SSN
H
H
N
H
NN
H
H2N O
O
cationic, 
reduction-
sensitive 
disulfide bond, 
improved DNA 
[51] 
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release in the 
cytoplasm 
BCAT O-(2R-1,2-di-O-(1'Z, 
9'Z-octadecadienyl)-
glycerol)-3-N-(bis-2-
aminoethyl)-carbamate 
 
cationic, acid-
labile, increase 
endosomal 
escape  
[52] 
BPDAB bis[2-(11-
phenoxyundecanoate)e
thyl]-
dimethylammonium 
bromide 
cationic, 
compaction and 
penetration of 
DNA 
[45] 
HADAB N-hexadecyl-N-(10-
[O-(4-acetoxy)-
phenylundecanoate] 
ethyl) dimethyl 
ammonium bromide NOO
O
H
N
O  
cationic, 
compaction 
and 
penetration of 
DNA 
[45] 
BBDAB bis[2-(11-
butyloxyundecanoate)
ethyl] 
dimethylammonium 
bromide 
cationic, 
compaction and 
penetration of 
DNA 
[45] 
Guanidin
ylated 
deriv. 
N,N-di-n-octadecyl –
N-(2-guanidinyl) 
ethyl-N-methyl 
ammonium chloride  
 
cationic, 
compaction and 
penetration of 
DNA 
[108] 
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Steroid structures 
Dc-chol 3ß-[N-(N',N'-
dimethylaminoethane)
-carbamoyl]cholesterol 
hydrochloride  O NH
N
O
 
cationic,  
cholesterol 
derivative 
[109] 
DS dexamethasone-
spermine 
NH2
NH
NH
NHS
NH
O
OHHO
F
O
polycationic, 
antiinflamatory 
[54] 
Polycationic delivery agents 
DOSPA 2,3-dioleyloxy-N-
[2(sperminecarboxy
amido)ethyl]-N,N-
dimethyl-1-
propaniminium 
bromide 
R O
R O N N
H
N
H
O
HN
NH2
R = oleyl
 
polycationic, 
compaction and 
penetration of 
DNA 
[48, 
105] 
PLL Poly-L-lysine  polycationic, 
compaction and 
penetration of 
DNA 
[21] 
DPK 
6th 
generation 
Dendritic poly-L-
lysine 
polycationic, 
compaction and 
penetration of 
DNA 
[90] 
Poly 
histidine 
Poly-histidine-PEG 
conjugates 
 
polycationic, 
compaction and 
protection of 
DNA 
[110] 
Poly 
ornithine 
Polyornithine polycationic, 
compaction and 
penetration of 
DNA 
[86] 
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Polymeric agents 
PEI Polyethyleneimine 
H2N
N
N
H
NH2CH2CH2
x
y
polycationic, 
compaction and 
penetration of 
DNA 
[93] 
pGuaMA poly(3-
guanidinopropyl 
methacrylate)  
polycationic, 
penetration of 
DNA 
[76] 
Chitosan Polysaccharide built 
mainly of D-
glucosamine 
Condensation of 
DNA 
[111-
113] 
GBs glycine betaine 
derivatives 
glycine betaine compounds 
covalently linked to acyl 
chains by enzymatically 
hydrolysable peptide and 
ester bonds 
cationic, 
enhanced DNA 
unpacking 
reduced 
cytotoxicity 
[56] 
Prot- 
amine 
arginine and lysine 
rich protein - 
polycationic, 
compaction and 
penetration of 
DNA  
[114] 
Amino acid derivatives as adjuvants 
Cross-
linked 
systems 
peptides of cysteine 
and lysine, ± histidine 
or tryptophan 
 
stabilizes lysine-
conjugated DNA 
via cysteine 
residues 
[78] 
H5WYG histidine-rich peptide 
- 
adjuvant for PLL 
complexed DNA, 
increases escape 
from endosomes 
[88] 
Fuso 
genic 
peptides 
fusogenic peptide of 
influenza virus 
haemagglutinin - 
adjuvant for PLL 
complexed DNA, 
increases escape 
from endosomes 
[98] 
Nicotine Nicotinylated PLL - increases escape from endosomes 
[89] 
Tf Transferrin 
- 
receptor binding 
ligand, increased 
targeting for PEI-
DNA system 
[96] 
PECAM
-1 
antiplatelet endothelial 
cell adhesion molecule 
1 - 
receptor binding 
ligand, increased 
targeting for PEI-
DNA system 
[95] 
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Molossin a 15-amino acid 
moiety for targeting 
cellular integrins, 
derived from snake 
venom 
- 
targeting vector 
fused with PLL 
[81] 
RDG lipopeptide 
- 
receptor binding 
ligand, increased 
targeting for 
cationic lipid-
DNA system 
[87] 
HMGB-
1 
High mobility group 
box -1 
- 
protein having 
DNA binding 
domain and 
nuclear 
localization 
signal 
[99] 
Sugar-based receptor targeting agents 
Mannose Mannosylated PLL - mannose receptor targeting 
[85] 
Galactose Galactosylated 
polyornithine - 
galactose 
receptor targeting
[86] 
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I.2.3. Novel cationic gemini surfactants as delivery agents in gene therapy 
Cationic gemini surfactants (Figure I.2) are a novel category of delivery agents 
with potential use in gene therapy. Since the description of these agents in 2000 by 
Menger [115], only a few publications have described their transfection efficiency in 
vitro. Based on their versatility, high potential for combinatorial chemistry, modeling, 
ability to bind and condense DNA, and relatively low toxicity, the gemini surfactants 
may have the potential to be used not only in vitro, but also in vivo as delivery agents for 
macromolecules. 
Cationic gemini surfactants are molecules with two ionic head groups attached to 
their hydrocarbon tails and connected with a spacer or linker [115]. These compounds 
are capable of compacting DNA and have several advantages compared to classic 
monovalent surfactants: lower cellular toxicity [116], lower critical micellar 
concentration (generally one or two orders of magnitude), higher efficiency in reducing 
surface tension, greater tendency to self-assemble, and greater variety due to the nature 
of the spacers separating the two quaternary nitrogen atoms. This variety contributes to 
flexibility in designing suitable delivery systems for different target cells [117]. 
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TAIL TAILION IONSPACER  
 
Figure I.2.  General structure of gemini surfactants.   
The two hydrophobic alkyl chains (tail) with charged head groups (ion) are connected 
with a carbon spacer [115]. By modification of the spacer length and chemical nature 
(saturation degree and length) of the tail by combinatorial chemistry, a great variety of 
surfactants tailored for specific needs could be generated. 
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Table I.3.  Gemini surfactants used as delivery agents for genetic material 
Surfactant 
category Chemical structure 
Head 
spacer Tail Ref. 
Alkyl 
m-s-m 
surfactants 
N+
CH3
H3C
(CH2)n
(CH2)m-1
2Br-
CH3
N+H3C
CH3
(CH2)m-1 CH3
 
Alkyl Alkyl [117]
Substituted 
m-s-m 
surfactants 
N+
N+
OH
HO
Br-
Br-  
Hydroxyl 
substituted 
Alkyl [118]
Ester-linked  
m-s-m 
surfactants 
N+
N+
O CnH2n+1
O CnH2n+1
O
OBr-
Br-
s
 
Alkyl Carboxy
lated 
[119]
Tetraalkyl 
N+
N+
Br-
Br-
s
 
Alkyl Alkyl [120]
Sugar-based 
NN
R R
HO OH
HO
OH
HO
OH
OH
HO
OH
HO
 
Sugar Alkyl [121, 
122] 
Peptide-based  
(GS) 
HN
S S
OH
NHR
NH
OH
NHR
NH
O O
O
O
n(AA)
HN
n(AA)
 
Peptide 
(lysine) 
Alkyl [123, 
124] 
Peptide-based 
(DSN) 
NH
NH
NH2
NH2
H
N
NH
O
O
O
O
s
  [125]
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Tartaric acid 
based 
 
 
C15H31
O
C15H31
O
HN
H3N
HN
H3N
O
O
Br
Br
C15H31
O
C15H31
OO
O
N
H
H
N
H3N
H3N
H
N
H3N
O
N
H
H3N O
C15H31
O
C15H31
OO
O
N
H
H
N
H3N
H3N
H3N O
H3N O
Br
Br Br
Br
Br
Br
Br
Br
 
Tartraric 
acid 
derivative 
Alkyl [126]
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DNA compaction by gemini compounds depends on both the nature of the head 
group (effective head group area, valence) and the length and saturation of the 
hydrophobic tail. The optimal aggregation of these surfactants can be expressed by the 
surfactant parameter, Ns,  
 
0la
vN s =            (I.1)  
where v = volume of alkyl tail, l = length of alkyl tail, and a0 = surface area occupied by 
the head-group. An Ns value, indicating the preferred curvature of the structure, of 0.3 is 
typical for spherical micelle organization (highly curved), whereas Ns = 1 represents 
planar bilayer formation and Ns > 1 applies to inverted micelles. Gemini surfactants 
efficiently compact DNA when the spacer length s is <4 or >10. Intermediate spacer 
lengths are less effective. Increase of the tail length from 12 to 18, hence 
hydrophobicity, also improves the compaction of plasmid DNA [127]. Contrary to the 
previously described principle regarding cationic transfection agents where higher 
compaction correlates with better transfection efficiency, Rosenzweig et al. [116] found 
the 16-6-16 surfactant transfected BHK cells more efficiently than the 16-2-16 and 16-3-
16 compounds. The presence of helper lipid in up to a 1:2 weight ratio to the gemini 
agent inhibited or substantially reduced cell transfection. Although these compounds 
present various morphological structures (lamellar for the compounds with saturated 
cetyl tail and micellar or mixed for the oleyl tail), the effect on DNA and interaction 
with biological membranes have not been explored. More recently, the role of helper 
lipids as DNA stabilizing agents for the gemini surfactants with C10, C12 and C14 tails 
was demonstrated [119]. The transfection efficiency (expressed as number of cells 
expressing the reporter gene) was comparable to the commercial GenePorter agent. 
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 Measuring the adiabatic compressibility, an indicator of the micelle formation 
process of the gemini surfactants, the authors demonstrated that the gemini surfactants 
showed lower isentropic compressibilities compared to monocationic counterparts due to 
the ability of the gemini surfactant to form chain associations before the critical micellar 
concentration (CMC) is reached. The transfection efficiency was inversely proportional 
to the CMC. Differential scanning calorimetry indicated that these surfactants were 
active at the membrane surface, rather than affecting the phospholipids bilayers.   
Another group of cationic alkyl gemini derivatives with two oleyl tails attached 
to each positively charged nitrogen and a C3 or C6 spacer has shown the ability to 
deliver DNA in vitro. The surfactant having a spacer of 6 carbons (Table I.3) was able to 
transfect cells at higher efficiency compared to its monovalent counterpart, DODAC 
(Table I.2), especially at +/- charge ratios greater than 2. This effect was due to the 
ability of the surfactant to induce non-bilayer phase transition in the lipid bilayer. The 
presence of the helper lipid DOPE increased the transfection efficiency about ten-fold 
[120]. Gemini surfactants having sugar spacers in their head groups and two palmitoyl 
or oleyl tails were able to transfect CHO-K1 cells at comparable levels to 
Lipofectamine. The cationic nitrogen atoms were separated by either 4 or 6 carbon 
spacers [121]. Peptide-based gemini transfection agents having C12, C16 saturated or 
C18:1 unsaturated tails were used in vitro to evaluate transfection efficiency. Consistent 
with the findings of Karlsson et al. [125], increasing tail lengths were associated with 
higher transfection efficiencies. The nature of the head-group was also important. Three 
lysine residues linked through the Є-amino group (GS surfactants; see Table I.3), rather 
than α-nitrogen, were found to yield the highest transfection of CHO-DG44 cells [124]. 
The optimal concentration of the delivery agent was 10 µM. The amide linkage in the 
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headgroups is biodegradable, conferring lower cytotoxicity to these molecules [123]. L-
tartaric acid derivatives were tested in CHO-K1 cells to determine their transfection 
efficiency. Cellular toxicity creates difficulties in the evaluation of these compounds as 
transfection agents [126].  
Overall, gemini surfactants demonstrate great potential for gene delivery. Due to 
the low CMC compared to their monovalent counterparts, these surfactants associate 
more readily in aqueous environments, bind DNA with higher efficiency creating higher 
local concentrations around the negatively charged macromolecule, and thus are 
efficient in lower concentrations. Their lower toxicity compared to monocationic 
surfactant also contributes to their usefulness in vivo. Their versatility is attributed to the 
length and nature of the hydrophobic tails (length of carbon chain, degree of saturation 
and symmetrical or asymmetrical nature) and nature of head group (i.e., length of the 
alkyl spacer and nature of the functional substitutes). These chemicals can generally be 
easily synthesized at low cost, a major advantage for industrial drug manufacturing.     
I.3. Structural requirements for efficient DNA delivery systems 
Physico-chemical characterization of delivery systems is important in order to 
better understand the mechanism of delivery. An abundance of assays have tried to 
explain the relationship between physical and chemical behaviour and efficiency, from 
classical encapsulation assessments by zeta potential measurements, fluorescence 
measurements, gel electrophoresis [128, 129] and electron microscopy (EM) [130] to 
differential scanning calorimetry (DSC) [45], circular dichroism (CD) [131], 
synchrotron X-ray scattering [132] and X-ray diffraction [133, 134] studies. 
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An efficient DNA delivery system has to fulfill several criteria: ability to bind 
DNA and create complexes of a certain size and morphology, neutralize surface charges 
to facilitate cellular uptake, induce changes in the DNA structure favorable for efficient 
delivery, protect the genetic material against intracellular degradation, and ability to 
undergo polymorphic phase changes.  
Particle size and the morphology of the complexes are generally important 
characteristics of the DNA delivery. Sternberg et al. [135] studied the relationship 
between the morphology and size of cationic lipids. DNA/DDAB/DOPE complexes 
presented higher in vitro transfection efficiency compared to complexes containing 
DOPE. The size of the particles was 100-300 nm with a tendency for fusion of the 
liposomes upon standing due to the ability of the DOPE to form non-bilayer structures 
[135]. DNA condensed with a spermine derivative (alpha-galacto-omega-spermine 
bolaamphiphile–GalSper) formed particles with a bimodal distribution of 100 and 800 
nm. Addition of DOPE further increased the size to 1100 nm. The DNA/GalSper/DOPE 
lipoplexes transfected HepG2 cells compared to DNA/GalSper complexes [136]. The 
effect of the size of the particles upon the mechanism of uptake, fusion [44, 137] or 
endocytosis [39, 138] has been debated in the literature, although the combination of two 
pathways has not been excluded [139].  Recent publications shed light on the uptake of 
cationic delivery particles larger than 100nm (the optimal size for endocytosis). 
Although the main process of internalization into the cells was endocytosis, lipoplex-cell 
fusion could also occur, as evidenced by the reduced gene expression caused by the 
addition of fusion inhibitors [140]. Moreover, DNA could induce changes in the lipid 
organization of cationic vesicles. DNA addition to cationic liposomes induced fusion of 
the vesicles [141]. Small-angle X-ray scattering (SAXS) measurements of mixtures of 
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Dc-Chol/DOPC and DOTAP/DOPE vesicles indicate no fusion, explained by the 
repulsion of particles due to electrostatic charges. However, addition of DNA to the 
mixture of the two types of vesicles caused changes in the SAXS pattern indicating lipid 
mixing.  
The morphology of the liposomes might also modulate the transfection 
efficiency. Multilamellar vesicles (MLV) transfect cells more efficiently than large 
unilamellar vesicles (LUV) [66, 118, 142], and are taken up by cells more efficiently 
[143]. Zabner et al. describe heterogeneous morphology of cationic lipid/DNA 
complexes that efficiently deliver DNA in vitro [39].   
Another important feature that influences transfection efficiency is the +/- charge 
ratio. A wide variety of optimal charges is described in the literature. Generally, the 
cationic agent/DNA complexes show increasing transfection efficiency with increasing 
charge only to a certain point (optimal charge ratio), after which efficiency decreases. 
This decline might be due to the relative toxicity of the cationic lipid. Wang et al. found 
the transfection efficiency of monocationic alkyl acyl carnitine derivatives was optimal 
at +/- ratios of 5, and cell survival drastically decreased at values of 8-32. Two studies 
on airway epithelial cells demonstrate that a +/- charge ratio >1 is required in this type of 
cell. An early transfection experiment shows the optimal  +/- charge ratio using cationic 
DMRIE is 1.25 [144]. In a recent publication, a novel cationic cholesterol derivative at a 
+/- charge ratio of 2.8 effectively transfected three different epithelial cell lines in the 
presence of eqimolar DOPE. At this charge ratio, the DNA was fully associated with the 
liposomes (gel-retardation assay) and presented maximum compaction (dye exclusion) 
[145]. Cationic gemini lipids, formulated with various amounts of DOPE at a +/- charge 
ratio of 3 showed transfection efficiency comparable to a commercial agent [119]. 
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DOTAP-containing liposomes were mixed with DNA at increasing +/- charge ratios and 
the charged particles separated from the excess of empty liposomes. These cationic 
lipoplexes with +/- charge ratios of 2-4 showed more compact structure than the 
mixtures before separation. The isolated fraction of positively charged liposomes 
demonstrated higher transfection efficiency compared to the neutral or negatively 
charged fractions, low cytotoxicity and resistance to inhibitory effect of serum. The 
negatively charged complexes (+/- charge ratios of 0.25-0.5) showed moderate 
transfection efficiency [146]. In some cases,  +/- charge ratios <1 were optimal for 
delivery of genetic material in certain tumours [147-149] or brain cells [150].  
In the majority of cases, the ζ-potential of the particles in the delivery system is 
positive in order to achieve optimal transfer through the cell membrane. The positive 
overall surface charge is necessary for interaction of the particles loaded with the genetic 
material with the cell membrane. In the case of the cationic lipid DC-6-14/DOPE 
complexes, a +13mv ζ-potential and a +/- charge ratio of 1.5 were optimal for high 
transgene expression [140]. The transfection efficiency of cationic cholesterol 
derivatives in the presence of DOPE as helper lipid paralleled the ζ-potential (values of 
+9 to +33mV), with increasing ζ-potential inducing higher levels of reporter gene 
expression [151]. In addition to the positive surface charge of cationic lipids, the surface 
charge density of the particles is another parameter indicating the degree of interaction 
with the cell membrane and the transfection efficiency. This parameter can be controlled 
by the addition of neutral lipids. For example, substituted alkyl gemini derivatives with a 
low cationic/neutral lipid ratio (0-0.25) transfected cells inefficiently. The protein 
expression gradually increased between molar rations of 0.25-0.5, then remained 
unchanged with further increase of the proportion of the cationic lipid [118].  Lin et al. 
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[152] expanded the concept to monovalent and polyvalent cationic compounds, 
demonstrating that the transfection efficiency of all studied cationic agents (DOTAP, 
DOSPA amd DMRIE) as a function of surface charge density (σM – the average charge 
per unit surface area of the lipid membrane) fitted into a universal curve. For all 
compounds, σM values between 0.0015 e/Å2 and 0.012 e/Å2 were optimal, rendering 
universality to this parameter for cationic liposomes with lamellar structure [152].  
Cationic lipids induce changes in the structure of the DNA, imposing a 
conformation advantageous for transmembrane delivery of the genetic material. 
Monocationic (DMRIE, DOTAP) or polycationic (DOSPA) lipids aided by DOPE as 
helper lipid induced changes in the original CD spectrum of the B-DNA, inducing the 
formation of Ψ– form, a more organized, highly compacted DNA structure. CD spectra 
of the newly created structure showed depression of the 270-280-nm peak. A more 
pronounced depression was present with the DOTAP/DOPE vesicles, correlating with 
the highest transfection efficiency [131, 153].  
A key factor in understanding the mechanism by which cationic lipids are able to 
deliver DNA into the cells and facilitate the release from the endosomes is the 
interaction between the lipid and the DNA. Cationic lipids of various composition 
assume lamellar or non-bilayer (hexagonal) structure. Koltover et al. demonstrated that 
DOTAP/DNA formulations present modifications of the Bragg reflections in the 
scattering pattern measured by SAXS as increasing amounts of DOPE are added to the 
system. In the absence of DOPE, a lamellar structure (Lα) is detected, where the DNA is 
sandwiched between two bilayers [154]. The thickness of bilayer–DNA unit was 57 Å 
[155]. Addition of DOPE gradually changed the scattering profile to a hexagonal 
arrangement (HII), due to the membrane-bending shape of the molecule. In this 
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conformation, the DNA strands are surrounded by the inverted lipid molecules, packed 
in cylindrical units, with a unit spacing of 67 Å [154].  DNA–cationic liposome 
(containing CTAB or sodium octylsulfate) interaction with linear DNA (~700bp) was 
studied by cryo-transmission electron microscopy (TEM) and SAXS, demonstrating that 
DNA strands were intercalated between double layers of the liposomes, with the 
thickness of one DNA-bilayer unit being 60 Å [156]. Comparison of scattering patterns 
of DODAB (two tails) and CTAB (single tail) complexed with linear dsDNA indicated a 
lamellar structure for the double-tailed surfactant and hexagonal for the single-tailed 
compound [157], but no correlation with their transfection efficiency was presented. 
Small- and wide-angle X-ray diffraction (SAXD and WAXD) studies of DNA–cationic 
gemini surfactant–helper lipid complexes demonstrate that both DNA and lipid undergo 
major structural changes. At increasing cationic surfactant/helper lipid molar ratios, a 
non-linear decrease of the repeat period of the lamellar lipid phase was observed 
(meaning a decrease in the bilayer thickness), accompanied by a modification of the 
DNA-DNA interhelical distances [133]. The structural periodicity of DOTAP/DNA 
complexes was demonstrated to be a function of +/- charge ratio and ionic strength, as 
indicated by fluorescence resonance energy transfer (FRET) studies. A short DNA/lipid 
distance (18-21Å) was observed at +/- charge ratios of 3 or above [158], consistent with 
calculations of the water gap (28 Å) based on SAXS measurement of a lamellar system 
[154]. At lower charge ratios, the DNA lipid distance increased proportionally with the 
decrease of charge ratio. Similar structural organization was described by Tarahovsky et 
al. [159] as revealed by electron microscopic visualization of thermostable DNA–
cationic lipid complexes. These complexes, with a lamellar periodicity of 60-65 Å, 
transfected cells more efficiently compared to thermolable complexes [159], 
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demonstrating that complexes assuming lamellar lipid organization are able to transfect 
cells efficiently.  At the other end of the spectrum, Zuhorn et al. [160] indicated the 
presence of hexagonal phase is crucial for efficient cellular delivery and endosomal 
escape of the DNA. When pyridinium-based cationic lipid SAINT-2 was mixed with 
DOPE, the structural organization showed hexagonal conformation and cell transfection 
was effective, while SAINT-2/DPPE complexes with mixed lamellar-hexagonal 
structure showed 2-3 fold lower efficiency.   
Since both lamellar and hexagonal structures can facilitate DNA delivery, 
lipid/DNA organization in the formulation may not be the basic requirement for efficient 
transgene expression, but rather the ability of the system to adopt various phases 
according to their milieu. For example, it has been shown that unsaturated cationic 
pyridinium derivative/DOPE/DNA mixtures form lamellar structure in water but 
hexagonal conformation in HEPES saline buffer [70].  Other formulations might have 
similar behaviour: lamellar in formulation and hexagonal in biological media 
(intercellular fluid, endosomal lumen). Another aspect that could be explored is the 
ability of the delivery systems to induce membrane fusion and phase transition, 
regardless of their original phase characteristics. For example, fusion of a lamellar 
delivery system with the lamellar endosome and lipid mixing could yield a new 
composition, favouring hexagonal conformation [61].  Moreover, addition of DNA to a 
mixture of two liposomes induces fusion and lipid reorganization [141]. Foldvari et al. 
[161] showed that efficient cell transfection can be achieved due to the ability of the 
gemini cationic lipid/DOPE/DNA systems to adopt polymorphic structures coexisting 
with lamellar phases.  
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In conclusion, effective cationic lipid delivery systems have the following 
properties: (1) they interact with the DNA, creating complex structures, (2) they are 
generally efficient in +/- charge ratios >1, (3) their surface charge density, as a universal 
indicator of the transfection efficiency, is greater than 0.0015 e/Å2 but lower than 0.012 
e/Å2, (4) they can induce changes in the native structure of DNA, yielding highly 
compacted particles able to penetrate through biological membranes, and (5) they adopt 
or induce hexagonal or polymorphic phase as a basic criterion of cellular uptake and 
escape from endosomes. 
As these various examples have revealed, not only the chemical nature of the 
transfection agents plays a role in the delivery of the genetic material, but also the 
physical properties; their ability to induce changes in the structure of the DNA, the type 
and strength of interaction with the DNA, chain packing, size, morphology and ζ-
potential of the particles are aspects that contribute to successful gene delivery. 
Modeling of the cationic lipid–DNA complexes can lead to further understanding of the 
requirements governing the efficient gene delivery, such as phase behavior, packing 
capabilities and electrostatic interactions [162-164]. Characterization of the cationic 
lipid-based formulations and correlation with transfection efficiency using multifactorial 
design can help in selecting various delivery systems and predicting the suitability of 
new compounds for gene delivery [165]. Further research should capitalize on 
corroboration of experimental results and mathematical models in order to select 
delivery agents suitable for dermal and transdermal delivery. 
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I.4. Skin as a target organ 
The skin (Figure I.3) is probably the most accessible of somatic tissues for drug 
delivery. The molecular characterization of several cutaneous disorders reveals the 
potential of using gene therapy in these diseases [107, 166-168].  
Cutaneous absorption is limited by the stratum corneum (SC), the outer 
protective layer of the skin. This highly lipophilic barrier consists of several layers of 
flattened keratinized cells, which are continuously replaced from the epidermis. Most 
drugs penetrate the stratum corneum by passive diffusion, described by Fick’s law: 
C
e
DkJ ∆−= 1  (I.2) 
where:  J = flux (quantity of drug penetrating per unit area in unit time); 
∆C = drug concentration difference above and below the membrane (stratum 
corneum); 
D = diffusion constant of the drug in stratum corneum; 
 k1 = partition coefficient of the drug between stratum corneum and vehicle; and 
e = thickness of the stratum corneum. 
 The partition coefficient depends on the solubility of the drug and its oil/water 
partitioning coefficient [169]. The total amount of drug absorbed depends on the drug 
concentration in the vehicle, dosage regimen, site and area of application, and 
application method (e.g., occlusion, rubbing, etc). The brick-and-mortar model for the 
stratum corneum presumes it is built of protein-rich cell layers, separated by intercellular 
lipids [170].  
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 Figure I.3.  Light micrograph of murine skin stained with 1% toluidine blue.  
The skin is composed of three distinct layers, each with specific functions. The 
epidermis (E) is a stratified, continuously renewing layer. Keratinocytes, Langerhans’ 
cells, melanocytes and Merkel cells reside in the epidermis. The outermost layer, the 
horny layer or stratum corneum (SC with arrow), functions as a barrier and thus limits 
drug penetration into the skin. The dermis (D) confers mechanical strength to the skin. 
Fibroblasts, macrophages and mast cells are supported by the extracellular matrix. Nerve 
endings, vascular network (blood and lymph vessels), apocrine and eccrine glands and 
hair follicles (HF with arrowheads) are located in the dermis. The subcutaneous tissue 
(ST) is a fatty layer that plays a role in thermoregulation and cushioning against 
mechanical injuries. Bar 100 µm, bar inset 50 µm. 
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 Depending on the physicochemical characteristics of the drug, the two main 
pathways of permeation through the skin are intercellular, involving penetration along 
the lipid channels, and intracellular, through the cellular content. By this model the 
mechanism of enhancers can also be explained [171]. Penetration enhancers can enhance 
drug diffusion into the skin by increasing the permeability of the stratum corneum. Polar 
enhancers such as dimethylsulfoxide, propylene glycol, and surfactants increase the 
hydration of the statum corneum, thus favour the delivery of hydrophilic drugs, whereas 
nonpolar solvents (e.g., hexamethyldisiloxane, isopropyl palmitate, and oleic acid) 
perturb the lipid bilayer structure [172]. Combination of polar-nonpolar permeation 
enhancers can increase drug penetration by affecting both the “bricks” and “mortar” in 
the model. Cutaneous and percutaneous absorption of drugs depends on 
physicochemical characteristics of the drug (solubility, particle size, oil/water 
partitioning coefficient), the nature of vehicle or delivery system, and skin-related 
factors such as site of application, age and skin condition. In vitro and in vivo models 
exist for quantitative evaluation of drug absorption. The in vitro methods include study 
of drug penetration in diffusion cells using intact or stripped skin (human or animal) as 
the membrane. In vivo absorption is studied in animal models and humans. Percutaneous 
absorption is measured as the amount of drug either in the receiving chamber of the 
diffusion cell or in serum. Cutaneous delivery is defined as the amount of drug in the 
whole skin, and in the separated stratum corneum, epidermis and dermis. In vivo, the 
biological response can also be monitored [173]. 
Delivery of genetic material is greatly hindered by the large molecular weight, 
low diffusion constant, and highly hydrophilic nature of DNA. However, keratinocytes 
can be transfected efficiently and sufficient protein can be expressed (“bioreactor” 
 42
concept), making topical administration an attractive approach for gene therapy (Figure 
I.4) [174]. In a review, Vogel describes two ways of using keratinocytes for expressing 
immunogenic and therapeutic proteins. One is ex vivo transfection, when keratinocytes 
removed from the patient are genetically modified, then grafted back for long-term 
expression. The other is an in vivo approach, based on direct delivery of genetic material 
into the skin cells using various delivery systems to achieve transient gene expression 
[175]. As mentioned previously, subcutaneous injection of plasmid DNA containing 
genes of several cytokines (e.g., IL-4, IL-6, IL-10, TGF-β1, MACAF, GM-CSF, TNF-α 
and IFN-γ) resulted in markedly increased levels of these cytokines at the site of 
injection; IL-4, IL-6 and IL-10 concentrations reached high enough serum levels to exert 
a biological effect [33]. Intradermally injected plasmid was taken up by keratinocytes 
relatively readily, as shown with rhodamine-labeled plasmid, but gene expression 
depended on the ability of the genetic material to enter the nucleus [176]. 
Keratinocytes are part of the immune system and are able to secrete cytokines 
and growth factors, such as IL-1, IL-6, IL-12, IL-15, IL-18, TNF-α, GM-CSF, IL-7 and 
vascular endothelial growth factor (VEGF). The interactions among the cytokines, 
chemokines and growth factors are complex (Figure I.4). For instance, IL-18 increases 
the Th1 responses triggered by IL-12, a cytokine responsible for triggering IFN-γ 
secretion of the lymphocytes. Expression of HLA DR on human keratinocytes strongly 
suggests the immunocompetent nature of the keratinocytes [177]. The interactions 
among immune elements might play important roles in the development of scleroderma, 
and could be the target for treatment options with the aim being the restoration of the 
Th1/Th2 balance [178]. Evidence suggests targeting dendritic cells is a potential 
application of gene delivery to achieve a long-lived immune response [179-181]. 
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 igure I.4.  Schematic representation of the function of keratinocytes and 
interaction with immune cells.  
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external stimulation in keratinocytes. Pro-inflammatory cytokines such as IL-1, IL-6, IL-
7, IL-12, IL-18 and TNF-α are secreted by keratinocytes when stimulated by 
chemotactants, such as IL-1, ultraviolet (UV) light, bacterial lipopolysacharides (LPS), 
or mechanical injury. These cytokines regulate T-cell proliferation and antibody 
secretion by B-cells. Prostaglandin E2 (PGE2), IL-1 receptor antagonist (IL-1ra) and IL-
10 are some of the down-regulatory cytokines modulating the immune response in the 
skin. Growth factors such as the vascular endothelial growth factor (VEGF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-7 are involved in 
cell proliferation and tissue regeneration [182].   
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Epidermal stem cells are attractive targets for long-lasting gene therapy. 
Transduction of this cell population could induce prolonged protein expression in the 
skin, a useful feature for the treatment of genetic diseases [183, 184]. Although viral 
vectors are more efficient for the delivery of genes, they are toxic, highly immunogenic 
and more difficult to prepare. Also, viral vectors can only be loaded with relatively small 
genes (e.g., AAV can package only 2.4kb double stranded DNA) [185]. Despite the fact 
that non-viral approaches at present have lower efficiency, they have the advantages of 
low immunogenicity and easy preparation [26]. 
I.5. Topical gene delivery 
Some hindrances to systemic administration, such as the passage through 
epithelial cells of the circulatory system to the target organs and interaction with 
elements of the blood are not present when DNA is applied topically. However, several 
major obstacles to topical gene delivery remain. The stratum corneum, the outer 
protective layer of the skin, presents a barrier difficult to penetrate by the large DNA 
molecules [27]. Furthermore, once DNA passes through this barrier, it meets the defense 
mechanism of the skin, represented by the dendritic cells in the epidermis; these 
powerful antigen-presenting cells recruit scavenger cells from the blood circulation. The 
uptake of the DNA into target cells (i.e., keratinocytes or fibroblasts) in the skin requires 
passage through the cell membrane, another rate-limiting step impeding gene 
expression. Escape from the endosomes and intracellular degradation can also diminish 
the amount of the DNA available for nuclear transport. Figure I.5 presents the barriers to 
efficient DNA delivery and protein expression.  
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Figure I.5.  Schematic representation of the obstacles to the delivery of DNA-drugs 
and protein expression in the skin. 
The figure demonstrates limited and slow penetration through the stratum corneum, 
phagocytosis, slow uptake by the target cells, lack of release from endosomes, instability 
in cytoplasm and lack of nuclear uptake. 
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Although several studies demonstrate the efficiency of lipid-mediated delivery of 
the DNA in vitro [44, 186, 187], including delivery into keratinocytes [188, 189] and 
fibroblasts [190, 191], little is known about the cutaneous delivery of the liposomal 
plasmid DNA. There are two ways to deliver DNA into the skin: ex vivo by insertion of 
genes into keratinocytes removed from the patient and reinsertion after transgene 
expression [192, 193], or in vivo, involving direct introduction of the genetic material 
into the skin followed by local or systemic gene expression [27, 175].   
Gene expression in intact skin was achieved ex vivo by cutaneous delivery of a 
cationic liposome-DNA system. The DOTAP-DNA complexes were incubated in Franz 
cells with intact excised skin for 6 hours, followed by a 24-hour incubation to allow 
gene expression. The β-galactosidase expression was 16 fold higher in the skin treated 
with the liposomal DNA compared to the naked plasmid [194]. 
In vivo delivery of DNA could be achieved in various ways: by invasive 
intradermal injection [195-197], jet propulsion or biolistic delivery [180, 198, 199], or 
non-invasive topical DNA application [200]. All these methods can be associated with 
physical or chemical enhancement. Physical methods include electroporation, 
sonophoresis and iontophoresis. Chemical formulations, including lipid-based delivery 
systems, can aid topical DNA delivery.   
Early studies demonstrated the feasibility of topical DNA delivery using reporter 
genes in liposomal formulation [107, 201]. Liposomal delivery systems containing 
DOTAP delivered the β-galactosidase expression gene into the skin, and protein was 
detected in epidermis, dermis and hair follicles [107]. 
Typically, studies demonstrated delivery after the skin permeability was 
increased in some way. Stratum corneum was removed by stripping the skin with 
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cellotape [55], adhesive glue [202], brushing with firm bristles [203] or treating with 
depilatory agents that remove the upper cornified layer of the skin [166]. Microneedles 
create superficial damage in the stratum corneum, allowing direct access of the DNA 
molecules to the epidermis, enabling delivery and enhanced expression 2800-fold by the 
“dip and scrape” method compared to intact skin [203-205]. Although the method is 
semi-invasive, no pain was associated with the use of microneedles in human volunteers 
[206]. Thus, this might be an attractive method for vaccination in pediatric population. 
Delivery of genetic material into the skin first found application in vaccine 
therapy. Of the 715 clinical trials in the world, 6.7% are focusing on vaccine 
development [http://www.wiley.co.uk/genetherapy/clinical/]. 
Fan et al. [200] demonstrated that naked DNA can penetrate the unaltered skin 
and elicit immune responses. Topical vaccination in mice with aqueous solution of 
HBsAg expression plasmid elicited antigen-specific immune responses. The magnitude 
of antibody production was about half the response following intramuscular injection. 
The hair follicles played an important role in the DNA delivery, since transgene 
expression could not be detected in hairless animals [200], and thus penetration through 
the intact stratum corneum was not achieved. Although naked DNA could generate 
enough protein to trigger immune responses, therapeutic feasibility of the method is 
questionable. For gene therapy, larger amounts of the therapeutic proteins need to be 
generated, and application of plasmids might not involve a hairy skin surface. Cationic 
nanoparticles and ethanol-in-fluorocarbon microemulsion [207, 208] were also used for 
dermal delivery of genetic materials, and the immune response to the generated protein 
was biased to Th1-type in the microemulsion system. Topical application of antigen-
coding DNA in lipid-based delivery systems also elicit immune responses. Application 
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of biphasic lipid vesicles containing plasmid encoding for the bovine herpesvirus type-1 
glycoprotein D (pgD) was followed by 5 fold higher antibody titers compared to control 
animals, and similar in magnitude to intradermal injection of a lower dose plasmid. The 
topical biphasic formulation triggered a Th2 type of response, whereas the intradermal 
injection elicited Th1 type [209]. This fact confirms the route of administration might be 
important for tailoring vaccination strategies. Although no clinical trials involve non-
viral cutaneous gene delivery for therapeutic purposes, efforts are being made to create 
efficient non-invasive delivery systems and devices.   
Nonionic/cationic liposomes (NC) are able to enhance transfection in vivo, 
facilitating the delivery of plasmid DNA into the skin, mostly into perifollicular cells. 
Protein levels after delivery of plasmid DNA encoding for IL-1 receptor antagonist (IL-
1ra) were four fold greater compared to naked DNA (165 pg/cm2 vs. 32.5 pg/cm2). 
Expression of transgenic protein can correct perturbance in cytokine production, which 
is the cause of several diseases affecting the skin. Liposomal delivery of IL-1ra and 
expression of protein in the cells inhibited the pathological effects of the endogenous IL-
1 in skin cells, provided the levels of the antagonist are 10-100 fold higher than the 
cytokine levels [210]. Similar findings were shown in another study where the ability of 
nonionic and nonionic/cationic liposomes to deliver plasmids DNA into the skin was 
twice as high compared to polymer compounds and polyethylene glycols, with peak 
expression at 24 hours [168].    
Transgene expression was reported following topical application of plasmid 
DNA in nanoemulsions of polyoxyethylene 20 sorbitan monooleate, sorbitan 
monooleate and olive oil. C57 BL/6J mice and hairless Skh-hr-1 mice were treated with 
plasmid DNA encoding for human interferon-α2 and the protein expression found to be 
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significantly higher in the hairy mice. Although the mechanism of transfection is 
unclear, the uptake of the genetic material seems more active in the hair follicles [211].  
In most publications, the relative differences between different formulations 
compared to naked DNA or control vehicle were assessed, but the specific gene 
expression levels actually obtained as well as levels required for successful treatment 
were not examined. In some articles, either the activity of reporter genes (measured in 
light emission units) [166, 212] or immune response against reporter genes, such as β-
galactosidase [200, 207] or messenger RNA expression [55], were presented. However, 
performing quantitative comparisons on the amounts of protein expressed is possible in 
some cases. For example, Wu et al. [211] indicate application of 10 µg plasmid coding 
for human interferon α2 (pNGVLhuIFN α2) on four consecutive days (total DNA dose: 
40 µg) in a nanoemulsion formulation in mice generates approximately 100 pg 
protein/cm2 skin. Chiotti et al. [213] show levels of expression of human interleukin-1 
receptor antagonist (IL-1ra) of approximately 165 pg/cm2 in hamster ear, after topical 
application of 2x350 µg plasmid DNA for three days. Similar protein levels were 
obtained in another study using the gene gun, by administering 5 µg/site of murine 
interleukin-12 (IL-12) coding plasmid on 4 sites, 1.5 x 1.5 cm2 skin surface, covering an 
intradermal tumour. The IL-12 level was 266±27.8 pg in the epidermal layer, this level 
of expression being sufficient to exert a biological effect, causing tumour regression in 
mice [214]. Although further experiments are necessary to evaluate the biological 
implications of these protein levels, the use of the non-viral DNA delivery as a 
therapeutic tool might be feasible. Moreover, these protein levels are comparable to 
those generated using lentiviral vectors. Siprashvili and Khavari [215] showed that after 
intradermal injection of 5 µg of GRE-Epo lentivirus in human skin grafts transplanted on 
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mice, human erythropoietin (Epo) levels of 25mIU/mL were achieved, corresponding to 
357 pg protein. The generated Epo was sufficient to exercise biological effect causing an 
increase in hematocrit from 40-45% to 60-65% [215]. Although direct comparison 
cannot be made, the protein levels achieved by intradermal injection of lentivectors (357 
pg Epo/mL) and non-viral topical delivery systems (165 pg IL-1ra/cm2 skin and 266 pg 
IL-12/cm2 skin) are in the same range, proving once more the potential of non-viral 
vectors and topical delivery systems in gene therapy. 
DNA delivery can be achieved by physical delivery methods, such as 
iontophoresis and electroporation. These methods alone or in conjunction with chemical 
delivery systems, such as liposomes, could efficiently increase transgene expression. 
Iontophoresis used for the delivery of antisense oligonucletodes (ODNs) targeting IL-10 
for treatment of atopic dermatitis induced a decrease in cytokine levels, accompanied by 
physical improvement, such as reduction of inflammation, erythema and scaling at the 
site of application, but not distant locations [216]. The mechanism of penetration and 
delivery is electromigration and electroosmosis [217]. Electroporation produces transient 
perturbation of lipid bilayers in the skin by cavitation. Since the created transmembrane 
potential is larger than that of the resting membrane, electroporation causes dielectric 
breakdown of membrane and creates hydrophilic pores for drug delivery [218]. Immune 
response to hepatitis B increased significantly in pigs injected intradermally with 
plasmid DNA coding for the antigen together with electroporation compared with 
animals injected intradermally, without electroporation [219].  
The mechanism of the interaction of the liposomes with the skin [220], as well as 
the potential application of this technology for in vitro and in vivo delivery of the 
macromolecules such as proteins and peptides [11, 221-223], has been described. 
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Structural and functional differences exist among proteins, peptides and DNA. The 
transdermal delivery of these compounds requires different conditions and their fate in 
cells is different. Understanding the mechanism of the lipid-mediated cutaneous delivery 
of DNA may lead to increased possibilities for the use of DNA in gene therapy. 
 Novel approaches, such as targeting dendritic cells, can be achieved with 
specifically designed plasmids, driven by dectin-2 promoter, characteristic only for 
Langerhans’ cells. Reporter genes carried by such vectors were expressed in the 
dendritic cells only. If certain antigen-coding genes are delivered by this type of system, 
the immune response to the generated antigen can be modulated [224].  
Topical application of liposomal DNA transfects hair follicles in a cycle-
dependent manner, being the most efficient in the anagen phase of the hair growth [225]. 
Topically applied fluorescent-labelled plasmid was retained in hair follicles of hair-
bearing skin, but was not detected in skin lacking normal hair follicles [200]. 
Topical delivery of genetic material is gaining importance for both therapy and 
immunization. The accessibility of the application site, ease of administration, non-
invasiveness, uptake of the DNA by specialized cells and the “bioreactor” nature of the 
skin are the advantages of this delivery approach. However, barriers such as penetration 
through the stratum corneum, the protective layer of the skin, and slow and still 
inefficient delivery into the viable cells have to be overcome. The mechanism of 
delivery needs to be elucidated for the majority of promising dermal and transdermal 
delivery systems. Physico-chemical characterization of the formulations, interactions 
with the skin lipids and cells, and correlations between the properties and efficiency 
could lead to improved gene delivery.  
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I.6. Localized scleroderma as a potential target for topical gene therapy 
I.6.1 General description of the clinical problem 
Scleroderma or progressive systemic sclerosis (PSS) is a chronic disease 
manifested by the excessive deposition of collagen (both type I and type III) in skin and 
connective tissue, vascular abnormalities and autoimmunity. Sclerotic fibroblasts 
(myofibroblasts) are capable of multiple in vitro passages, thus their accumulation might 
be responsible for the fibrosis characteristic for the disorder [226]. These fibroblasts 
produce excessive collagen even in the absence of the immune stimulus, suggesting the 
dysfunction of some regulatory genes associated with phenotypic selection (i.e., the 
subpopulation of fibroblasts producing excessive collagen is amplified at the expense of 
the normal fibroblasts). The stimulus for the excessive collagen production originates 
from immune mechanisms (Figure I.6).  
The development of sclerosis consists of three major steps: (1) cellular 
infiltration and vascular damage due to external stimuli or genetic factors, (2) 
inflammation due to the activation of monocytes and T-cells, and (3) fibrosis [227]. 
Almost all activated T-cells are predominantly CD4+ cells in the skin. The number of T-
cells expressing the CD8+ cell surface marker found on suppressor cells is diminished. 
The levels of both TGF and IL-4 are increased in the blood. Activated T cells produce 
TGF-β, IL-4 and lymphotoxin that stimulate fibroblast growth. 
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 igure I.6.  Pathogenesis model of scleroderma.  
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TGF-β selectively induces the connective tissue growth factor (CTGF), platelet-
derived growth factor (FDGF) and metalloproteinase-3, all increasing the mitogenic 
activity in fibroblasts [229]. TGF-β stimulates the synthesis of several extracellular 
matrix proteins, such as collagens, fibronectin, tenascin, tissue inhibitor of 
metalloproteinase-1 and plasminogen inhibitor-1, and induces TGF-β secretion in 
fibroblasts (autoinduction). The fibrosis is induced through the Smad pathway (Figure 
I.7); the intracellular Smads (e.g., Smad3) are activated by the binding of the TGF-β to 
its receptor on the surface of the fibroblast. The Smads than translocate into the nucleus, 
where they activate or repress gene transcription (e.g., activation of procollagen type I α 
gene, COL1A2) via the p300/CBP cofactor [230]. The profibrotic activity of IL-4 results 
in increased production of extracellular matrix via signal transducer and activator of 
transcription 6 (STAT6) protein. This protein binds a STAT (signal transducers and 
activator of transcription) responsive element facilitated by the p300/CBP cofactor 
(Figure I.7). STAT6 might also activate transcription of the TGFβ [231]. T-cells produce 
factors such as IL-6 and IFN-γ that suppress fibroblast growth and collagen synthesis. 
IFN-γ directly suppresses collagen synthesis in two ways (Figure I.7): through Janus 
kinase (Jak)/ STAT1 signaling and the Y box-binding protein (YB-1) pathway. The IFN-
γ blocks COL1A2 promoter activity by the JAK/STAT1α activation. The activated 
STAT1α competes with the TGF-β-activated Smad3 for the limited amount of the 
cellular cofactor p300/CBP, blocking the transcription of COL1A2 [232]. The second 
pathway involves the activation of YB-1, which directly interacts with the promoter 
region of the COL1A2, blocking its transcription. Additionally, the YB-1 binds mRNA 
in the cytoplasm, which could constitute yet another way to block collagen synthesis at 
the translational level [233]. Moreover, IFN-γ directly stimulates prostaglandin 
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production (another fibroblast growth inhibitor) in monocytes. Monocytes play an 
important role in the fibrosis; they express on their surface antigens characteristic of 
activated cells, and produce reduced amounts of interleukin-1 (IL-1) as demonstrated by 
monocytes removed from patients suffering form systemic sclerosis [227]. Depending 
on which cytokines are predominant, upregulation or suppression of the tissue fibrosis is 
controlled by the immune system; presence of IL-4 and IL-10 inhibits secretion of IFN-γ 
by Th1 cells, thus fibrosis is favoured. Conversely, if the IFN-γ is present, Th2 cells are 
inhibited, and production of IL-4 and IL-10 is blocked [234]. Recent evaluation of the 
cytokine balance in scleroderma patients revealed the presence of IL-4, IL-10 and TGF-
β (induced by IL-4) characteristic of Th2 immune responses, agents that induce tissue 
fibrosis. Altered B-cell activity might also contribute to the response shift, by activation 
of Th2 lymphocytes [178]. Since the clinical presentation of the disease has multiple 
components, research groups are focusing on the evaluation of the pathological markers 
as possible treatment targets. 
The pathological markers of sclerosis are: (1) vascular infiltration and cell 
damage, (2) imbalance of the cell mediated and humoral immune responses, (3) 
abnormal response of the fibroblasts to the immune stimulus, (4) increased number of 
activated mast cells, and (5) increased levels of cytokines. Immunohistochemistry and 
electron microscopy reveal that both type I and III collagen species are increased in 
scleroderma-affected skin, where the ratio of the two collagens is 5:1, similar to the 
normal skin [235].  
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 Figure I.7.  Schematic representation of the role of IFN-γ, IL-4 and TGF-β in the 
regulation of collagen synthesis.  
IFN-γ supresses gene transcription directly via the YB1 pathway and indirectly by 
inhibition of the P300/CBF protein [233]. IL-4 and TGF-β both stimulate COL1A2 
transcription via STAT6 and Smad3 pathways [231, 232]. Additionally, TGF-β 
autoinduces additional TGF-β production by fibroblasts through stimulation of the 
TGFB gene.   
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Localized forms of scleroderma, including morphea (patches of scleroderma) and 
linear scleroderma (linear bands of sclerodermatous tissue) are the most frequent form of 
scleroderma [229] (Figure I.8). In morphea, the lesions are confined to the skin, and 
occur as plaques (morphea en plaque) or indurated papular lesions (guttate morphea). As 
the disease evolves, more extensive lesions appear, the subcutaneous tissue is replaced 
by dense collagenous tissue, a process that can progress to involve deeper tissues 
including muscle and fascia [228]. Morphea is also characterized by the absence of 
visceral involvement, and coexistence with systemic scleroderma is infrequent [229]. 
Skin involvement in the systemic sclerosis presents similar clinical signs to the localized 
scleroderma, and the two conditions are histopathologically identical, thus treatment 
approaches could be applied for both localized scleroderma and the skin in systemic 
sclerosis.  
I.6.2. Animal models of scleroderma  
To study the cutaneous modifications in scleroderma, different animal models 
have been developed and used by research groups. One model, the tight skin-1 (Tsk1) 
mouse, has been proposed due to increased collagen synthesis in the skin and 
accumulation in the dermis. The morphological changes are caused by a spontaneous 
mutation of fibrillin-1 gene (FBN1) on chromosome 2. Homozygous Tsk1+/+Tsk1 
embryos die in utero, but the heterozygous Tsk1+/+pa animals are viable and present the 
pathological changes characteristic of scleroderma [236].  
 58
A B C
D E F
 
 
Figure I.8.  Clinical presentation of morphea and linear scleroderma.  
The lesions might appear on any area of the body. Lesions on the face and scalp, 
although less common, can be quite disfiguring when they occur. The morphea plaques 
are indurated, hyper- or hypopigmented with erythematous and/or violaceous halo 
(Panels A-C). The size of the lesions can vary considerably in size. Panels D-F are 
representative of linear scleroderma. (Courtesy of Dr. Alan Rosenberg). 
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 The mutation is inherited as an autosomal dominant trait. Electron microscopic 
evaluation reveals increased thickness of the dermis and denser packing of the fibrills 
compared to normal mice [237]. Osborn et al. indicate both increased thickness of the 
skin and twice the collagen content of the normal animals for both one and six month 
old Tsk1 mice [238]. High levels of TGF-β are detected in the early stages of 
development (first 16 days) paralleled by increased collagen synthesis in the skin of Tsk 
mice [239, 240]. The presence of immune cells and autoimmune antibodies in the 
mutated strain has also been demonstrated [241]. Altered B-cell function in the Tsk1 
mice could be the leading cause for the cytokine imbalance and presence of 
autoimmunity [178]. Recent studies question the morphological changes in the Tsk1 
mice, demonstrating the lack of differences in skin thickness and collagen content 
compared to pa+/+pa animals [242, 243]. However, with all its imperfections, the 
presence of pathological markers such as immune cells and cytokines similar to 
scleroderma patients proves the usefulness of the model. In the Tsk2 model, the 
mutation of FBN2 on chromosome 1 leads to the mononuclear infiltration and apparition 
of tight skin [244]. Autoimmunity has also been demonstrated in this model [245].  
Dermal sclerosis can be induced by injection of bleomycin, an anti-tumour agent. 
Side effects such as Raynoud’s phenomenon, lung and cutaneous fibrosis are frequent in 
the bleomycin treatment. Experimentally, scleroderma-like symptoms can be induced by 
injecting more than 1 µg bleomycin subcutaneously for 3-4 weeks in mice. The animals 
presented cutaneous changes (increased thickness of the dermis, excessive collagen I 
production), persistent for 6 weeks after the last treatment. Myofibroblasts present in the 
dermis can be reduced by anti-TGF-β antibody treatment. Immunological markers of 
scleroderma (immune cells, cytokines, chemokines) are found in the bleomycin-treated 
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animals [246]. The bleomycin-induced scleroderma has been useful for the study of the 
pathogenesis in scleroderma. Using the model for scleroderma therapy might pose 
questions such as characterization of the individual lesions, duration of the sclerotic 
modifications and of the treatment, and spontaneous remission of the lesions.  
The murine sclerodermatous graft-versus-host disease model is a useful tool in 
evaluation of the cellular and molecular mechanisms in the apparition and progression of 
scleroderma, as well as the key elements in the abrogation of excessive collagen 
synthesis. The model is especially useful for the study of rapidly progressing disease 
(months instead of years), since early recognition of the rapidly progressing scleroderma 
(before the appearance of irreversible tissue damage) improves the treatment outcome 
[247].  
The relaxin gene knockout model provides useful information on the evolution of 
progressive sclerosis, and the possibility of treatment with relaxin. Relaxin-deficient 
mice show age-related increases in collagen deposition that can be reversed by 
administration of relaxin at the early stages of the excessive collagen deposition (at the 
age of one month), but are not affected at advanced dermal scarring [248]. Transgenic 
mice overexpressing negative-type II TGF-β receptor were developed to study the effect 
of TGF-β on cell growth [249]. An interesting approach of using the murine 
sclerodermatous graft-versus-host disease model capitalizes on the similarities in the 
immunological make-up and fibrotic processes between the model and human 
progressive scleroderma. The model is useful for the study of cellular and molecular 
processes involved in scleroderma [247]. The necessity of bone marrow transplants for 
each animal could represent a hindering factor in the therapeutic studies, where a 
relatively large number of well-characterized animals are required. 
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I.6.3 Current treatment options and clinical challenges  
The clinician is faced with significant challenges in the treatment of systemic 
sclerosis (SSc) due to the various clinical manifestations, the presence of the 
autoimmune components and the diversity of the laboratory features. In a recent review 
[250], the cited treatment options are directed to alleviate the clinical signs of the 
disease: 1) vascular therapy is attempted by Ca-channel blockers, angiotensin-converting 
enzyme (ACE) inhibitors, antiplatelet drugs, prostaglandins, phosphodiesterase 
inhibitors, and nitroglycerin; 2) autoimmune therapy is initiated with methotrexate, 
cyclophosphamide, and antithymocyte globulin followed by mycophenolate mofetil (an 
immunosuppressive agent); and 3) antisclerotic therapy, such as prostacyclin, 
ecteinascidin, atorvastatin, integrin and UV radiation is administered to slow the 
progress of disease in the early inflammatory stages. Encouraging results in the 
prevention of the progression of the autoimmune component have been shown using 
high-dose immunosuppressive agents and stem-cell replenishment in early stages of 
diffuse scleroderma [251]. The treatment consists of total body irradiation, and 
administration of cyclophosphamide, antithymocyte globulin and autologous stem cells 
[252]. Pulmonary hypertension, digital ulceration and the Raynaud phenomenon (a 
vasospastic process affecting the blood vessels of fingers, toes, nose and ears) may be 
controlled by bosentan, an endothelin-1 antagonist compound [253-255]. Thalidomide, 
an agent known to increase CD8+ T cells in HIV infected patients, can be used in the 
treatment of SSc. Oral administration of the drug increased the plasma levels of IL-12, a 
potent inducer of IFN-γ, and improved healing digital ulcers in scleroderma patients 
[256]. Collagen type I synthesis can be inhibited by halofuginone (an anticancer drug 
that specifically inhibits the synthesis of collagen type I). Additionally, intraperitoneal 
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injection of this agent reduces the number of cells producing collagen [257]. Clinical 
signs of localized scleroderma can also be successfully improved by UVA irradiation 
resulting in decreased morbidity [258]. Current treatment possibilities for localized 
scleroderma also include topical corticosteroids, calcitriol and calcipotriene, 
methoxsalen followed by UVA exposure and methotrexate. All these treatments improve 
the clinical appearance, but do not cure the disease [259, 260]. Current clinical trials by 
the US National Institutes of Health (Table I.4) are mainly oriented towards the 
improvement of clinical aspects of the disease, rather than causal treatment. 
 Novel approaches for decreasing the fibrosis include modulation of cytokine 
expression in the sclerotic tissue. TGFβ, IFN-γ, IL-4, endothelin, CTGF are some of the 
targets [261]. Imiquimod, an IFN-γ inducer, was successfully used to clinically improve 
signs of morphea. Topically applied imiquimod 5% cream induced Th1 type response 
and induced regression of morphea plaques in patients [262]. Animal studies in tight-
skin mice, the genetic model for scleroderma, indicate administration of IL-12 coding 
plasmid significantly reduces skin thickness and production of IL-4, and increases IFN-γ 
levels at a dosing regimen of 100 µg plasmid injected once every three weeks for 21 
weeks [263].  The same effect can be achieved by blocking the endogenous TGF-β 
signaling with anti-TGF-β antibodies or TGF-β1 antisense oligonucleotide [264]. Zhou 
et al. [265] analyzed fibroblasts from scleroderma patients and found increased SPARC 
(secreted protein, acidic and rich in cystein) levels. This protein regulates the assembly 
and deposition of extracellular matrix components, and its modulation might contribute 
to the control of the disease. IFN-γ decreases collagen production in vitro in 
overproliferative fibroblasts from hypertrophic scars and in vivo improves the clinical 
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 Table I.4.  Ongoing clinical trials sponsored by the US National Institutes of Health or other agencies in 2005 
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   Study Agent Characteristics Form of
scleroderma 
 Sponsor/ Phase (ClinicalTrials.gov 
Identifier) 
Oral Type I 
Collagen for 
Relieving 
Scleroderma 
Drug: bovine type I collagen Daily oral dose of 
bovine type I 
collagen  
Diffuse 
systemic 
scleroderma 
National Institute of Arthritis and 
Musculoskeletal and Skin Diseases 
(NIAMS)  
Phase II  (NCT00005675) 
Safety and Value of 
Self Bone Marrow 
Transplants 
Following 
Chemotherapy in 
Scleroderma 
Patients 
Drug: fludarabine,  
cyclophosphamide, 
thymoglobulin 
Procedure:  
leukapheresis, self bone 
marrow transplant 
Safety and value of 
self bone marrow 
transplants after 
chemotherapy  
Systemic 
Sclerosis 
National Institute of Arthritis and 
Musculoskeletal and Skin Diseases 
(NIAMS)  
University of Pittsburgh Cancer 
Institute Amgen Genzyme 
Phase I (NCT00040651) 
Efficacy and Safety 
of Oral Bosentan on 
Healing/Prevention 
of Digital (Finger) 
Ulcers in 
Scleroderma  
Drug: bosentan Prevention and 
healing effects of 
bosentan versus 
placebo on digital 
ulcers  
Scleroderma 
patients with 
or without 
digital ulcers 
at baseline 
Actelion 
Phase III (NCT00077584) 
 
Scleroderma: 
Cyclophosphamide 
or Transplantation 
(SCOT) 
Procedure: self blood cell 
transplantation Drug: high-
dose immunosuppressive 
therapy: cyclosphosphamide, 
equine antithymocyte 
globulin, 
methylprednisolone, growth 
colony stimulating factor  
Comparison of two 
treatments: 
1- high-dose 
immunosuppressive 
therapy followed by 
self blood cell 
transplantation  
2- high-dose pulse IV 
cyclophosphamide  
Severe 
systemic 
sclerosis 
National Institute of Allergy and 
Infectious Diseases (NIAID) 
Phase II/III (NCT00114530) 
 
 
 Efficacy and Safety 
of Oral Bosentan in 
Pulmonary Fibrosis 
Associated with 
Scleroderma 
Drug: bosentan Possibility of oral 
administration of 
bosentan 
Diffuse or 
limited 
systemic 
sclerosis 
associated by 
significant 
interstitial 
lung disease 
Actelion 
 
Phase II/III (NCT00070590) 
Safety, Tolerability, 
and 
Pharmacokinetics 
of CAT-192 
(Human Anti-TGF-
Beta1 Monoclonal 
Antibody) in 
Patients with Early 
Stage Diffuse 
Systemic Sclerosis 
Drug: human anti-
transforming growth factor 
beta-1 monoclonal antibody 
Evaluation the safety, 
tolerability, and 
pharmaco-kinetics of 
repeated treatments 
with CAT-192  
Early stage 
diffuse 
systemic 
sclerosis 
Genzyme  
Cambridge Antibody Technology 
Phase I/II (NCT00043706) 
 
 
Rapamycin Vs 
Methotrexate in 
Diffuse SSc 
Drug: rapamycin 
Drug: methotrexate 
Determination of 
safety of the 
rapamycin compared 
to methotrexate  
 
Diffuse 
systemic 
sclerosis 
University of California, Los 
Angeles 
Phase I/II (NCT00241189) 
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Ultraviolet B 
(UVB) Light 
Therapy in the 
Treatment of Skin 
Conditions With 
Altered Dermal 
Matrix 
Procedure: UVB irradiation Evaluation the
effectiveness of high 
dose UVB light 
therapy 
Keloid (or 
hypertrophic 
scar), 
scleroderma, 
acne 
keloidalis 
nuchae, old 
burn scars, 
granuloma 
annulare or 
related 
conditions in 
subjects with 
darkly 
pigmented 
skin 
University of Michigan 
Phase II/III (NCT00129428) 
 
Treatment of Early 
Systemic Sclerosis 
by Bosentan 
Drug: bosentan Inhibition of 
fibroblast activity 
early in the disease 
course 
Systemic 
sclerosis 
Rikshospitalet University Hospital 
Phase I/II (NCT00226889) 
Imiquimod in 
Children with 
Plaque Morphea 
Drug: imiquimod Pilot study to assess 
to potential efficacy 
and relative safety of 
Imiquimod  
Children with 
morphea 
(localized 
scleroderma) 
The Hospital for Sick Children 
Phase IV- not recruiting yet 
(NCT00147771) 
 
Imiquimod 5% 
Cream in Plaque-
Type Morphea: A 
Pilot, Prospective 
Open-Label Study 
Drug: imiquimod 5% cream 
(Aldara) 
Safety and efficacy of 
imiquimod 5% 
Morphea University of Alberta  
3M Pharmaceuticals 
Phase III- not recruiting yet 
(NCT00230373) 
 
 
 Safety and Efficacy 
of Pletal 
(Cilostazol) for the 
Treatment of 
Juvenile Primary 
and Secondary 
Raynaud’s 
Phenomenon 
Drug: cilostazol (Pletal) Safety and 
effectiveness of 
cilostazol to lessen 
the severity of the 
symptoms and 
decrease the number 
of secondary 
Raynaud’s episodes 
in juvenile patients 
Raynaud's 
Disease 
Otsuka America Pharmaceutical 
Phase IV (NCT00048776) 
 
Phase III 
Randomized, 
Double-Blind, 
Placebo-Controlled 
Study of Oral 
Iloprost for 
Raynaud's 
Phenomenon 
Secondary to 
Systemic Sclerosis 
Drug: iloprost Evaluation of the 
safety and efficacy of 
oral iloprost 
Raynaud's 
Disease 
secondary to 
systemic 
sclerosis 
National Center for Research 
Resources (NCRR)  
University of Pittsburgh 
 
Phase III (NCT00004786) 
Phase II Pilot Study 
of 
Cyclophosphamide 
and Rabbit Anti-
Thymocyte 
Globulin as Salvage 
Therapy in Patients 
With Diffuse 
Systemic Sclerosis 
Drug: anti-thymocyte 
globulin, cyclophosphamide 
Determination of the 
toxicity of 
cyclophosphamide 
and rabbit anti-
thymocyte globulin 
Diffuse 
systemic 
sclerosis 
Fred Hutchinson Cancer Research 
Center 
Phase II (NCT00016458) 
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Stem Cell Transplant 
to Treat Patients with 
Systemic Sclerosis 
Drug: cyclo- 
phosphamide, 
mesna, growth colony 
stimulating factor 
Procedure: leukopheres
is, total body 
irradiation 
Discovery if stem 
cell transplantation 
can help patients 
with systemic 
sclerosis 
Systemic 
sclerosis 
Baylor College of Medicine  
The Methodist Hospital 
Phase I (NCT00058578) 
 
 
Source: http://clinicaltrials.gov/ct/gui/ 
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 signs of overproliferative skin conditions such as scleroderma, morphea and keloids 
[266, 267].The mechanism by which the collagen synthesis is reduced is complex [268]. 
In vivo studies on experimentally induced scleroderma in mice demonstrate that after 
injecting the sclerotic agent (bleomycin), subcutaneous administration of 5x105U/mL 
IFN-γ for three weeks reduces the hydroxyproline content of the skin significantly by up 
to 72% [269]. Delivery of IFN-γ to the skin could provide the required amount of drug at 
the target site without systemic exposure. After injection of gene expression vectors of 
eight human cytokines (IL-4, IL-6, IL-10, TGF-β1, TNF-α, MACAF, GM-CSF and IFN-
γ) into rat skin, transgenic cytokine expression in keratinocytes and serum were 
assessed. All cytokines were expressed in the keratinocytes (20-200pg/µg protein). The 
interleukins and TGF-β, but not the other cytokines, were detected in the sera of the 
animals [33]. These findings demonstrate that the kerationocytes in the epidermis can be 
used to express genes introduced via plasmid vectors. The generated proteins might 
exhibit local or systemic effects. 
Early clinical studies indicated significant decrease of the skin thickness score 
and the area score in systemic sclerosis after intramuscular IFN-γ administration (100-
500 µg/m2 three times weekly for 18 weeks) [270]. More recent studies indicate mixed 
results and the side effects are common, mainly with flu-like symptoms [271]. The poor 
clinical results might be attributed to the low levels of IFN-γ in the tissues affected by 
sclerosis, due to its short half-life of only 1-3  to 30 minutes [272, 273], and the presence 
of the side effects might be associated with the systemic administration of the protein-
based treatment. Injection of 100 µg IFN-γ subcutaneously in the periphery of localized 
lesions did not produce the desired effect of reducing the size or fibrosis in the existent 
lesions, but was able to prevent the apparition of new lesions. The reason might be that 
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 IFN- γ inhibits the synthesis of collagen, but has no effect on collagen-degrading 
enzymes [274]. The invasive administration of the therapeutic protein and the tissue 
damage caused might also have triggered an unwanted cytokine cascade.   
Currently, approved treatment options for IFN- γ do not include localized 
scleroderma. Accepted indications for the recombinant human IFN-γ1b are in reduction 
of frequency and severity of infections associated with chronic granulomatous disease 
and as adjuvant in severe malignant osteopetrosis [275]. Due to its antiproliferative, 
antifibrotic, antitumour and antimicrobial properties, IFN-γ opens new perspectives in 
clinical dermatology [276]. New applications include viral infections, as adjuvant in 
IFN-α treatment in human papillomavirus infections [277], bacterial infections due to its 
Th1/Th2 modulatory effect in leishmaniasis [278], and mycobacterial infections [279]. 
Other potential topical applications include atopic dermatitis [280], decrease of 
fibroblast proliferation in hypertrophic scars [281] and malignant melanoma [282].    
Treatment of scleroderma with IFN-γ could have several advantages compared to 
other treatment options. Through the YB1 pathway, IFN-γ directly inhibits the Col1A2 
transcription. Moreover, due to its inhibitory action on the p300/CBP cofactor, IFN-γ 
neutralizes the effect of both IL-4 and TGF-β on fibroblasts and inhibits the transcription 
of both Col1A2 and TGFB in the target cells. Anti IL-4 or TGF-β would abolish only the 
mediation through either STAT6 or Smads, leaving the other pathways open. A 
disadvantage of blocking the TGF-β is that it can affect not only the hypertrophied skin 
but other tissues such as vascular walls, cartilages and ligaments. The same disadvantage 
is valid for systemic halofuginone treatment that reduces the collagen-producing cells 
[283]. In fibrotic disorders, the number of fibroblasts decreases with the progression of 
the disease and many of them differentiate into myofibroblasts, which are characterized 
70 
 by excessive extracellular matrix synthesis, synthesis of tissue inhibitor of 
metalloproteinase (inhibits collagen degradation), increased reactivity to TGF-β, and 
decreased sensitivity to IFN-γ [284, 285]. Due to its effect on fibroblast proliferation 
IFN-γ could expand the number of healthy fibroblasts and restore the normal collagen 
homeostasis in the dermis. IFN-γ can also play a role in the restoration of the immune 
balance by stimulation of the Th1 cells.  
Relaxin could be considered as an alternative treatment option to decrease of 
collagen in the skin. Relaxin is a polypeptide with hormone function secreted by the 
ovary in high amounts during pregnancy. One of its functions is to reduce collagen 
synthesis during pregnancy in order to soften the birth canal. In fibroblasts derived from 
scleroderma patients, both relaxin and IFN-γ reduced collagen synthesis, and when used 
in combination relaxin augmented the effect of IFN-γ [286]. 
For localized scleroderma, the topical application of IFN-γ protein or the 
encoding gene has several advantages such as ease of self-administration, good patient 
compliance, maximum effect at site of application without increased plasma 
concentration, avoidance of RES clearance and controlled release of the macromolecular 
drug. In addition, the treatment can easily be terminated at the point where clinical 
assessment confirms the remission of the sclerotic lesions on the skin. 
 Administration of plasmids coding for IFN-γ could have several advantages over 
protein administration: (1) generation of the biologically active protein in the skin, using 
the bioreactor function of the keratinocytes, (2) increase of the half-life by sustained 
gene expression, (3) possibility of insertion of two or more genes in the same vector 
(i.e., IFN-γ and Relaxin), and (4) reduction of systemic side effects, due to the dermal 
localization of the generated protein [33]. 
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 II HYPOTHESIS 
 The main hypothesis is that IFN-γ coding plasmid can be delivered into the skin 
after topical application using gemini surfactant-based delivery systems and IFN-γ will 
be expressed in the skin. 
 Sub-hypothesis 1: Gemini surfactants will be suitable DNA-complexing 
biomaterials for topical gene delivery. 
 Sub-hypothesis 2: IFN-γ expressed within the skin will have an impact on the 
pathophysiological markers of localized scleroderma in a mouse model.    
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 III. RATIONALE 
The skin is the largest somatic organ in the body. It is easily accessible, and 
represents an attractive site for treatment of various dermatological and systemic 
disorders. Previous studies demonstrate that keratinocytes can act as a bioreactor. The 
bioreactor concept means that transfected keratinocytes continuously express the desired 
therapeutic protein for a specific period of time. The duration of gene expression is 
modulated by the transfer vector; viral vectors tend to incorporate the foreign gene into 
the genomic DNA causing long-term expression, while non-viral carriers (plasmids) do 
not have the ability to insert DNA into the chromosomes, and the gene expression is 
transient. Moreover, keratinocytes are immunocompetent cells able to express surface 
antigens and secrete (constitutively or stimulated) cytokines, chemokines and growth 
factors that modulate the cell-mediated and humoral immune responses. Conversely, 
fibroblasts are not part of the immune cells, thus are void of the ability to express surface 
antigens and participate in immunological processes.  
Localized scleroderma is a cutaneous disorder characterized by excessive 
collagen deposition in the skin. The disease is progressive, and in severe cases can cause 
severe disfiguration. The etiology of the disease is unknown. Current antifibrotic 
treatment options are limied, and include iloprost (prostacyclin), a vasodilator, 
Ecteinascidin 743, a compound with antitumour activity, atorvastatin, a drug used to 
treat hyperlipidemia, with some immunomodulatory properties, and UV radiation. 
Evaluation of the efficacy of the treatments is difficult due to (1) the skin softens 
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 spontaneously after a maximal degree of fibrosis, (2) the treatment started at advanced 
stages of sclerosis resolves the sclerosis slowly, (3) the degree of skin sclerosis is not 
correlated with the overall disease stage, and (4) the evaluation of skin score is 
subjective [250].     
Extracellular IFN-γ can inhibit the excessive collagen production in fibroblasts 
by direct action (YB1 pathway) and by interference with the P300/CBP cofactor. This 
inhibition blocks the profibrotic effect of IL-4 and TGF-β, with both STAT6 and Smad 
pathways needing the P300/CBP protein in order to activate COL2A1 transcription. At 
the same time, autoinduction of TGF-β is also inhibited by IFN-γ at the transcriptional 
level.   
In pathological conditions, IFN-γ is effective in reducing excessive deposition of 
collagen both in vitro in fibroblasts, grown in three dimensional collagen lattices, and in 
vivo in clinical studies with scleroderma patients. However, due to clinical side effects, 
systemic use of IFN-γ for scleroderma may not be possible.  
To locally treat scleroderma, the keratinocytes in the epidermis can transiently 
express IFN-γ from plasmid DNA. By establishing an appropriate treatment regimen, 
therapeutic protein levels could be reached directly in the skin, and the length of therapy 
could be decided based on the clinical appearance of the lesions (remission of the 
plaques), reduction of skin thickness score and increase of the elasticity of the skin.   
 By developing an effective topical non-invasive dosage form for IFN-γ coding 
plasmid and providing a sustained supply of IFN-γ within the skin, a more effective 
approach for the management of the cutaneous form of scleroderma can be achieved.  
 Cationic lipids are able to bind DNA and neutralize the surface charges of the 
phosphate backbone of the molecule. By this interaction, the plasmid is compacted and 
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 can penetrate through biological membranes. Intracellularly, the cationic surfactants 
protect the DNA against degradation by endonucleases. The nature of the cationic 
surfactant and the presence of helper lipids that enhance permeation by temporarily 
perturbing lipids cell membranes and the stratum corneum will determine the in vitro 
and in vivo transfection efficiency of the delivery system. Physico-chemical 
characterization of the delivery systems, and study of their interaction with the plasmid 
and biological membranes, could lead to development of topical formulations with 
improved efficiency.  
 Several strategies could be explored in order to increase transgene expression 
and achieve therapeutic protein levels: (1) optimization of the plasmid construct (i.e., 
appropriate backbone and promoter region), (2) optimization of the delivery system 
(effect on the genetic material, such as compaction and protection, and on the stratum 
corneum and cell membranes), and (3) use of permeation enhancers to facilitate the 
penetration of the plasmid DNA into the skin in order to reach target cells.  
 In this project we will assess: 
(1) formulation development and characterization for in vitro and in vivo gene delivery; 
(2) quantitative aspects of DNA plasmid delivery by in vitro and in vivo experiments; 
(3) the efficiency of topical delivery; and  
(4) the therapeutic role of the IFN-γ in scleroderma-affected skin (Tsk tight skin mouse 
model).  
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 IV. PRIMARY OBJECTIVE 
The primary objective is to investigate the feasibility of delivering plasmid DNA 
coding for IFN-γ into skin using a novel cationic gemini delivery system and to evaluate 
the level of expression of IFN-γ in normal, IFN-γ-deficient and disease (scleroderma) 
mouse models.  
V. SPECIFIC OBJECTIVES 
V.1 To prepare and characterize lipid-based DNA delivery systems 
a. Purify and characterize plasmids designed for mammalian expression of the IFN-γ 
gene, to be used for delivery studies in vitro (in murine keratinocyte cell line) and in vivo 
in mice.  
b. Prepare novel gemini surfactant–DNA complexes, for in vitro and in vivo delivery. 
c. Evaluate physicochemical characteristics and pharmaceutical properties of the 
delivery agents by light, atomic force and electron microscopy, circular dichroism, size 
and ζ (zeta) potential measurements, dye binding and small angle X-ray scattering.  
d. Evaluate the relationship between physicochemical properties of cationic gemini 
delivery systems and their efficiency in vitro and in vivo. 
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 V.2 To develop methods suitable for evaluation of DNA delivery in vitro and in vivo 
a. Optimize PAM 212 keratinocyte cell culture, transfection, sample collection and 
detection methods. 
b. Develop topical treatment regimens, sample collection and analysis methods. 
c. Set-up and validate enzyme-linked immunosorbent assay (ELISA), fluorescence 
activated cell sorting (FACS) and fluorescent microscopy for protein detection, and 
polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR) methods for 
skin homogenate to determine the amount of plasmid DNA and mRNA in the skin.  
V.3 To evaluate the rate and extent of DNA delivery  
a. Quantify by PCR the delivered plasmid into the skin in an animal model by 
comparing the quantity of the amplified fragment to known amount of templates. 
c. Determine the protein expression by ELISA and fluorescent microscopy.   
d. Evaluate the effect of IFN-γ in a localized scleroderma model (tight skin mouse).  
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 VI. MATERIALS AND METHODS 
VI.1 Plasmids 
The plasmid pIRES2.EGFP (Clontech, Palo Alto, CA) contains the gene 
encoding for the enhanced green fluorescent protein (GFP) fused with internal ribosomal 
recognition sequence (IRES), preceded by a multiple cloning site for gene insertion. The 
gene of murine IFN-γ, containing the sequence coding for 155 amino acids of the murine 
IFN-γ [287], was obtained by restriction digest with Bgl II from the pSLRSV.IFN 
plasmid. The pGT plasmid (kindly supplied by Dr. R. Pontarollo, VIDO, Saskatoon, 
SK), a vector designed for gene therapy, has the CpG motifs removed and contains the 
human cytomegalovirus (CMV) promoter, kanamycin resistance site. The murine 
cytomegalovirus promoter [288] was obtained from the pLMCMVgDt plasmid (kindly 
supplied by Dr. S. Tikoo, VIDO, Saskatoon, SK) by PCR, having the two primers 
designed in such way that the promoter included a Kpn I and a Pst I site.  
a. pGTmCMV plasmid was obtained by replacing the human CMV promoter in the 
pGT vector with the murine CMV promoter. 
b. pIRES.IFN-GFP plasmid contains the IFN-γ gene inserted into the multiple cloning 
site of the pIRES2.EGFP vector at the Bgl II- BamH I site. The plasmid was grown 
in dam-/dcm- E.coli and the IFN-γ–IRES–GFP coding sequence cut with Bgl II and 
Xba I.    
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 c. pGT.IFN plasmid was constructed by inserting the IFN-γ gene into the Bgl II site of 
the pGT vector. 
d. pGTmCMV.IFN plasmid was created by inserting the IFN-γ gene into the Bgl II site 
of the pGTmCMV vector. 
e. pGT.IFN-GFP was obtained by inserting the IFN-γ–IRES–GFP fragment into Bgl II 
and Xba I sites of the pGT vector. 
f. pGTmCMV.IFN-GFP was constructed by inserting the IFN-γ–IRES–GFP fragment 
into Bgl II and Xba I sites of the pGTmCMV vector. 
 Primers were designed and two fragments of the pIRES.IFN-GFP plasmid, one 
containing the gene of IFN-γ and one containing the IRES-GFP construct, were 
sequenced with automated sequencer (PBI/NRC, Saskatoon, SK) and compared with 
sequences retrieved from GenBank (NCBI databases).  
 Reagents were purchased from Invitrogen Life Technologies (Carlsbad, CA), and 
restriction enzymes from Amersham Pharmacia Biotech (Baie d'Urfe, QC). 
VI.2 Formulation development for in vitro transfection  
For transfection, a group of eleven gemini surfactants [115] were used (Figure 
IV.1). 
1.5 mM aqueous solutions of the gemini cationic surfactants were prepared. The 
solutions were filtered through 0.2 µm Acrodisc® filters (Pall Gelman, Ann Arbor, MI).
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Figure IV.1.  Structure of gemini surfactants.  
The head group is composed of two positively charged nitrogen atoms each containing 
two methyl groups, a saturated hydrocarbon chain of 12 (m=12) or 16 (m=16) or an 
unsaturated carbon chain of 18 (m=18:1) carbon atoms, connected by a saturated carbon 
spacer of n carbon atoms (Table VI.1). 
 
 
Table VI.1.  Numerical designation for the gemini surfactants. 
n m Chemical name Symbol 
3 12 1,3 propanediyl-bis(dimethyl-dodecylammonium) bromide 12-3-12 
4 12 1,4 butanediyl-bis(dimethyl-dodecylammonium)bromide 12-4-12 
6 12 1,6 hexanediyl-bis(dimethyl-dodecylammonium)bromide 12-6-12 
8 12 1,8 octanediyl-bis(dimethyl-dodecylammonium)bromide 12-8-12 
10 12 1,10 decanediyl-bis(dimethyl-dodecylammonium)bromide 12-10-12 
12 12 1,12 dodecanediyl-bis(dimethyl-dodecylammonium)bromide 12-12-12 
16 12 1,16 hexadecanediyl-bis(dimethyl-dodecylammonium)bromide 12-16-12 
3 16 1,3 propanediyl-bis(dimethyl-hexadecylammonium)bromide 16-3-16 
2 18:1 1,2 ethanediyl-bis(dimethyl-oleylammonium) bromide 18:1-2-18:1 
3 18:1 1,3 propanediyl-bis(dimethyl-oleylammonium) bromide 18:1-3-18:1 
6 18:1 1,2 hexanediyl-bis(dimethyl-oleylammonium) bromide 18:1-6-18:1 
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 Lipid vesicles were prepared using sonication techniques. 1,2 dioleyl-sn-glycero-
phosphatidylethanolamine (DOPE) (Avanti Polar Lipids, Alabaster, AL) and α-
tocopherol (Spectrum, Gardena, CA) in 1:0.2 weight ratios were dissolved in 100% 
ethanol (Commercial Alcohols Inc., Brampton, ON) at 10 mg lipid/mL in a round 
bottom flask. The solvent was evaporated by rotary evaporation (Rotavapor RE111 
BÜCHI Laboratoriums-Technik AG, Switzerland) at 100 rpm at 55oC, producing a thin 
film deposited on the walls of the flask. Traces of organic solvent from the lipid were 
removed with high vacuum overnight. Glass beads were added to the flask and the lipid 
was resuspended at 1 mmol concentration in 9.25% isotonic sucrose (Spectrum) solution 
(pH= 9). The suspensions were bath-sonicated (Branson 2200, Cleansonic, Orange, VA) 
for 3 hours at 55oC. The suspensions were filtered through 0.45 µm Acrodisc® filters. 
 The plasmid–gemini complexes (PG) were prepared as follows: 0.2 µg plasmid 
was mixed with an aliquot of gemini surfactant solution added to obtain a 5, 10, 20 or 40 
+/-charge ratio and incubated at room temperature for 15 minutes prior to transfection. 
The plasmid–gemini–DOPE systems (PGL) were prepared by mixing the plasmid (0.2 
µg/well) with the gemini surfactant solution (5, 10, 20 or 40 +/- charge ratio) and 
incubating at room temperature for 15 minutes. To this mixture, 25 µL of DOPE vesicles 
was added. Cells were transfected after a 30-minute incubation at room temperature. 
VI.3 Transfection of PAM 212 cells with plasmid constructs 
VI.3.1 Transfection using Lipofectamine 
PAM 212 murine keratinocyte cells (kindly provided by Dr. S. Yuspa, NCI, 
Bethesda, MA) were grown to 90% confluency in 75-cm2 tissue culture flasks in 
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 supplemented MEM, prepared from minimal essential media (MEM) (Gibco BRL, 
Burlington, ON) with Antibiotic Antimycotic Solution (Sigma, Oakville, ON) 1:100 
dilution, and 10% fetal bovine serum (FBS) (Cansera, Etobicoke, ON). The day before 
transfection, 5x104 cells/well were seeded on 24-well plates (Greiner Labortechnik 
GmbH, Germany). For fluorescence imaging, the cells were grown on 13-mm diameter 
cover slips (Canemco, St. Laurent, QC) overnight at 37oC with 5% CO2 in an incubator 
(Sanyo Electric Co. Ltd., Japan) to 70-80% confluency. The supplemented MEM was 
replaced with MEM one hour prior to transfection. The cells were transfected with the 
following plasmids: pSLRSV, pSLRSV.IFN, pIRES.GFP, pIRES.IFN-GFP, pGT, 
pGT.IFN, pGT.IFN-GFP, pGTmCMV, pGTmCMV.IFN and pGTmCMV.IFN-GFP, 
using Lipofectamine PLUS® (Invitrogen Life Technologies, Carlsbad, CA). For each 
well, 0.2 µg plasmid was used. The transfection method followed the manufacturer’s 
protocol and was optimized for the PAM 212 cells. Briefly, 0.2 µg plasmid was mixed 
with 10 µL Plus reagent in 25 µL MEM and incubated at room temperature for 15 
minutes. Four µL of Lipofectamine reagent mixed with 25 µL of MEM was added to the 
plasmid. After incubating the mixture for 15 minutes at room temperature, it was added 
dropwise to cells covered with 200 µL of fresh MEM. The plates were incubated for 5 
hours at 37oC in a CO2 incubator, then the transfection mixture was replaced with 
supplemented MEM, and the incubation continued for 24 hours, after which the 
supernatants were collected. Media on the cells was replaced with fresh media. After 
another 24-hour incubation period, the second supernatants were collected and stored at 
-20oC. 
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 VI.3.2 Transfection of PAM 212 cells with pGTmCMV.IFN-GFP plasmid using 
PG and PGL systems  
PAM 212 murine keratinocyte cells were prepared for transfection as described 
earlier. The transfection mixtures were prepared as described earlier, and then added to 
the cells dropwise. The plates were incubated for 5, 6, 8, 10 or 24 hours at 37oC in a CO2 
incubator. The transfection mixture was replaced with supplemented MEM and the 
plates further incubated for 24 hours. The supernatants were collected and stored at -
20oC. For positive control, the cells were transfected with Lipofectamine PLUS® as 
described above.  
VI.4 Topical formulations 
Three dermal delivery systems were prepared with the 12-3-12, 16-3-16 and 
18:1-3-18:1 gemini surfactants. A cationic nanpoarticle formulation (NP) was prepared 
with DOPE 10 mg/mL, 1,2 dipalmitoyl-sn-glycero-phosphatidylcholine (DPPC) (Sigma) 
10 mg/mL, the gemini surfactant 10 mg/mL, and diethylene glycol monoethyl ether 
(Gattefossé, Saint-Priest, France) 25 mg/mL, containing 25 µg of plasmid in 50 µL of 
formulation (NP12, NP16, NP18 formulations). As a comparison, cholesteryl 3β-(-N-
dimethylamino-ethyl carbamate) (Dc-chol, Sigma) was used in a nanoparticle 
formulation: DOPE 10 mg/mL, DPPC 10 mg/mL, Dc-chol 10 mg/mL, and diethylene 
glycol monoethyl ether 25 mg/mL (NPDc formulation). The applied dose was 25 µg 
plasmid in 50 µL formulation. The nanoparticle formulation prepared with the 16-3-16 
surfactant (NP16) was further improved for application on the Tsk mice (to overcome 
the barriers created by the morphological changes in the skin, such as increased 
thickness and rigidity). The new formulation (NP16-PDM) had the following 
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 composition: DOPE 25 mg/g, purified phoshatidylcholine from soybean lechitin 25 
mg/g, and the 16-3-16 gemini surfactant 10 mg/g formulation. Two permeation 
enhancers were added: an in house synthesized amino acid derivative (PDM 27) 10 
mg/g, and propylene glycol 70 mg/g. The plasmid concentration was increased to100 µg 
in 100 µg formulation. All nanoparticle formulations contained α-tocopherol as an 
antioxidant agent. A cationic nanoemulsion (NE) was prepared with PEG-8 
caprylic/capric glycerides 200 mg/mL, polyglyceryl-3-isostearate 200 mg/mL, 
octyldodecyl myristate 400 mg/mL (all ingredients from Gattefossé) and the gemini 
surfactant 10 mg/mL. The topical formulations were characterized (by visual appearance 
such as consistency, colour, transparency, atomic force microscopy (AFM), TEM, size 
and ζ-potential measurement).   
VI.5 Topical treatment 
The animal experiments were approved by the University of Saskatchewan 
Committee on Animal Care and Supply Protocol Review. Four different strains of mice 
were used: 8-10-week old female CD1 mice (Animal Resource Center, University of 
Saskatchewan, Saskatoon, SK), 8-10-week old female IFN-γ-deficient mice (B6.129S7- 
IFNgtm1Ts/J, The Jackson Laboratory, Bar Harbor, ME) and 4-8-week old female Tsk-
mice (B6.Cg-Fbn1Tsk+/+Pldnpa/J, The Jackson Laboratory). The animals were 
anesthetized with isoflurane and close-shaved one day prior to treatment. For the short-
term treatment regimen, the topically treated groups of CD1, IFN-γ-deficient and Tsk 
animals were anesthetized with acepromazine/ketamine (5 mg/100 mg per kg) injected 
intraperitoneally. The shaved area was cleaned with distilled water and was dried using 
sterile gauze. Nanoparticle and nanoemulsion formulations (50 µL containing 25 µg 
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 pGTmCMV.IFN-GFP plasmid for each animal) were painted on the shaved area using a 
pipette, and covered with Parafilm for 2-3 hours (Figure IV.2). For the CD1 mice the 
treatments were repeated at 24 and 48-hour intervals. Each animal received a total dose 
of 75 µg pGTmCMV.IFN-GFP plasmid. The IFN-γ deficient and Tsk animals were 
treated for four days, receiving a total dose of 100 µg pGTmCMV.IFN-GFP plasmid. 
For the 20-day treatment of the Tsk mice, the animals were anesthetized with isoflurane. 
On the shaved back area, 100 mg formulation was applied then covered with Parafilm 
and sealed with Op-site. The animals were placed in individual restrainers for 2 hours. 
The treatment was applied once daily for five days per week and lasted for 4 weeks. The 
animals were reshaved once weekly. Each animal received 500 µg pGTmCMV.IFN-
GFP plasmid per week. In the injected CD1 animals were intradermally treated on their 
backs at three locations with NE plasmid formulation (5 µg plasmid/site), low and high 
concentration of aqueous plasmid solution (2.5 and 5 µg plasmid/site) or phosphate 
buffered saline pH=7.2 (PBS). The total dose for the animals injected with NE-DNA 
formulation was 15 µg plasmid per animal and for the injected DNA solutions was 7.5 
µg plasmid (low dose) and 15 µg plasmid per animal (high dose). The Tsk mice for the 
4-day treatment were injected intradermally on their shaved back once 24 hours prior to 
sample collection at four locations (2.5 µg plasmid/site, total dose 10 µg)  For the 20-day 
treatment the animals were injected intradermally with 2.5 µg plasmid at four locations 
twice weekly, for a total duration of four weeks. The total dose was 20 µg plasmid per 
week. The control animals were shaved and left untreated. Blood, skin biopsies, lymph 
nodes from inguinal and axillary sites and spleen were harvested 24 hours after the last 
treatment.
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 A              B 
 
Figure IV.2.  Topical and intradermal treatment of the animals.  
A – Mice treated with topical nanoparticle and nanoemulsion formulation (illustrated on 
an IFN-γ-deficient mouse). The treatment area (2x2cm) was shaved one day prior to the 
first application. The skin was cleaned with sterile gauze and purified water. The 
formulations were painted on the shaved area, covered with parafilm and sealed with 
Op-site. The animals were immobilized for 2-3h (anesthesia or restraining cages) to 
allow absorption of the formulation. 
B – Mice injected intradermally with nanoparticle formulation, plasmid solution or PBS 
(illustrated on a CD1 mouse). The shaved area (2x2cm) was cleaned with sterile gauze 
and purified water before the injections. The injection sites are visualized with trypan 
blue dye. 
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 VI.6 Sample processing 
Plasma was separated by centrifugation from blood collected from animals by 
cardiac puncture, and stored at -20oC. The skin was rinsed with distilled water using 
sterile gauze and the treated areas were excised. The samples were snap-frozen in liquid 
nitrogen, and stored at -80oC. The axillary and inguinal lymph nodes were collected, 
snap-frozen in liquid nitrogen, and stored at -80oC. The skin was homogenized under 
liquid nitrogen using a biopulverizer. The device was thoroughly cleaned, disinfected 
with 70% ethanol and dried in a laminar flow hood under UV light for 15 minutes 
between the recoveries from different groups to avoid cross-contamination. The lymph 
nodes were homogenized in microfuge tubes with disposable pellet pestles (Kontes, 
VWR, Mississauga, ON).  
The homogenized skin samples dedicated for ELISA and the lymph nodes were 
resuspended in 500 µL protein resuspension buffer (PBS containing leupeptin 10 µg/mL 
(Sigma) and soybean trypsin inhibitor 20 µg/mL (Sigma)). The homogenates were 
vortexed for 1 minute, sonicated for 30 seconds and kept on ice for 1 minute. This cycle 
was repeated three times. All samples were centrifuged at 16,000g for 15 minutes. The 
supernatants, free of cell debris, were collected and stored at -20oC.  
The homogenized skin samples dedicated for plasmid quantification by PCR 
were resuspended in proteinase K solution (200 µg/mL), incubated for 2 hours at 56oC, 
heated for 10 minutes to 95 oC, chilled on ice for 10 minutes and centrifuged at 16000g 
at 4oC for 20 minutes. The supernatants were collected and used for PCR.  
The total RNA from skin homogenates was isolated using RNeasy Lipid Tissue 
Mini Kit (Qiagen, Mississauga, ON) according to the manufacturer’s protocol. 
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 Approximately 20 mg of skin from each animal was used. To the tissue, 500 µL Qiazol 
Reagent was added, and the samples further homogenized with a Pro200 rotor-stator 
homogenizer (Pro Scientific Inc., Oxford, CT). Another 500 µL of Qiazol Reagent was 
added and incubated for 5 minutes at room temperature to dissociate the nucleoprotein 
complexes. The RNA was extracted after adding 200 µL chloroform (Sigma) by shaking 
the samples vigorously for 15 seconds by hand. After two minutes of incubation, the 
samples were centrifuged at 12000g for 15 minutes at 4oC. The mixture separated into a 
bottom phenol-chloroform layer, an intermediate film and a top aqueous layer 
containing the total RNA. The clear supernatant (~600 µL) was carefully transferred into 
a fresh tube, and the RNA precipitated with 600 µL of 70% ethanol (prepared with 
endonuclease-free purified water; Gibco). The samples were added onto the binding 
membrane in 6-700 µL portions and centrifuged at 8000g at room temperature for 20 
seconds. The flow-through was discarded after each centrifugation. The membrane was 
washed consecutively with 700 µL RW1 wash buffer and twice with 500 µL RPE wash 
buffer. The membrane was dried by centrifugation at 12000g for 1 minute. The binding 
columns were transferred into fresh microfuge tubes. The RNA was eluted twice with 30 
µL of purified water by centrifugation at 12000g at room temperature for 1 minute. The 
total RNA was quantified and integrity verified using Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA).  The single- and double-stranded DNA was digested from 
RNA samples (1 µg total RNA) with DNase I (1U/µL) and incubated for 15 minutes at 
room temperature to complete the reaction. The DNase I was inactivated by addition of 
25 mM EDTA. Samples were heated for 10 minutes at 65oC, when the RNA samples 
were ready to be used in reverse transcription prior amplification. First-strand cDNA 
was synthesized using Superscript II for RT-PCR. RNA sample (1 µg), 20 µM 
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 Oligo(dT)12-18 and 10 mM dNTPs were mixed and heated at 65oC for 5 minutes, then 
quickly chilled on ice. The contents of the tube were collected by brief centrifugation. 
First strand buffer, 0.1 M DTT and RNase inhibitor (40 U/µL) were added. The contents 
of tubes were mixed gently and incubated at 42 oC for 2 minutes. Superscript II was 
added and mixed by pipetting up and down. After 50 minutes of incubation at 42oC, the 
enzyme was inactivated by heating at 70oC for 15 minutes. The cDNA was used for real-
time PCR and PCR to quantify the mRNA.  
VI.7 ELISA 
ELISAs were performed using round bottom 96-well plates (Immulon II, 
Dynatech Laboratories, Chantilly, VA). The plates were coated with 50 µL/well capture 
antibody: rat anti-mouse IFN-γ (2 µg/mL) in coating buffer (0.05 M NaHCO3, pH=9.6) 
and incubated for 24 hours at 4oC. The wells were blocked with 1% bovine serum 
albumin (BSA) (New England Biolabs, Mississauga, ON) in PBS at room temperature 
for one hour. Recombinant murine IFN-γ standard was used at a 2000 pg/mL 
concentration and was consecutively diluted one in four with 1% BSA solution on 
plates. 1% BSA solution was used as a blank control. The supernatants from cell 
cultures, as well as the skin and lymph homogenates and the serum from mice, were 
diluted one in four on plates. The plates were incubated overnight at 4oC. Biotinylated 
rat anti-mouse IFN-γ (0.5 ng/mL in 1% BSA solution) was added. The plates were 
incubated for 2 hours at room temperature. The streptavidin-alkaline phosphatase 
conjugate (Invitrogen Life Technologies, Carlsbad, CA) was added in 1:1000 dilution, 
and incubated for 1 hour at room temperature. The 4-nitrophenyl phosphate di(tris) salt 1 
mg/mL in PNPP buffer (1% diethanolamine, 0.5 mM MgCl2, pH=9.8; Sigma) was used 
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 to develop the assay. Optical density of the samples was measured at 405 nm, using a 
Benchmark Microplate Reader (BioRad, Mississauga, ON) instrument and the 
concentration of the IFN-γ was calculated from a standardized IFN-γ curve. Antibodies 
and recombinant murine IFN-γ were purchased from Pharmingen, Mississauga, ON. 
VI.8 Bioassay 
The murine IFN-γ was tested for biological activity based on the reduction of the 
viral cytopathic effect [27]. The protocol, cells, virus and antibody were kindly supplied 
by Dr. C. Havele, University of Saskatchewan, SK. On a 96-well flat bottom plate 
(Greiner Labortechnik GmbH, Germany) 5x104 L929 cells (ATTC# CCL-1) grown in 
RPMI-1640 medium supplemented with 10% FBS, 0.1 mM 2-mercaptoethanol (Sigma, 
Burlington, ON), 0.8 mM sodium pyruvate (Sigma) and antibiotic-antimycotic solution 
(Sigma) 1:100 dilution were plated together with 1:2 serial dilutions of the supernatants 
from PAM 212 cells transfected with pGTmCMV.IFN-GFP. The plates were incubated 
for 24 hours in a CO2 incubator. The media were replaced with a 100-fold dose of the 
TCD50 (tissue culture dose 50) of endomyocarditis (EMC) virus [289] in 100 µL media. 
The TCD50, determined by Karber assay, defines the dose of virus required to cause 
death of 50% of the cells in culture. The cells were incubated with virus and the 
endpoint determined as the moment when the virus caused the death of 100% of cells 
untreated with IFN-γ. The wells were washed with PBS, the cells fixed for 15 minutes in 
4% formaldehyde (Sigma) and stained with 0.05% crystal violet (Sigma) solution in 
20% methanol for 15 minutes. The plates were washed and dried. Before measuring, 100 
µL methanol/well was added to the plates. The absorbance was read at 595 nm on 
automated plate reader (PowerWavex, Biotech Instruments Inc., Winooski, VT). To 
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 verify the non-specific antiviral effect, monoclonal antibody against IFN-γ activity 
XMG1.2 [290] was added to the supernatants. Standard recombinant murine IFN-γ 
(Pharmingen, Mississauga, ON) was also included in the assay.  
VI.9 PCR 
For the detection of the plasmid DNA, four primers were designed for nested 
PCR. The external primers were: sense (pKanEF) 5’–ACT CAC CGA GGC AGT TCC 
AT-3’ and antisense (pKanER) 5’–GGT AGC GTT GCC AAT GAT GT–3’, amplifying a 
540-bp fragment of the pGTmCMV.IFN-GFP plasmid. The internal primers were: sense 
(pKanIF) 5’–ATG GCA AGA TCC TGG TAT CG–3’ and antisense (pKanIR) 5’–TTA 
TGC CTC TTC CGA CCA TC–3’, which amplify a 459-bp fragment from the previous 
reaction. All primers were purchased from Invitrogen Life Technologies, Carlsbad, CA. 
Thirty five µL of supernatant from skin homogenate were used for the amplification 
with the external primers, and 2 µL of the PCR product were used for amplification with 
the internal primers. Standard dilutions were prepared with the pGTmCMV.IFN-GFP 
plasmid at 102, 103, 104, 105 and 106 copies/PCR reaction. PCR Reagent System 
(Invitrogen Life Technologies, Carlsbad, CA) was used for the reactions. The PCR 
mixtures were prepared according to the manufacturer’s protocol. 
PCR to detect murine procollagen type Iα2 from cDNA was performed using 
custom primers: forward primer: 5’–CCA GGC CAA CAA GCA TGT CT–3’, reverse 
primer: 5’–GTC AGC ACC ACC AAT GTC CA–3’, amplifying a 400-bp fragment. For 
each reaction, 2 µL of cDNA were mixed with 1 µL of each primer (10 pmol/µL) and 
22.5 µL of PCR Supermix (Invitrogen). Glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) primers were used for the housekeeping gene (452-bp fragment). The PCR 
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 conditions were: hot start for 4 minutes at 94oC, denaturation at 94oC for 45 seconds, 
annealing at 56oC for 30 seconds, extension for 30 seconds at 72oC and final extension 
at 72oC for 7 minutes. The reaction was carried out in thirty cycles. A Techne Genius 
unit (Techne Incorporated, Princeton, NJ) was used. Band intensities were quantified 
using AlphaImager software. 
VI.10 Real-time PCR  
The cDNA was used to run real-time PCR using RT2 Real-timeTM gene 
expression kit and primer sets for mouse procollagen type Iα1 (NCBI RefSeq Accession 
# NM 007742) amplifying 122 bp fragments and mouse ICAM-1 (NCBI RefSeq 
Accession # NM 010493) amplifying 185 bp fragments. Glyceraldehyde-3-phosphate 
dehydrogenase (Gapd; NCBI RefSeq Accession # NM 008084), a ubiquitous gene was 
used as housekeeping gene (two primer sets amplifying 203 and 128 bp fragments) 
(Superarray, Frederic, MD). SYBR green was used to quantify double-stranded DNA. 
The reactions were carried out under the following conditions: hot start for 15 minutes at 
94oC, denaturation at 94oC for 30 seconds, annealing at 56oC for 30 seconds, extension 
at 72oC for 30 seconds in 40 cycles and final extension at 72oC for 7 minutes, followed 
by melting curve between 45-100oC in 1oC increments for 10 seconds. The 
quantification was based on the ratio between the gene of interest detected in the treated 
and untreated animals, standardized to the housekeeping gene [291]: 
][2 controlsample CpCpratio ∆−∆−=  (VI.1) 
where ∆Cpsample is the Cp deviation of untreated–treated of the target gene transcript; 
and ∆Cpcontrol is the Cp deviation of untreated–treated of the reference gene transcript.  
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 The increase or decrease in the mRNA levels of the genes of interest was expressed as 
percentage of the control animals: 
         (VI.2) 100% ratioxchange =
To confirm the size of the product, the fragments were separated by 2% agarose 
gel electrophoresis at 10 V/cm voltage. 
VI.11 Fluorescence activated cell sorting (FACS) 
PAM 212 cells were seeded on 6-well plates (Costar, Corning, NY) at 1x106 
cells/well density and grown to 60-80% confluency. The supplemented MEM was 
changed to MEM one hour prior to transfection. The transfection mixtures were 
prepared with 1 µg pGTmCMV.IFN-GFP, using the 16-3-16 gemini surfactant at 5, 10, 
20 or 40 +/- charge ratios, as described earlier, keeping the concentration of the reagents 
constant. The supernatants were collected and stored at -20oC. The cells were detached 
using Versene solution containing 0.05% trypsin (Sigma), centrifuged at 4oC and 1000g 
for 5 minutes, washed twice with PBS and resuspended in Fa-cola (PBS with 0.2% 
gelatin and 0.03% Na azide). Triplicate samples were pooled. The cell sorter was 
calibrated with non-transfected cells and 104cells were counted of each sample. 
VI.12 Microscopy 
VI.12.1 Fluorescent, light and confocal microscopy 
 Cells were grown in 24-well plates on cover slips and transfected with plasmids, 
as described. Twenty-four hours after transfection, the cells were washed twice with 
PBS and mounted on cover slips. Skin samples snap-frozen in liquid nitrogen were 
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 embedded in Tissue-Tek O.C.T. Compound (Canemco), and cut in 7 µm thick sections. 
They were mounted on poly-D-lysine-coated microscope slides. Phase contrast and 
fluorescent images were registered using an Axiovert 200M inverted microscope (Zeiss, 
Germany), with LD-A Plan 40X objective lens. The excitation and emission 
wavelengths for GFP were 488 nm and 507 nm, respectively (FITC filter). 
Autofluorescence was detected with a rhodamine filter (excitation at 570 nm, emission 
at 590 nm). Confocal one-photon images were collected from whole skin biopsies using 
an argon ion laser source and a Zeiss LSM410 microscope. A baseline measurement 
(autofluorescence) was performed at a 488 nm excitation wavelength and a 630-680 nm 
emission band, and the laser intensity adjusted. GFP fluorescence was measured using 
the same settings with a 514-560 nm band filter. The two obtained images were merged. 
The skin samples for light microscopy were fixed in 4% paraformaldehyde solution and 
embedded in paraffin. Sections of 7 µm thickness were stained with hematoxylin-eosine. 
VI.12.2 Atomic force microscopy (AFM) 
Atomic force microscopy images were obtained using a Pico SPM instrument 
(Molecular Imaging Inc., Tempe, AZ), with MAC-mode, and MI MAC cantilever type II 
(K=1.2-5.5N/m). The PG complexes were spread on the surface of freshly cleaved mica 
(Grade V-4, SPI Supplies, West Chester, PA), and incubated for 30 seconds or 15 
minutes at room temperature. The PGL systems, topical nanoparticles or nanoemulsion 
(10 µL each) were spread on the surface of freshly cleaved mica, and incubated for 15 
minutes at room temperature. The excess formulation was removed with lint free 
absorbent tissue, and the surface dried with N2. A 4x4 µm area was scanned for the PGL 
systems, and nanoemulsion, and a 35x35 µm area for the topical nanoparticles. 
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 VI.12.3 Transmission electron microscopy (TEM) 
Transfection mixtures and topical formulations were prepared as described 
earlier. Carbon coated 300-mesh copper grids were discharged with UV light for 10 
minutes prior to use. A 20 µL aliquot of sample was dropped on the grid and incubated 
for 15 seconds. The liquid was blotted with absorbent tissue. The specimens were 
stained with either 1% phosphotungstic acid (PTA) or 2% uranyl acetate (UA) for 15 
seconds, and blotted with tissue. The dried samples were examined with a Philips CM 
10 electron microscope at an accelerating voltage of 60 kV, and pictures taken on 3 ¼” x 
4” Kodak Electron Microscope Film 4489. 
VI.13 Dye-binding assay 
 Plasmid pGTmCMV.IFN-GFP (final concentration of 20 µg/mL) was complexed 
with the gemini surfactants at a +/- charge ratio of 10 in the presence or absence of 
DOPE as described for in vitro transfection on 96-well plates, with samples prepared in 
triplicates. Ethidium bromide (Sigma) was added to the samples at 0.1 µg/mL final 
concentration. The samples were incubated for 10 minutes at room temperature. 
Fluorescence excitation was carried out at 530 nm and emission measured at 590 nm 
using a BioTek FL600 plate reader (BioTek Instruments, Winooski, VT). The relative 
fluorescence of the PG complexes was expressed as a percentage of the fluorescence of 
a 20 µg/mL plasmid solution. The fluorescence of the PGL systems was compared to a 
plasmid–DOPE mixture. 
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 VI.14 Circular dichroism (CD) 
 Aqueous gemini surfactant solutions and the DOPE suspension were prepared as 
for in vitro transfection and degassed at 37oC in a bath sonicator. Plasmid 
pGTmCMV.IFN-GFP (20 µg/mL) and gemini surfactant were mixed at a +/- charge 
ratio of 10 using water or DOPE liposomes as a vehicle. The samples were incubated for 
10 minutes at room temperature before measurements were carried out. Spectra were 
obtained by using an Applied Photo Physics π* 180 instrument (Leatherhead, UK) with 
a 1 nm slit, at 37oC.   
VI.15 Size and ζ-potential measurement by dynamic light scattering (DLS) 
An aqueous solution of pGTmCMV.IFN-GFP plasmid was prepared at 500 
µg/mL concentration. The transfection mixture with the pGTmCMV.IFN-GFP plasmid 
(20 µg/mL final concentration in the formulation), gemini surfactants (charge ratios of 
+/- 0.1 to 10) and DOPE vesicles was prepared as described earlier for transfection of 
PAM 212 keratinocytes. A control mixture was prepared by replacing the plasmid DNA 
with water. Topical nanoparticle and nanoemulsion formulations of the 
pGTmCMV.IFN-GFP plasmid (500 µg/mL) using the 12-3-12, 16-3-16, 18:1-3-18:1 
gemini surfactants and Dc-chol were prepared as described under “Topical 
formulations”. Blank formulations without plasmid were also prepared. The size of the 
particles was measured with a Nano ZS instrument (Malvern Instruments, 
Worcestershire, UK). Samples were run in triplicates, and represented as average ± SD. 
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 VI.16 Small angle X-ray scattering (SAXS) 
Transfection mixtures were prepared as for in vitro transfection experiments and 
concentrated 5 times under vacuum to a final DNA concentration of 200 µg/mL. Topical 
nanoparticle, and nanoemulsion formulations were prepared, similar to samples 
described above in the “Topical formulation” section. Samples were loaded into 1.5 mm 
borosilicate capillaries (Charles Supper, Natick, MA). Stratum corneum isolated from 
human skin was incubated with topical nanoparticles and nanoemulsion at 4oC for 24 
hours. The samples were rinsed three times with 400 µL purified water (Gibco) and 
introduced in borosilicate capillaries. Scattering was measured for 15-30 seconds using 
the synchrotron light source (Beam X21A, National Synchrotron Light Source, 
Brookhaven, NY). Beamline X21 is based on a wiggler source, with a helium gas-cooled 
Si(111) monochromator selecting the photon energy. The X-ray beam was focused by a 
toroidal mirror into the experimental station. Three pairs of precision slits, positioned at 
4 m, 1 m, and 5 cm upstream of the sample, defined the beam. The scattering pattern 
was recorded using a 13 cm Mar CCD detector (Mar USA, Evanston, IL) at 1.26 m 
(calibrated with the scattering pattern of Ag-behenate) downstream of the sample. The 
measurements were performed with 12KeV X-rays and the data covered a q-range from 
0.008 Å-1 to 0.5 Å-1. All beam paths were under vacuum, except at the sample position, 
where the sample was in air. Kapton windows terminated the vacuum beam paths. The 
data were recorded at room temperature.  All spectra were processed to remove 
background contributions by subtracting the scattering profile obtained for a capillary 
containing water only. The scattering profiles obtained for the formulation-treated 
stratum corneum have been analyzed using PRIMUS and PEAK software obtained from 
the EMBL Biological X-ray Scattering Group in Hamburg, Germany [292] 
97 
 (http://www.embl-hamburg.de/ExternalInfo/Research/Sax/). The radial averaged data 
files of samples were input into the PRIMUS program and the DNA solution file was 
used as background correction for each data file. The background corrected data were 
then used as input files in the PEAK program using 1.24 as the X-ray wavelength. The 
features observed were fit as separate peaks and the structural parameters associated 
with the peak obtained directly from the fit. The results of this fit are (1) the d-spacings 
(d):  
 
max
2
q
d π=  (VI.3)  
where qmax is the position of the peak maximum, (2) the long range order parameter 
(L):  
 θβ
λ
cos
=L  (VI.4) 
where λ is the wavelength of the incident X-rays, θ is the scattering angle corresponding 
to qmax, and β is the full width at half max of the peak (in radians), and (3) the degree of 
disorder (∆/d): 
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VI.17 Statistics 
Statistical analysis was done with SPSS 13.0 software, using ANOVA (Tukey’s 
multiple comparison test), non-parametric analysis (Kruskal-Wallis test) and Pearson’s 
correlation. Significant differences between the experimental groups were established at 
the p<0.05 level of significance. 
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 VII. RESULTS AND DISCUSSION 
VII.1 Plasmid constructs and evaluation of their in vitro transfection efficiency  
 In the first phase of this project, a suitable plasmid encoding IFN-γ was 
constructed. Initially, several plasmids were designed and constructed, based on the pGT 
backbone, CMV promoters and the two genes of interest (IFN-γ and GFP). The plasmids 
were characterized and tested in vitro with Lipofectamine Plus, a commercial 
transfection agent, in order to evaluate differences caused by the nature of the backbone 
and promoters. The expression of the IFN-γ was quantified by ELISA and antiviral 
assay (in order to verify bioactivity) and the GFP was identified by fluorescence 
microscopy. 
VII.1.1 Plasmid constructs 
 The different vectors used for the initial selection exhibit different features 
(Table VII.1). The promoter region for the pSLRSV contains the Rous sarcoma virus 
(RSV) promoter. The pIRES and pGT plasmids contain the human cytomegalovirus 
(hCMV) promoter, while the pGTmCMV contains the murine CMV (mCMV). All 
plasmids contain a bovine growth hormone polyadenylation signal (polyA) and an origin 
of replication (Ori) for propagation in E. coli. The antibiotic resistance site (ABR), 
ampicillin (Amp) for pSLRSV and kanamycin (Kan) for the other vectors, ensures 
clonal selection.  
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 Table VII.1.  Characteristics of the cloned plasmids. 
Plasmid Promoter Gene(s) IRES PolyA Ori ABR Source 
pSLRSV RSV Null  No Yes Yes Amp Gift (VIDO) 
pSLRSV RSV IFN-γ No Yes Yes Amp Gift (VIDO) 
 
pIRES.GFP hCMV GFP Yes Yes Yes Kan Clontech 
pIRES.IFN-GFP hCMV IFN-γ, 
GFP 
Yes Yes Yes Kan Cloned 
pGT hCMV Null  No Yes Yes Kan Gift (VIDO) 
pGT.IFN hCMV IFN-γ No Yes Yes Kan Cloned 
pGT.IFN-GFP hCMV IFN-γ, 
GFP 
Yes Yes Yes Kan Cloned 
 
pGTmCMV mCMV Null  No Yes Yes Kan Cloned 
pGTmCMV.IFN mCMV IFN-γ No Yes Yes Kan Cloned 
pGTmCMV.IFN
-GFP 
mCMV IFN-γ, 
GFP 
Yes Yes Yes Kan Cloned 
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  The gene for IFN-γ is inserted in all plasmids with the appropriate ligation to the 
multiple cloning sites (MCS). IRES was inserted into the pIRES, pGT and pGTmCMV 
vectors. The IRES sequence is a feature of picornaviruses such as encephalomyocarditis 
virus (ECMV), and initiates mRNA translation at this site [293]. In eukaryotic cells, 
translation occurs by the scanning mRNA from the 5’ end until an initiation codon is 
reached, thus one expression cassette allows the expression of one gene. If the IRES 
sequence is inserted into the expression cassette of a vector after the stop codon of the 
first open reading frame (ORF), the ribosomes attach to the mRNA at the 5’ end and the 
IRES site, translating the two ORFs simultaneously, eliminating the need of co-
transfection of the cells with two different vectors. The two proteins are not fusion 
products, thus their biological function is unaltered. Therfore, the pGTmCMV.IFN-GFP 
plasmid (Figure VII.1), containing the genes coding for IFN-γ and GFP in such a 
bicistronic system was constructed as described in the “Materials and methods” section. 
 The murine cytomegalovirus promoter was obtained from pLMCMVgDt plasmid 
by PCR, having the two primers designed in such way that the promoter included a Kpn 
I and a Pst I site. The IFN-γ gene was obtained by restriction digest with Bgl II from the 
pSLRSV.IFN plasmid [294], which contained the sequence coding for 155 amino acids 
of murine IFN-γ. The gene was inserted into the MCS of the pIRES.GFP vector at the 
Bgl II–BamH I site. The plasmid was grown in dam-/dcm- E.coli and the IFN-γ–IRES–
GFP coding sequence cut with Bgl II and Xba I. The pGTmCMV plasmid was obtained 
by replacing the human CMV promoter in the pGT vector with the murine CMV 
promoter. 
101 
  
 
 
Figure VII.1.  pGTmCMV.IFN-GFP plasmid.   
The genes coding for IFN-γ and GFP, in a bicistronic system, were inserted into the Bgl 
II–Xba I site of the pGTmCMV vector. The pGTmCMV plasmid was obtained by 
replacing the human CMV promoter in the pGT vector with the murine CMV promoter. 
The plasmid also features bovine growth hormone polyadenylation sequence (BGHpA), 
Col E1 plasmid replication region (ori) and the selection marker in E. coli host of 
kanamycin resistance (KanR).   
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  The pGTmCMV.IFN-GFP was constructed by inserting the IFN-γ–IRES–GFP 
fragment into the Bgl II–Xba I site of the pGTmCMV vector. All structures were 
verified by restriction digest and agarose gel electrophoresis. As a result of the 
preliminary testing of the intermediary plasmids in PAM 212 cells, the plasmids used for 
in vitro and in vivo experiments were the plasmids containing the murine CMV promoter 
(pGTmCMV) and the coding plasmid derived from this vector, pGTmCMV.IFN-GFP. 
There are several benefits for using this plasmid. The backbone is designed for gene 
therapy, with the immunogenic CpG motifs removed, thus it could be used for a 
sustained period without triggering immune reactions. The species-specific mCMV 
promoter features a strong enhancer region [288], thus it could yield strong gene 
expression in the murine keratinocytes PAM 212 and in the skin of different mouse 
strains. The IRES sequence permits co-expression of two individual proteins. According 
to the literature, IL-7 and the low-affinity nerve growth factor receptor (LNGFr) gene 
were both expressed in cells transfected with a bicistronic system [295]. In our case, the 
expression of the two genes allows both quantification of the therapeutic protein, IFN-γ, 
and localization of gene expression at the cellular and tissue level of the marker protein 
GFP. Two other plasmids, the pGT and pGT.IFN-GFP plasmids were kept as back-up 
plasmids. 
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 VII.1.2 Evaluation of gene expression 
VII.1.2.a IFN-γ expression assessed by ELISA 
The expression of the IFN-γ gene was tested in PAM 212 murine keratinocyte 
cell culture. ELISA of the cell supernatants showed high expression of IFN-γ 24 hours 
after transfection with pGTmCMV.IFN-GFP plasmid, compared to the null plasmid 
(Figure VII.2).   
 The pGT backbone (in pGT.IFN and pGTmCMV.IFN plasmids) increased the 
IFN-γ expression significantly (p<0.05) compared to the pSLRSV backbone 
(pSLRSV.IFN) and the pIRES vector (pIRES.IFN-GFP). The highest transfection 
efficiency was observed with the pGTmCMV.IFN-GFP plasmid (158±5 ng IFN-γ/5x104 
cells, n=3). No significant differences were noted between using the CMV promoter of 
human or murine type. No IFN-γ was secreted by the cells transfected with the null 
plasmids. IFN-γ expression was sustained and could be detected at 48 hours, which is 
significant given the short biological half-life of the protein, 0.5 and 4.5 hours (biphasic 
elimination) for murine recombinant IFN-γ [296].  
VII.1.2.b Biological activity of the IFN-γ  
 IFN-γ inhibits multiplication of several DNA and RNA viruses in host 
organisms. Contrary to the IFN-α family, which inhibits mRNA translation, IFN-γ can 
block viral replication at the transcriptional level [297].  
 The biological activity of the IFN-γ was tested by antiviral assay. The EMC virus 
infected the L929 cells, causing cell lysis (Figure VII.3 Panel L929-EMC). 
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Figure VII.2.  IFN-γ expression in PAM 212 cells. 
Cells were transfected with 0.2 µg of the following plasmid constructs: pSLRSV, 
pSLRSV.IFN, pIRES.GFP, pIRES.IFN-GFP, pGT, pGT.IFN, pGT.IFN-GFP, 
pGTmCMV, pGTmCMV.IFN and pGTmCMV.IFN-GFP, using Lipofectamine Plus 
Reagent. 
Results are shown as mean (n=3), error bars represent standard deviation.  
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  Addition of IFN-γ expressed from pGTmCMV.IFN-GFP by transfection of PAM 
212 cells prevented cell death in a concentration-dependent manner (Figure VII.3, top 
row). The IFN-γ concentration in the supernatant was 240±79 ng/mL (~140 
ng/5x104cells, n=3), compared to null plasmid where no activity could be detected 
(results not shown). The detected quantity was consistent with the ELISA assay. When 
the IFN-γ was blocked with the monoclonal antibody XMG1.2 against IFN-γ activity, no 
cytoprotective activity was detected (Figure VII.3, bottom row). Antiviral assay 
confirmed that the IFN-γ gene inserted into the pGTmCMV vector was expressed, and 
able to exercise biological activity (i.e., cytoprotection against viral infection) in cell 
culture.  
VII.1.2.c GFP expression by fluorescence microscopy 
 The GFP expression followed the pattern of IFN-γ expression, with the cells 
transfected with pGTmCMV.IFN-GFP presenting stronger fluorescence than those 
transfected with pIRES.IFN-GFP (data not shown). The null plasmids did not show any 
fluorescence even though cells were exposed to a 3-times more intense beam than the 
GFP-coding plasmids. Figure VII.4 shows the merged images of cells transfected with 
pGTmCMV.IFN-GFP (Figure VII.4A) and pGTmCMV (Figure VII.4B). 
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Figure VII.3.  Phase contrast micrographs of L929 cells infected with EMC virus 
and protected by IFN-γ. 
Top row: supernatants from cells transfected with pGTmCMV.IFN-GFP in two-fold 
serial dilutions from left to right, starting at 1/10 dilution (L20-10) to 1/1280 dilution 
(L20-1280). Cell viability decreases with increasing dilution. 
Middle row: IFN-γ standard two-fold dilution from 2000 pg/mL (STD2000) to 31.2 
pg/mL (STD31.2) 
Bottom row: untreated cells (L929), cells infected with EMC virus (L929-EMC), and 
cells treated with supernatant from cells transfected with pGTmCMV.IFN-GFP in 1/10 
dilution, blocked with XMG1.2 antibody (L22-10-ab). 
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igure VII.4.  Fluorescence microscopic evaluation of the GFP expression in PAM 
12 cells. 
ells were transfected with 0.2 µg pGTmCMV.IFN-GFP plasmid (A) or 0.2 µg 
GTmCMV plasmid (B) using Lipofectamine Plus Reagent. Phase contrast micrographs 
ere overlaid on fluorescent micrographs. GFP expression can be seen only in the cells 
ransfected with the plasmid containing the GFP-gene (Panel A). 
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 VII.1.3 Conclusions 
 Murine PAM 212 keratinocytes were used as an in vitro model for cutaneous 
gene delivery in mice. Both genes, IFN-γ and GFP, inserted into the pGTmCMV 
plasmid are expressed in PAM 212 cells, using Lipofectamine Plus reagent. Quantitative 
measurement and biological activity of the generated IFN-γ were demonstrated by 
ELISA and antiviral assay. The extent of expression was dependent on the nature of the 
backbone. The pSLRSV and pIRES backbones were less efficient than the pGT 
backbone. The highest IFN-γ expression was observed with the pGT and pGTmCMV 
vectors. Replacement of the human CMV (hMCMV) promoter with murine CMV 
(mMCMV) promoter was also beneficial in the case of the bicistronic systems. The 
pGTmCMV.IFN-GFP plasmid was selected for further experiments. 
VII.2 Formulation development and physicochemical characterization of the in vitro and 
in vivo delivery systems  
A series of gemini surfactants (Figure VI.1) with different alkyl chain (m=12, 16 
or 18:1C) and spacer lengths (n=3-16) (Table VI.1) were synthesized and characterized 
in collaboration with Dr. Verrall’s group (Department of Chemistry, University of 
Saskatchewan), and were tested for transfection efficiency using the pGTmVMV.IFN-
GFP plasmid coding for IFN-γ and GFP.  
VII.2.1 Physicochemical characterization of the PG complexes and PGL systems 
used for the in vitro transfection 
 In order to characterize the in vitro delivery systems, three aspects were 
explored: (1) the morphology, size distribution and ζ-potential of the PG complexes and 
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 PGL systems, (2) structural modifications of the plasmid DNA caused by the delivery 
systems, and the effect of the gemini surfactant alone or in the presence of helper lipid 
and (3) structural phase behaviour of gemini surfactants and helper lipid and 
modifications induced by the DNA in the lipid packing. The first characteristic can 
provide information on the overall structure of the delivery systems, differences or 
similarities among formulations containing various surfactants and comparison of the 
structure of the PG complexes to the PGL systems, while the second and third 
characteristics can evaluate the interaction between the DNA and delivery system and 
indicate what features are important for efficient gene delivery.    
VII.2.1.a. Characterization of the PG complexes and the PGL systems: 
morphology, size and charge  
Selected PGL systems at a +/- charge ratio of 10 were viewed with TEM (Figure 
VII.5). In all three formulations, the particle size is heterogeneous. Most of the particles 
(probably single vesicles) had a maximum dimension of 100-200 nm, indicated by solid 
arrows. Aggregated particles of 300-600 nm could be seen in all formulations (open 
arrows). No free DNA strands were visualized by the negative staining. The aggregates 
are smaller for the P–12-3-12–L systems (Figure VII.5A) and larger for the P–18:1-3-
18:1–L systems (Figure VII.5C). The pattern and distribution of the P–16-3-16–L 
systems visualized by TEM (Figure VII.5B) was similar to that obtained by AFM 
(Figure VII.7D). The AFM image shows small (~100nm) uniform particle-like 
structures and larger (400-600nm) vesicle-like features.  
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Figure VII.5.  Transmission electron micrograph of PGL systems negatively 
stained with 1% phosphotungstic acid.  
A— Vesicles prepared with the 12-3-12 gemini surfactant 
B— Vesicles prepared with the 16-3-16 gemini surfactant 
C— Vesicles prepared with the 18:1-3-18:1 surfactant 
Solid arrows indicate single vesicles, while open arrows point to larger aggregates. 
Bar represents 500 nm. 
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 Morphological heterogeneity of transfection agents was addressed by Zabner et al. [39]. 
Electron micrographs of DNA–DMRIE–DOPE lipoplexes (weight ratio of 1:5 
DNA/DMRIE) show that highly compacted dense particles of ~100 nm were present 
together with free DNA, partially complexed DNA and large aggregates of >500 nm. 
These lipoplexes were able to transfect cells in vitro, thus homogeneous structural make-
up of the transfection agent is not necessary. Moreover, it has been shown that 
heterogeneous MLVs formed with cationic DOTAP induced higher transgene expression 
compared to large unilamellar vesicles (LUVs) [142].  Size measurements were carried 
out by using dynamic light scattering (Table VII.2). The measured average sizes of the 
PG complexes and PGL systems were approximately 100 nm and 150-200 nm, 
respectively, consistent with the size of individual particles visualized using TEM. The 
size of the PG complexes was smaller for all surfactants compared to PGL systems. The 
distribution was monomodal (average polydispersity index of 0.173±0.06), thus no large 
aggregates were present in the formulations. The absence of the 400-600 nm particles 
could be the result of the repulsion of the similarly charged particles and uniform spatial 
distribution in the liquid environment. To obtain a realistic image of both size and 
morphology of the particles, the three methods, TEM, AFM and DLS, have to be 
interpreted together. While the TEM and AFM imaging reveal the morphology of the 
particles, they also indicate that the particles aggregate on the substrate surfaces. On the 
other hand, DLS provides accurate information on the hydrodynamic diameter of a 
sphere that has the same translational diffusion coefficient as the particle, but the shape 
and morphology are not revealed by this method. High efficiency cationic lipid-based 
delivery agents of various sizes have been described in the literature. The particle sizes 
have ranged from 50-70 nm for DODAC containing self-assembling lipid-DNA particles 
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 [298] to over 4 µm aggregates for a monocationic lipid (YKS-220)–DOPE system [299]. 
The particle sizes of the PGL systems reported here,150-200 nm, fall in the middle of 
this range. It has been shown that small particle size is not a crucial criterion for high 
efficiency cellular uptake and heterogeneous morphology and the ability of the particles 
to form larger aggregates does not seem to hinder their transfection efficiency [39, 300]. 
Based on the observed morphology and particle sizes, the mechanism of uptake for the 
PGL systems could be a mixture of endocytosis [39, 138] (favouring the 100-200 nm 
particles) and fusion with the cell membrane [44, 137] (due to the presence of the 
fusogenic DOPE, heterogeneous morphology and the ability of the particles to 
aggregate). In conclusion, heterogeneous morphology including particle-like and 
vesicular structures was observed, with a size distribution of 100-200 nm.  
 ζ-potential measurements indicated electrostatic interactions between the gemini 
surfactants and plasmid DNA since the negative potential of the DNA (-47 mV) shifted 
to positive values of  +30-50 mV. Generally, the ζ-potential of the PGL systems is 
higher compared to the PG complexes with the exception of the 12-16-12 and 16-3-16 
surfactants. The 35-45mV values for the PGL systems indicate the presence of high 
repulsive forces among the particles that icreases the stability of the system. It has been 
indicated that the coagulation of particles in colloidal systems occur when the ζ-potential 
is reduced below a critical value (20-50 mV) [301]. The generally higher ζ-potential of 
the PGL systems compared to the PG complexes is due to the  microenvironment 
created around PG particles upon addition of the amphipatic DOPE [302]. 
Measurements of the ζ-potential at various +/- charge ratios indicated that neutralization 
of the particles occurred at +/- charge ratios <1 (Figure VII.6).  
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 Table VII.2.  Size and ζ-potential measurement of PG complexes and PGL systems.  
Size (nm) ζ-potential (mV) Gemini 
Surfactant PG PGL PG PGL 
12-n-12 series     
12-3-12 137±31 143±21 15±1.6 40.6±4.8 
12-4-12 146±44 154±15 16.4±1.7 42.5±3.4 
12-6-12 153±49 155±16 23.2±6.5 39.21±6.75 
12-8-12 125±27 153±15 20.7±3.2 37.55±3.18 
12-10-12 85±7 158±14 26.5±3 43.19±6.68 
12-12-12 103±17 158±13 29.8±7.7 42.23±0.93 
12-16-12 119±16 161±11 54.8±5.4 37.13±9.39 
m-3-m series     
12-3-12 137±31 143±21 15±1.6 40.6±4.8 
16-3-16 219±75 210±29 58.3±1.5 44.2±4.4 
18:1-3-18:1 161±45 214±59 19.3±0.2 45.2±3.6 
DNA N/A 111±4 -47.1±15.1 -26.4±2.7 
 
 
0.1 1 10
-40
-20
0
20
40
60
 plasmid/18:1-3-18:1/DOPE
 plasmid/16-3-16/DOPE 
 plasmid/12-3-12/DOPE
Ze
ta
 P
ot
en
tia
l (
m
V
)
Charge ratio
 
Figure VII.6.  ζ-potential measurement of selected PGL systems at various +/- 
charge ratios.  
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  The difference in the neutralization pattern of the 12-3-12 vs. the 16-3-16 and 
18:1-3-18:1 surfactants might be due to its higher CMC. Comparison of the ζ-potential 
of several cationic lipids, having double C12 to C18 tails and single head groups having 
1, 2, 3 or 5 net positive charges, revealed that transition from overall negative to positive 
charges occurred at charge ratios of 1.25 to 1.75 for all compounds [303].  
Gemini surfactants, on the other hand, are able to neutralize particles at charge 
ratios < 1, indicating a better “utilization” of charges because of the fixed distance 
between the two nitrogen centers, leading to more efficient ionic interaction.  
VII.2.1.b. Characterization of the interactions between the plasmid and gemini 
surfactants and the influence of the helper lipid DOPE on the nature of 
complexes. AFM, CD and dye binding evaluation 
Gemini surfactants rapidly bind plasmid DNA as demonstrated here using naked 
DNA and 16-3-16 surfactant on a mica surface (Figure VII.7). The DNA is represented 
as open circular or loosely coiled strands (Figure VII.7A). Within 30 seconds, a bead-
on-string-like structure formed (Figure VII.7B) followed by formation of more compact 
structures of ~100 nm within 15 minutes (Figure VII.7C). Recent AFM studies by 
Miyazawa et al. revealed that gemini surfactants, namely the 12-3-12 surfactant, induced 
rings-on-a-string chain formation in the linear DNA macromolecule, alternating the 
ordered “rings” with disordered “strings” in a concentration-dependent manner. The 
number of formed rings and the size of the rings were determined by the balance 
between the entropy associated with the formation of the rings and the bending energy. 
High concentration of surfactants (above 10 µM) caused fusion of the rings collapsing 
the DNA into a compact structure [304]. 
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Figure VII.7.  Atomic force microscopy images showing plasmid DNA compaction 
by the gemini surfactant 16-3-16 on freshly cleaved mica surface.  
A – Naked DNA. A 20 µg/mL plasmid solution applied on the mica surface was 
incubated for 2 minutes before imaging;  
B – PG complex formation. A 20 µg/mL plasmid solution applied on the mica surface 
was incubated for 2 minutes. The 16-3-16 gemini surfactant solution was added to the 
DNA in situ and incubated for 30 seconds before imaging;  
C – PG complex formation. A 20 µg/mL plasmid solution applied on the mica surface 
was incubated for 2 minutes. The 16-3-16 gemini surfactant solution was added to the 
DNA in situ and incubated for 15 minutes before imaging;  
D – P–16-3-16–L system.  
Bar represents 400 nm. 
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   We observed similar behaviour of the plasmid DNA in a time-dependent manner. 
In our case, the 30-second incubation time probably enabled only limited DNA-gemini 
surfactant interaction, corresponding to low local concentrations of the surfactant, 
whereas the longer incubation permitted accumulation of the 16-3-16 surfactant on the 
surface of the DNA and compaction into small particles. Addition of DOPE to the 
system further modified the morphology (Figure VII.7D), yielding a more 
heterogeneous composition of small complexes and larger (2-3 µm) vesicles. 
 Circular dichroism provides information on the helical conformation of the 
double-stranded DNA. Cationic lipids bind the native B-form of the DNA and induce 
secondary structure formation, which reduces the number of basepairs/turn from 10 to 
9.33, characteristic for C-form DNA [305]. Increase in the +/- charge ratio causes 
condensation of the DNA into Ψ– DNA, a left handed highly organized tertiary structure, 
characterized by an increase of the negative signal of the CD spectra [306].  The 
spectrum of the plasmid DNA in water presented two positive peaks at 260 and 290 nm 
(Figure VII.8A and B). The gemini surfactants, upon interaction with the native DNA 
induced changes in the CD spectrum, causing a blue shift in the 290 nm peak, and 
depression of the 260 nm peak into the negative region (Figure VII.8A), indicating the 
appearance of C-form DNA. The degree of depression was dependent on the spacer and 
tail length. Short and long spacers, n=3 and 16, caused deeper shifts of the 260nm peak 
compared to the intermediate spacer, n=8. The 16-3-16 surfactant (m=16 tail) induced a 
higher degree of depression compared to the 12-3-12 surfactant (m=12 tail). Addition of 
DOPE to the PG complexes further increased the interhelical interactions inducing Ψ–
DNA formation (Figure VII.8B), indicated by an increase of the overall negative signal 
due to the flattening of the 290 nm peak, in addition to the shift of the 260 nm positive 
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 peak into the negative region in a structure-dependent manner. DOPE alone in the 
absence of the gemini surfactants could not cause disappearance of the 290-nm peak, but 
caused a shift of the 260 nm peak into the negative region. This shift might be the result 
of enhancement of the counterion release by DOPE on the DNA surface [307]. Figure 
VII.8C illustrates the degree of depression caused by PGL systems containing 12-n-12 
series gemini surfactants. Generally, the depression was more pronounced for 
surfactants with short and long spacers compared to intermediate spacers. Monocationic 
lipids such as DDAB, DOTAP and DMRIE and polyvalent DOSPA could also induce 
formation of Ψ– DNA in the presence of DOPE [131, 306]. Simberg et al. demonstrated 
that formation of the compact Ψ– DNA is necessary for efficient gene delivery [131].  
 DNA gemini surfactant interaction and compaction of the polynucleotide was 
evaluated by fluorescent dye exclusion. Ethidium bromide can freely intercalate between 
the DNA base-pairs, resulting in a marked increase in fluorescence due to the 
hydrophobic environment that slows down the excited-state proton transfer rate. Dye 
binding can occur due to the flexibility of the native DNA and causes helical dislocation 
of ~1 Å [308]. The double-stranded DNA is considered saturated at a 1:4 dye to basepair 
ratio. Cationic lipids compact DNA and reduce its flexibility, thus preventing 
intercalation of the ethidium bromide between the base-pairs [309]. This causes a 
reduction in fluorescence intensity compared to naked DNA.  
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Figure VII.8.  Circular dichroism spectra of the pGTmCMV.IFN-GFP plasmid in 
water and selected PG complexes and PGL systems. 
A – CD spectra of pGTmCMV.IFN-GFP plasmid 20 µg/mL in water (solid diamond), 
and selected PG complexes 
B – CD spectra of pGTmCMV.IFN-GFP plasmid 20 µg/mL in water (solid diamond), 
PG (solid rectangles) and PGL systems  
C – Degree of depression of the 260 nm peak of the pGTmCMV.IFN-GFP plasmid (20 
µg/mL in water) by the PGL systems of the 12-n-12 gemini surfactants  
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  Gemini surfactants electrostatically bind the plasmid DNA causing a collapse of 
the helical structure into a compact particle. Upon addition of ethidium bromide, 
fluorescence is quenched due to the inability of the dye to penetrate between the 
nucleotides. The better the shielding of the DNA by the cationic gemini surfactant, the 
more pronounced the fluorescence quenching.  
 Titration of the plasmid DNA with selected gemini surfactants in the presence of 
DOPE (Figure VII.9A) indicated that the fluorescence quenching is concentration-
dependent. At low +/- charge ratios of 0.1-1, fluorescence quenching is minimal for all 
surfactants. At a +/- charge ratio of 1.25, the fluorescence increases abruptly, due to the 
increase in the turbidity of the system. The fluorescence reached the lowest point at a +/- 
charge ratio of 10, and remained unchanged at ratios of 20 and 40. The fluorescence 
intensity at a +/- charge ratio of 10 was reduced by 75-90%, indicating a strong shielding 
of the DNA by the gemini surfactants. In similar conditions, DOTAP-DOPE and 
DOTAP-cholesterol complexes reduced the fluorescence by only 55-65%, albeit at a +/- 
charge ratio of 4 [309]. The better shielding of the DNA by the gemini surfactants 
compared to the monovalent DOTAP could provide better protection against 
endonucleases, increasing the transfection efficiency of these compounds. 
 For the 12-n-12 series at a +/- ratio of 10, the fluorescence increases as the 
intermediate spacer lengths increase (FigureVII.9B), indicating that molecules with 4, 6 
and 8 carbons are less able to prevent dye penetration into the DNA. Fluorescence 
values were higher for the PGL systems, probably due to slight turbidity of the samples. 
Fluorescence quenching of the 12-n-12 series surfactants was dependent on the CMC 
(Pearson correlation of 0.901 at p=0.006 level of significance). For the PG complexes of 
the m-3-m series, increasing tail length induced higher levels of fluorescence quenching  
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Figure VII.9.  Fluorescent dye binding assay.  
pGTmCMV.IFN-GFP plasmid was complexed with gemini surfactants at various charge 
ratios and mixed with DOPE. Fluorescent marker, ethidium bromide was added to the 
system and the fluorescence intensity was measured.  
A –  Fluorescence intensity measurements of PGL systems prepared with selected 
gemini surfactants at +/- charge ratios of  0.1 to 40 
B – Fluorescence intensity measurements of PG complexes (rectangles) and PGL 
systems (diamonds) prepared with the 12-n-12 gemini surfactants 
C – Fluorescence intensity measurements of PG complexes (rectangles) and PGL 
systems (diamonds) prepared with the m-3-m gemini surfactants 
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 (Figure VII.9C). The variable value for the P–16-3-16–L system was due to the turbidity 
of the sample (Figure VII.9C). 
VII.2.1.c. Characterization of the lipid organization in PG complexes and PGL 
systems from SAXS studies  
 SAXS is a technique that provides structural information (size, shape and 
interaction of the particles) on poorly organized materials such as polymers, proteins, 
lipids, and biological tissues (e.g., muscles, skin) at a 1-15 nm scale (d). These materials 
broadly scatter the incident beam at small angles (usually less than 3-5° for standard 
wavelengths). The requirements for the x-ray beam are low divergence to compensate 
for weak scattering, small cross-sections to reduce distortions, high flux to facilitate 
isolation of scattering at small angles from the direct beam, and tunability of the energy 
level. Contrary to x-ray crystallography of organized materials where the scattering 
planes are parallel and the scattering vector (q) is perpendicular to those planes, in 
SAXS measurements averages of amplitudes are calculated for all secondary waves of 
partially ordered systems. The Bragg peaks indicate the diffuse scattering of these 
various planes. Their positions in q-space reveal the structural organization of the 
material, and the intensity of the peaks (I) is a quantitative measure of the degree of 
organization of the system. Lipid dispersions in aqueous media are characterized by 
structural heterogeneity and are suitable for SAXS analysis. Bragg reflections of these 
systems indicate nanostructural organization into micellar, lamellar, hexagonal or 
various cubic phases. Micellar microemulsions are characterized by a single broad peak 
whose position depends on the water content of the system. Higher water content shifts 
the peak position to lower angles, indicating increasing distances [310]. Inverted 
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 hexagonal phase structure ratios are 1: √3: √4: √7, reflecting the peak positions, while 
lamellar structures show linear ratios of 1:2:3:4 [154]. Cubic lattices show characteristic 
ratios of Bragg reflections depending on the polymorphs (e.g., √2: √3: √4:√6 for Pn3m) 
[311]. The Bragg peak intensities reveal the degree of the lipid organization, i.e., the 
fraction of lipids organized into vesicles, micelles or other structures. The higher the 
degree of organization, the more rigid the systems are, approaching the crystalline form 
of highly organized materials. 
 SAXS measurements of the PG complexes and PGL systems demonstrated 
measurable structural organization. The scattering profile for DNA was virtually 
featureless.  Gemini surfactants alone showed very weak scattering, indicating micellar 
organization, and the gemini surfactant–DOPE mixtures in the absence of the DNA 
indicated a high degree of disorganization (results not shown). For the PG complexes, a 
single sharp peak was observed at q-values of 0.12-0.176, corresponding to a d-spacing 
of 35-52 Å (Figure VII.10A). The addition of the neutral lipid DOPE to the system 
(PGLs) resulted in an increase of structural organization (FigVII.10B). The intensities of 
the main peaks (red arrows) were 2-3 orders of magnitude higher compared to the PG 
complexes. The DNA–DOPE mixtures without the gemini surfactants show hexagonal 
structure, with peak positions at q=0.109, 0.188 and 0.218 (Figure VII.10B). Addition of 
the gemini surfactants caused lamellar phase organization with q-values of 0.105 and 
0.210 for the P–12-3-12–L system and q= 0.098 and 0.194 for the P–16-3-16–L system 
(Figure VII.10B). The position of the main scattering peak corresponds to a d-spacing of 
50-65 Å, consistent with the results presented in literature for lamellar organization 
[141, 160].  However, for short spacers of the 12-s-12 series, multiple structural phases 
appear to be present (Table VII.3). Additional to the lamellar structure, a Pn3m cubic 
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 phase appears in the P–12-3-12–L and P–12-6-12–L systems, characterized by √2: 
√3:√4:√6 periodicity.   
Scattering studies of DNA–cationic gemini surfactant–helper lipid complexes 
demonstrate that both DNA and lipid undergo major conformational changes [133]. 
Tarahovsky et al.[159] demonstrated that complexes assuming lamellar lipid 
organization are able to transfect more efficiently compared to thermolable complexes. 
Conversely, Zuhorn et al. [160] indicate that the presence of hexagonal phase is crucial 
for efficient cellular delivery and endosomal escape of the DNA. Since both lamellar 
and hexagonal structures can facilitate DNA delivery in specific conditions, the ability 
of the system to adopt various phases according to their milieu can promote efficient 
gene delivery. Moreover, addition of DNA to a mixture of two nanoparticle formulations  
induces fusion and lipid reorganization [141]. This indicates that not only the delivery 
system influences the structure of the DNA (e.g., compaction), but also the DNA 
imposes a certain organization of the lipid systems (e.g., polymorphic phases and lipid 
mixing). 
Foldvari et al. [161] have shown that efficient cell transfection can be achieved 
due to the ability of the gemini cationic surfactant/DOPE/DNA systems to adopt 
polymorphic structures coexisting with lamellar phases, like the 12-3-12 and 12-4-12 
surfactants demonstrated here (Table VII.3).  
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Figure VII.10.  Small angle X-ray scattering (SAXS) indicated structural 
differences among PG complexes and PGL system.  
A – Scattering curves of selected PG complexes (12-3-12, 12-8-12 and 12-16-12 and 16-
3-16) show a shift in the position of the main scattering peak, depending on the spacer 
and tail length – intensities are measured on a linear scale.  
B – Scattering profiles of the selected PGL systems (12-3-12, 12-8-12 and 12-16-12 and 
16-3-16) are complex, showing polymorphic structure. Intensities are measured on a 
logarithmic scale. 
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 Table VII.3.  Scattering peak positions and d-spacings for transfection mixtures 
containing DNA (d-values were calculated from single-point measurements). 
 
PG PGL Gemini 
surfactant q (Å-1) d (Å) q (Å-1) Structure d 
(Å)
12-n-12 series      
12-3-12 0.142 44.2 0.105, 0.210 
0.074, 0.092, 0.133 
Lamellar 
Pn3m 
59.8 
12-4-12 0.154 40.7 0.107, 0.214 
0.105, 0.139 
Lamellar 58.5 
12-6-12 0.162 38.8 0.112 
0.086, 0.106, 0.123 
 
Pn3m 
56.2 
12-8-12 0.166 37.8 0.121  51.9 
12-10-12 0.174 36.1 0.113  55.6 
12-12-12 0.176 35.7 0.113  55.6 
12-16-12 0.158 39.8 0.116  54.2 
m-3-m series      
12-3-12 0.142 44.2 0.105, 0.210 
0.074, 0.092, 0.133 
Lamellar 
Pn3m 
59.8 
16-3-16 0.130 48.3 0.098, 0.194  64.1 
18:1-3-18:1 0.120 52.4 0.106  59.3 
DNA Featureless - 0.109, 0.188, 0.218  66.9 
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 VII.2.2 Physicochemical characterization of the topical formulations 
VII.2.2.a. Size and morphology 
 The in vivo formulations were based on the results obtained for cell culture 
experiments and optimized for topical application. Surfactants of the m-3-m series were 
selected for the topical formulations, due to their higher transfection efficiency in vitro 
compared to longer spacers. As a control, the gemini surfactants were replaced with Dc-
chol, a cationic cholesterol-derivative that was used for topical gene delivery into nasal 
epithelia in animal studies [312] and cystic fibrosis patients [313]. The +/- charge ratio 
was increased from 10 to 20 in order to facilitate protection of the DNA in the skin 
penetration process. In the nanoparticle formulations, the DOPE content was increased 
10 fold (from 1 mM for the in vitro transfection agents to about 10 mM in the topical 
nanoparticles) and additional lipids, DPPC or soybean PC were added. The neutral 
lipids, due to their amphiphilic character, can facilitate partitioning of the polynucleotide 
into the skin. Cutaneous permeation enhancers (diethylene glycol monoethyl ether, 
propylene glycol and PDM 27) were incorporated into the formulations. The diethylene 
glycol monoethyl ether is a hygroscopic liquid, miscible with both polar and apolar 
solvents. It is a permeation enhancer shown to work with small molecules by causing a 
swelling of the stratum corneum lipids [314]. PDM 27 is an acylated amino acid 
derivative that facilitates DNA delivery into intact skin [315]. Although it has been 
recognized that liposomal vesicles were present in these delivery systems and lammelar 
phase was the dominant nanostructural feature, the addition of permeation enhancers 
induced formation of polymorphic structure and morphological heterogeneity. Thus, the 
“nanoparticle” term is more appropriate than “liposomal system”. A cationic 
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 nanoemulsion system with the gemini surfactants was also included in the evaluation. 
Nanoemulsions are optically clear, thermodynamically stable disperse systems, used 
successfully as delivery systems for pharmaceutical agents [316]. Depending on 
oil/water/surfactant ratios, they can be oil-in-water, water-in-oil or bicontinuous (water 
and oil domains separated by the emulsifying agents) systems. The PEG-8 
caprylic/capric glycerides were used as primary surfactant and permeation enhancer to 
facilitate drug transport, polyglyceryl-3-isostearate is the co-surfactant, and octyldodecyl 
myristate as the oil component of the system with emollient properties. The DNA to 
cationic lipid ratio was the same as in the nanoparticles. 
Physicochemical characterization of the nanoparticle and nanoemulsion 
formulations was carried out using atomic force microscopy (AFM), particle-size 
measurement and SAXS. 
 AFM and size measurements indicated the presence of two populations of 
particles (100-200 nm and larger 2-5 µm particles) in the topical nanoparticle 
formulation prepared with the 16-3-16 surfactant (Figure VII.11A). The larger particles 
presented a rough surface morphology and the population of the smaller particles 
distributed evenly in the field were relatively uniform with smooth surfaces. TEM 
images of the same formulation showed particles ranging between 100-300 nm in 
diameter (Figure VII.11B). The smaller particles (indicated by the white arrows) are 
individual vesicles, while the larger particles (black arrows) are aggregates of the small 
vesicles. AFM imaging of the nanoemulsion system indicates the presence of particles of 
5-10 nm (Figure VII.11C), based on the amplitude of cantilever deflection. Since the 
removal of excess formulation from the mica with absorbent tissue removed the water 
phase, these particles represent the oil domain of the formulation.   
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Figure VII.11.  Structural characterization of the topical delivery systems. 
A – Atomic force microscopic evaluation of the structure of the topical gemini 
 of the structure of the topical gemini 
. Inset: size measurement based on 
A B
C
nanoparticle DNA formulation. Bar = 2 µm.  
B – TEM image of the NP16-DNA formulation.  
C – Atomic force microscopic evaluation
nanoemulsion DNA formulation. Bar = 400 nm
cantilever deflection. 
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  Light scattering size measurement of all topical nanoparticle formulations 
prepared with the gemini surfactants or Dc-chol indicated bimodal size distribution 
(Figure VII.12A1-D1). The three peaks of the DNA solution correspond to different 
topological forms (supercoiled, open circular and small amount of linear DNA) [317]. In 
the blank formulations prepared with the gemini surfactants, the largest percentage of 
particles (8-10%) were in the 100-200 nm range. The addition of the plasmid to the 
formulations shifted the size towards 500-1000 nm diameter. In the blank Dc-chol 
formulation, the bimodal distribution is present, but a larger portion of the particles is in 
the 1-2 µm range. By adding DNA to the formulation, the size of both populations (the 
100-200 nm and 1-2 µm particles) is reduced. Compared to the in vitro PGL system, a 
subpopulation of larger aggregates is present in the topical formulation due to the higher 
lipid content and more complex composition. Light microscopy images complement the 
light scattering measurements (Figure VII.12 A2-D2). While light scattering could 
detect particles in the 1 nm-10 µm range, larger particles of 1-100 µm could be 
visualized by light microscopy. Mixed population of lipid-like particles and vesicles 
(white arrows) of 2-10 µm are present in the blank formulations (Figure VII.12 A2-D2 
insets). Addition of DNA causes aggregation (black arrows), and fewer vesicles of small 
sizes (red arrows) are visible. In the DNA formulation prepared with Dc-chol (Figure 
VII.12 D2), larger numbers of small particles are visible compared to other DNA 
formulations. 
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The heterogeneous nature of the formulations is indicated by the bimo
distribution.  
A1 – Size measurement of the nanoparticle blank and DNA formulations prepared using 
the 12-3-12 ge
A2 – Light micrograph of the nanoparticle DNA formulations prepared using the 12-3-
12 gemini surfactant. Inset: blan
B1 – Size measurement of the nanoparticle blank and DNA formulations prepared using 
the 16-3-16 gemini surfactant. Bar represents 50 µm. 
B2 – Light micrograph of the nanoparticle DNA formulations prepared using the 16-3-
16 gemini surfactant. Inset: blank formulation. Bar rep
C1 – Size measurement of the nanoparticle blank and DNA formulations prepared using 
the 18:1-3-18:1 gemini surfactant. 
C2 – Light micrograph of the nanoparticle DNA formulations prepared using the 18:1-3-
18:1 gemini surfactant. Inset: blank
D1 – Size measurement of the nanoparticle blank and DNA formulations prepared using 
Dc-Chol. 
D2 – Light micrograph of the nanoparticle DNA formulations prepared using Dc-chol 
surfactant.
 
 
  The same formulations were used for ζ-potential measurements (Table VII.4). 
The plasmid solution showed a negative ζ-potential of -75 mV. The blank formulations 
had positive ζ-potentials, due to the cationic component. As expected, the addition of the 
negatively charged plasmid DNA reduced the ζ-potential by 20-30%, compared to the 
blank formulations, but remained positive due to the high +/- charge ratio. 
VII.2.2.b SAXS analysis of the topical formulations 
 The SAXS profiles of the nanoparticle and nanoemulsion formulations (Figure 
VII.13) showed differences in both scattering peak positions and intensities. Topical 
nanoparticle and nanoemulsion formulations with the 12-3-12, 16-3-16 and 18:1-3-18:1 
gemini surfactants were prepared as described in the “Materials and methods” section. 
The scattering profiles obtained for the topical nanoparticle formulations do not fit into a 
hexagonal or lamellar structure typically observed for cationic lipid–DNA complexes. 
Instead, in consideration of both the peak positions and the relative intensities (Table 
VII.5), there appears to be a coexistence of two structural phases: a lamellar phase, 
indicated by peaks 4 and 5 (q=0.104 Å-1 and 0.207 Å-1) for the NP12-DNA formulation, 
and a second unknown phase, peaks 1, 2 and 3 (q= 0.046 Å-1, 0.069 Å-1 and 0.092 Å-1), 
that might indicate the presence of one of the cubic polymorphs [311]. An emulsion 
phase is present in all nanoparticle formulations, indicated by the broad peak [310] 
underlying the Bragg peaks of these heterogeneous systems. Interestingly, the main 
scattering peak in the DNA gemini nanoparticles (indicated by arrow) was sharp above 
the broad scattering peak, indicating lipid-DNA interaction.  
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 Table VII.4.  ζ-potential measurements of the topical nanoparticles. 
Formulation ζ-potential 
DNA solution -75±13 
NP-12 61±1.2 
NP12-DNA 46±1.5 
NP-16 64±5.3 
NP16-DNA 51±2.4 
NP18 64±3.9 
NP18-DNA 46±2.1 
NPDc 62±4.5 
NPDc-DNA 44±7 
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 This peak was less evident in the Dc-chol formulation. Since light microscopy of 
this formulation showed a significant number of lipid-like and vesicular particles (Figure 
VII.12 D2), the broad peak in the scattering pattern might overlap the peak indicating 
interaction between the lipid and the DNA. It is difficult to interpret Bragg reflections of 
the gemini cationic nanoparticles due to the complexity of the system.  
Generally, SAXS profiles of simple DNA delivery systems are described in the 
literature as containing only complexes of the cationic lipid with the polynucleotides 
alone or in the presence of one helper lipid [141, 154, 318]. In topical nanoparticle 
delivery systems, co-existence of various phases such as micellar, lamellar or hexagonal 
might cause overlap of the Bragg reflections of the polymorphs. The scattering curves 
obtained for the nanoemulsion formulation (Figure VII.13E) are characteristic of those 
obtained in other emulsion systems, exhibiting a single broad feature characteristic of 
strong interparticle correlations. In all cases the scattering peak is observed at q = 0.030 
Å-1, corresponding to a d-spacing of 20.9 nm. It has been shown [319] that the scattering 
profiles of microemulsion system depend on the oil/water/surfactant ratios. High oil 
content present in the oil-in-water type of microemulsions induce weak scattering. 
Addition of water increases the scattering intensity and shifts the peak position to 
smaller q-values, corresponding to the presence of globular particles of 13 nm at 15% 
water content. At water concentrations of 25-50%, a bicontinuos system forms, 
characterized by a broad high intensity peak.  
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Figure VII.13.  Scattering curves of the topical nanoparticle and nanoemulsion 
formulations. 
A – Nanoparticle blank and DNA formulations prepared using the 12-3-12 gemini 
surfactant. 
B – Nanoparticle blank and DNA formulations prepared using the 16-3-16 gemini 
surfactant. 
C – Nanoparticle blank and DNA formulations prepared using the 18:1-3-18:1 gemini 
surfactant 
D – Nanoparticle blank and DNA formulations prepared using the Dc-Chol. 
E – Nanoemulsion DNA formulations prepared with 12-3-12, 16-3-16 and 18:1-3-18:1 
gemini surfactant or Dc-chol . 
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 Table VII.5.  SAXS peaks of the topical nanoparticle formulations (values of d and ∆/d 
were calculated from single-point measurements). 
Formulation q (Å-1) Structure d ∆/d 
NP12 0.101  62.4 0.127 
NP12-DNA 0.046, 0.069, 0.092, 0.104, 
0.207 
lamellar + 
other 
60.4 0.031 
NP16 0.093, 0.134  67.7 0.074 
NP16- DNAa 0.07, 0.094, 0.116, 0.143 lamellar + 
other 
67.2 0.052 
NP18 0.064, 0.098, 0.143  64 0.075 
NP18- DNA 0.047, 0.067, 0.093, 0.098, 
0.145, 0.193 
lamellar + 
other 
64 0.036 
NPDc 0.075, 0.105, 0.145  59.7 0.069 
NPDc- DNA 0.088, 0.089, 0.153, 0.176  lamellar 70.4 0.083 
Bold numbers indicate the main scatteing peak 
a – lamellar structure is hypothesized 
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  Formation of oil-in-water microemulsion at >52% water content is indicated by 
the appearance of a sharp peak [319].  Djordjevic et al. [316] demonstrated that 
formulations having 20-40% water content and 48-60% surfactants (PEG-8 
caprylic/capric glycerides and polyglyceryl-6 oleate mixture) formed optically clear 
bicontinuous microemulsion system. In the topical nanoemulsion DNA formulations, 
water content of 20% and the presence of intense scattering peaks at small q-values 
might also indicate the formation of a bicontinuous system (oil and water phases 
separated by surfactant layer). Although AFM images (Figure VII.11) show structures of 
5-10 nm, particle-formation might be due to the removal of the water phase before 
imaging.    
 VII.2.3 Effect of the gemini surfactants on the SC lipids 
Interaction between the gemini surfactant-based delivery systems (Figure VII.14) 
and the lipids in the stratum corneum could lead to better understanding of the 
mechanism of penetration of the DNA macromolecule into the skin. Peak positions of 
the bare stratum corneum before and after treatment with topical nanoparticle 
formulations are similar with q-values of the main peak of 0.098-0.101 Å-1. On the other 
hand, scattering intensies of the formulation-treated stratum corneum samples (with the 
exception of the NP12) are lower compared to the untreated stratum corneum, indicating 
a higher degree of disorder. Calculation of the d-spacing (Table VII.6) for the 
nanoparticle-treated stratum corneum showed that the values are consistently between 
62 and 65 Å (average = 63.3 ± 0.7 Å) with the exception of the stratum corneum treated 
with blank NP16 formulations. This indicates that the formulations do not induce 
significant changes in the repeat spacing of the stratum corneum, or that the d-spacing of 
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 the formulations alone (Table VII.5) and the lipids in the stratum corneum have similar 
values, and the scattering patterns overlap. This, however, does not imply that the 
formulations have no effect on the stratum corneum lipids, but rather that the bilayer 
thicknesses remain essentially unchanged. A better measure of the effect of the 
formulations on the stratum corneum lipids is the intensity of the scattering peak related 
to the degree of disorder in a partially ordered system (∆/d). When the plasmid DNA is 
added to the formulations, it induces organization of the formulation, reflected in the 
generally lower ∆/d values of the stratum corneum treated with the NP-DNA 
formulations compared to the blank formulations. From the ∆/d values (Table VII.6), we 
can conclude that the blank formulations have a pronounced effect on the organization 
of the stratum corneum lipids with the NP16 formulation inducing the highest degree of 
disorder (0.117) compared to the other formulations (generally ∆/d<0.1). Based on the d-
spacing of the stratum corneum lipids and the degree of disorder, we can conclude that 
the nanoparticle formulations had minimal influence on the distance between the lipid 
bilayers, while increase in the degree of disorder indicated that the continuity of these 
bilayers was interrupted by the delivery system, increasing lipid fluidity similar to 
laurocapram-type permeation enhancers [320].  
The nanoparticle formulation prepared with the 16-3-16 gemini surfactant 
(NP16) was the most efficient for in vivo DNA delivery, indicating that one of the 
important features of the formulation is to perturb the lipid organization in order to 
facilitate the penetration of the macromolecule.  
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Figure VII.14.  Scattering curves of the topical nanoparticle-treated stratum 
corneum 
A – Stratum corneum samples treated with NP12 and NP12-DNA formulations. 
B – Stratum corneum samples treated with NP16 and NP16-DNA formulations. 
C – Stratum corneum samples treated with NP18 and NP18-DNA formulations. 
D – Stratum corneum samples treated with NPDc and NPDc-DNA formulations. 
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 Table VII.6.  Calculation of d-spacing and degree of disorder (∆/d) for the topical 
nanoparticle-treated stratum corneum (values of d and ∆/d were calculated from single-
point measurements). 
Formulation d ∆/d 
Bare stratum corneum 64.5 0.090 
NP12 63.2 0.109 
NP12- DNA 64.3 0.090 
NP16 79.1 0.117 
NP16- DNA 62.4 0.089 
NP18 63.4 0.093 
NP18- DNA 63.3 0.102 
NPDc 62.7 0.097 
NPDc-DNA 63.2 0.095 
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 VII.2.4 Conclusions 
 Physicochemical characterization of the transfection agents has provided a better 
understanding of the interaction between the plasmid DNA and gemini surfactants and 
between PG complexes and helper lipid. The gemini surfactants are able to compact the 
plasmid. The multimodal size distribution characteristic of plasmid DNA, corresponding 
to linear, open circular and supercoiled species, becomes unimodal with the size of the 
PG complexes being around 100 nm. Gemini surfactants in the absence and presence of 
the helper lipid were able to induce changes in the structure of the DNA, confirmed by 
CD spectra. These changes depended on the distance between the two positively charged 
nitrogens, the length and nature of the hydrophobic tail, and the presence or absence of 
the helper lipid.  
Fluorescence intensity of an intercalating dye depended also on the structural 
features of the gemini surfactants influencing the ability of the dye to penetrate between 
the base-pairs. Scattering profiles of the PG complexes presented a single peak, whose 
position shifted depending on the spacer and tail length. The presence of DOPE 
increased the complexity of the system, as the scattering curves contained multiple peaks 
indicating polymorphic structure. Based on the physicochemical properties, in vitro 
delivery systems can be optimized in order to increase transfection efficiency. 
Additional issues such as the nature of the DNA complexation, localization of the 
plasmid in the complexes and vesicles, and influence of changes in environmental pH 
can be addressed. 
Delivery of plasmid into intact skin poses additional challenges compared to in 
vitro transfection. The stratum corneum represents a formidable barrier, thus the delivery 
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 system should be able to temporarily perturb the integrity of this layer and facilitate the 
diffusion of macromolecules. The delivery system should be non-toxic to avoid 
destruction of the delivered genetic materials by scavenger cells. Within the skin, the 
delivery system has to protect the DNA against lysosomal degradation by the 
endonucleases. The excipients included in the nanoparticle formulations to increase 
intradermal DNA delivery were penetration enhancers such as diethylene glycol 
monoethyl ether, propylene glycol and PDM 27. The increased complexity of the 
delivery system was reflected in various parameters. The size measurement of the 
nanoparticle formulation revealed polymodal particle distribution, confirmed by AFM 
and TEM images. The SAXS profiles of the topical nanoparticle formulations show 
multiple peaks, indicating polymorphic structure. The nanoemulsion systems 
haveuniform size distribution and SAXS profiles characteristic of emulsion systems. 
SAXS curves of the stratum corneum treated with topical formulations indicated that the 
distance between lipid layers is constant at 62-65 Å, but the degree of disorder was 
dependent on the nature of the gemini surfactant and the presence or absence of the 
plasmid in the formulations.  
Characterization of the nanoparticle and nanoemulsion formulations provided 
information about the interaction of the components with the plasmid DNA. The effect 
of the delivery system on the stratum corneum is important, since increased penetration 
is a major requirement in cutaneous gene delivery. The formulation selection for topical 
application was based on the following criteria: (1) induction of structural changes, i.e., 
compaction of the DNA achieved by the presence of the gemini surfactants, (2) 
structural polymorphism, contributing to the efficient cellular transduction, and (3) 
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 effect on the stratum corneum lipids, indicated by the increased degree of disorder 
induced by the topical formulations.  
VII.3 Transfection of PAM 212 cells with pGTmCMV.IFN-GFP plasmid using gemini 
surfactants as novel agents for the delivery of plasmid DNA 
The purpose of the study was to evaluate a series of novel gemini cationic 
surfactants as delivery systems for plasmid delivery in vitro. 
The expressed proteins were detected by ELISA (IFN-γ) and fluorescence 
microscopy (GFP). In order to establish a relationship between the structure of the 
gemini surfactants and their potency to transfect cells in vitro, correlations of physical 
characteristics of the compounds such as critical micelle concentration (CMC), the 
degree of micelle ionization at the CMC (α) and surface area (a) occupied by one 
molecule at the air-water interface with the transfection efficiency were evaluated.  
VII.3.1 IFN-γ expression in cells measured by ELISA 
A +/- charge ratio of 10 in PGL vesicles was selected based on the optimization 
studies with the 12-n-12 series and 16-3-16 surfactant. The transfection efficiency was 
found to be dependent on the length of the spacer between the two positively charged 
head groups, with the n=3 spacer showing the highest activity (12-3-12, 16-3-16 and 
18:1-3-18:1; Figure VII.15). In the 12-n-12 series of gemini surfactants, a hyperbolic 
pattern is noticeable with a minimum of protein expression occurring at spacer n=8 
(Figure VII.15A). Significantly higher IFN-γ levels were found when the cells were 
transfected with 12-3-12 and 12-4-12 versus the other compounds with longer linkers 
(p<0.05). No IFN-γ was detected when the cells were transfected without DOPE in the  
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Figure VII.15.  IFN-γ expression in PAM 212 cells transfected with 0.2 µg 
pGTmCMV.IFN-GFP and gemini surfactants in the presence or absence of the 
helper lipid DOPE.  
A – 12-n-12 gemini surfactant series at a +/- charge ratio of 10 in the presence of DOPE. 
The length of the spacer influences the transfection efficiency of the gemini surfactants.  
B – m-3-m gemini surfactant series at a +/- charge ratio of 10 with or without DOPE as 
helper lipid. The length and nature of tail influence the transfection efficiency of the 
gemini surfactants.  
C – 18:1-n-18:1 gemini surfactant at a +/- charge ratio of 10 with or without DOPE as 
helper lipid. The lengthof spacer influences the transfection efficiency of the gemini 
surfactants.  
Significant differences were observed at the p<0.05 level (ANOVA). 
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 12-n-12 series. The effect of the tail length influenced the transfection efficiency, with 
longer tails being associated with higher protein expression (Figure VII.15B). 
Transfections with the PGL systems of the 16-3-16 and 18:1-3-18:1 surfactants resulted 
in significantly higher IFN-γ levels compared to the P – 12-3–12–L system (p<0.01). 
The PG complexes of the 16-3-16 and 18:1-3-18 surfactants were able to transfect cells, 
albeit at lower efficiency than the corresponding PGL systems. Generally, the n=3 
spacer surfactants showed the highest transfection efficiency in both m=12 and 18:1 
series (Figures VII.15A and C). No IFN-γ was detected when the cells were transfected 
with DOPE alone, or with plasmid without transfection agents. 
 The transfection efficiency was found to be dependent on the length of both 
spacer and tail. The highest in vitro transfection efficiency was recorded with the     
18:1-3-18:1 surfactant (1475±393 pg/5x104cells) in the presence of helper lipid, DOPE. 
The transfection efficiency reached a minimum value with the 12-8-12 compound.  
 VII.3.2 Optimization of the transfection: effect of transfection time and charge 
ratio 
 As part of the optimization process, we tested the influence of the transfection 
time on gene expression (Figure VII.16). Although increased contact of the cells with 
the transfection agent (24 hours versus 6 hours) increased protein levels, microscopic 
evaluation of the cell viability showed many dead cells after 24 hours, due to nutrient 
depletion of the media (not shown). The higher IFN-γ levels might be due to the 
increased number of cells at 24 hour compared to 6 hours.For the 12-3-12 compound, 8-
24-hour incubation did not significantly improve the transfection efficiency, where as 
for the 16-3-16 surfactant the protein expression was the highest after a 24-hour  
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Figure VII.16.  Influence of transfection time on the efficiency of the transfection.  
PAM 212 cells were transfected with 0.2 µg pGTmCMV.IFN-GFP using the 12-3-12 
and 16-3-16 gemini lipids at a +/- ratio of 10. The mixtures were in contact with the cells 
for 6, 8, 10 or 24 hours. Protein levels were measured 24 hours after the transfection 
agent was removed from the cells. The longer transfection time yields higher 
transfection, but a high percentage of cells died due to chemical toxicity and depletion of 
nutrients. 
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 transfection period. However, due to the greater variability and the visually observable 
cell toxicity at longer incubation periods, a 6-hour incubation time was selected in 
further experiments. 
 The formulations using the 16-3-16 surfactant were optimized for the gemini 
surfactant/ plasmid DNA charge ratio by correlating with cell toxicity (Figure VII.17). 
The optimal +/- charge ratio was determined by comparing the percentage of fluorescent 
cells with cell viability. A high percentage (2.36%) of fluorescent cells were observed at 
a charge ratio of 10, with 74% cell viability. It is estimated that at 1x106-cell density, 
23,000 cells were producing the GFP protein. Since the two proteins (GFP and IFN-γ) 
coexpress, the same number of cells produced 10.8±0.3ng IFN-γ, hence each cell 
produced approximately 0.5 pg of IFN-γ.  
 Overall, an increase in the cationic charge ratio with gemini surfactants resulted 
in increasing transfection efficiency but lower cell viability. At a charge ratio of 40 the 
transfection efficiency was 3.13%, however, cell viability fell to 20%. The commercially 
available Lipofectamine PlusTM Reagent (DOSPA:DOPE 3:1; at the concentration 
recommended by the manufacturer), used as positive control yielded a slightly higher 
fluorescent cell count (5.87%), but cell viability was only 32%.  
 No fluorescence was detected in the non-transfected cells.
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Figure VII.17.  IFN-γ expression in PAM 212 keratinocytes assessed by ELISA and 
GFP expression and cell viability by FACS.  
The cells were transfected with either PGL systems, using the 16-3-16 gemini surfactant 
at +/- charge ratios of 5, 10, 20 and 40, or Lipofectamine PLUS Reagent, using 0.2 µg 
pGTmCMV.IFN-GFP. The primary y-axis represents the IFN-γ expression (bars); the 
secondary y-axis represents the percentage of fluorescent cells and viable cells. 
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 VII.3.3 Correlation of the physicochemical characteristics of the gemini 
surfactants and their transfection efficiency 
 In order to correlate the structure of the gemini compounds with the transfection 
efficiency, we compared the extent of IFN-γ expression (Figure VII.15) with the 
measured physical properties of the surfactants (Table VII.7).  
 A correlation at significant levels was found between the transfection efficiency 
and surface area occupied by one molecule (a) (Pearson correlation of 0.836 at p=0.019 
level of significance). 
 The size of the PGL system of the 12-n-12 series correlated with the binding 
properties (Pearson correlation of 0.943 at p=0.001 level of significance) and CMC 
(Pearson correlation of 0.778 at p=0.04 level of significance), with smaller particle size 
leading to lower dye binding and hence lower fluorescence. Size and ζ-potential 
measurements of both PG complexes and PGL system did not show marked differences 
among the formulations, yet transfection efficiency between the two systems and within 
the system was significantly different. The PG complexes showed particulate nature, 
whereas the PGL systems were vesiculate. The PGL systems with short spacers (n=3-4) 
and high transfection efficiency exhibited polymorphic structure, predominantly 
lamellar, with additional polymorphic phases.  
 The plasmid–DOPE system, showing typical hexagonal phase (Table VII.3), in 
the absence of the cationic gemini surfactant was not able to transfect the PAM 212 cells 
due to the negative ζ-potential.  
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 Table VII.7.  Measured physicochemical parameters of gemini surfactants.  
Gemini surfactant CMC [mM] a [321] [nm2/molecule] α [322] 
12-n-12 series    
12-3-12 0.98±0.04 0.98 0.23±0.02 
12-4-12 1.17±0.04 1.10 0.26±0.02 
12-6-12 1.09±0.04 1.40 0.34±0.02 
12-8-12 0.84±0.03 1.78 0.46±0.04 
12-10-12 0.62±0.03 2.16 0.51±0.06 
12-12-12 0.36±0.03 2.14 0.56±0.08 
12-16-12 0.12±0.01 1.44 0.59±0.08 
m-3-m series    
12-3-12 0.98±0.04 0.98 0.23±0.02 
16-3-16 0.026±0.001 1.21 0.35±0.02 
18:1-3-18:1 0.023±0.001 0.72 0.42±0.06 
 
 
CMC – critical micellar concentration 
a – surface area occupied by one molecule at air-water interface 
α – degree of micelle ionization at CMC 
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   Conversely, lamellar systems were shown to transfect cells with high efficiency 
if the average membrane charge density (σM) of the cationic component exceeded a 
threshold value (1.04x10-2e/Å2) [152]. The PGL systems with the 12-3-12 and 16-3-16 
surfactants meet and exceed this value [161]. Thus, although the PGL sytems show 
lamellar structure, they can transfect cells in vitro due to the high membrane charge 
density. 
 In vitro transfection efficiency was significantly dependent on the spacer lengths 
and the nature of the hydrophobic tail of the surfactants. A larger Gibbs area (a) per 
molecule (lower surface excess concentration, Г, at the air/water interface) [321] 
correlated with a lower transfection efficiency (Table VII.7). These parameters reflect 
the importance of the spacer length in binding of the gemini surfactant to DNA. The 
distance between two phosphate groups in a DNA molecule is 0.34 nm, whereas the 
distance between the cationic head groups in gemini surfactants 12-3-12 and 12-6-12 are 
estimated to be 0.49 and 0.91 nm, respectively at the air-water interphase [323]. Thus, 
when the distance between head groups in gemini surfactants approaches that between 
phosphate groups in DNA, stronger complexation can occur. There is also evidence that 
longer spacers will bend into a U shape and preferentially locate in the more 
hydrophobic environment of the hydrocarbon tails. This U shape formation and the 
resulting decrease in distance between the two cationic head groups are apparent at 
spacer lengths greater than twelve carbon atoms, and can be facilitated by the vicinity of 
the phosphate groups of the DNA [323]. Our results indicate that transfection efficiency 
begins to increase again at spacer C12 (Figure VII.15), consistent with a decrease in the 
head group distance and possibly an increase in DNA binding of the gemini surfactants 
with spacers n=12–16.  
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  Compaction studies of DNA with the 12-n-12 series of compounds also indicate 
that gemini surfactants with small spacer lengths of 2-3 carbon atoms, i.e., smaller head 
group area, have the highest capacity to compact DNA [127]. The charge concentration 
ratio, αC of gemini surfactant/DNA expressed in relative concentrations of equivalent 
charges, Cs, eq and CDNA, eq is given as  
DNADNA
ss
eqDNA
eqs
c c
c
c
c
ν
να ==
,
,        (VII.1) 
where ν is the valency and cs and cDNA are the concentration of gemini surfactant and 
DNA, respectively [127]. At αc = 1, a neutral complex is expected to form when 
sufficient numbers of gemini surfactants are present to bind all charges on the DNA. 
However, this may not be true if some gemini molecules self-associate instead of 
binding to DNA. The actual concentration of gemini surfactants that bind DNA can be 
calculated as  
)2(
1
2dRdhNc
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ADNA
s
local += π       (VII.2) 
where h is the helical rise per DNA base pair (0.34 nm), CDNA is the DNA basepair 
concentration, NA is the Avogadro number, R is the DNA helix radius (1 nm) and d is 
the length of the gemini surfactant [127]. Higher ratios of αc /clocal indicate lower binding 
efficiency and DNA compaction by the gemini surfactant, with the excess surfactant 
present in the formulation self-associating instead of binding to DNA. Of the 12-n-12 
and 16-n-16 series, the gemini surfactants with low αc /clocal ratios, but αc >1, could be 
considered more advantageous for increased transfection efficiency. However, the 
reverse may be true for transdermally effective formulations. Formulations with 
considerable excess gemini surfactant, i.e. concentration above the CMC, especially 
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 containing gemini compounds with short spacers that can form “worm-like” micelles 
[115], could create high αc /clocal ratios and provide greater interaction with skin lipids 
due to their better solubilizing ability.  
 Another important element, besides the electrostatically favorable interactions, 
leading to complexation of the gemini surfactant and DNA is the structural element. At 
the air/water interphase, the spacer of surfactants with n>8 folds into the hydrophobic 
domain, causing shortening of the distance between the two positively charged nitrogen 
[322]. Similar structural organization of the PGL systems with higher spacers (10-16 
carbons) might explain the increase of transfection efficiency in the 12-n-12 series. 
Rosenzweig et al. [116] found certain 16-n-16 series of diquaternary ammonium 
compounds were capable of transfecting BHK-21 hamster kidney cells in vitro in the 
absence of DOPE. Transfection efficiency was highest for an intermediate spacer length 
16-6-16; shorter spacers (2 or 3) were 5-10 fold less effective. DOPE inhibited 
transfection by the 16-2-16 gemini surfactant even at low amounts (2:1 gemini-DOPE 
ratio) [116]. In our study, it was observed that DOPE increased the transfection 
efficiency of the gemini surfactants regardless of the nature of head-group or tail-length. 
MacDonald’s group [116] used a low DNA/gemini ratio (1:1 mole ratio) and low 
amounts of DOPE (up to twice the amount of gemini surfactant) for transfection, while 
we found that the best basepair/gemini surfactant mole ratio was approximately 1:10 
(corresponding to a +/- charge ratio of 10) with the amount of DOPE eight fold 
compared to the gemini surfactant. Using the n=3 spacer with m=12, 16 and 18:1 tails, 
we detected increased transfection efficiency for the PGL systems with increasing tail 
length, and interestingly, the systems with the 16-3-16 and 18:1-3-18:1 surfactants were 
able to deliver the plasmid into the cells even in the absence of the helper lipid, albeit at 
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 much lower efficiency. Fisicaro et al.’s [119] recent results show that DOPE increases 
the transfection efficiency of C2 spacer alkyl-tail gemini surfactants. Although longer-
tail compounds (C14-18) are able to transfect cells even in the absence of helper lipid, 
their efficiency is low. These findings are consistent with results obtained in our 
laboratory [153]. Dauty et al. [324] suggest the CMC of certain gemini cationic 
surfactants (specifically C12-16 chain length ornithine based dimerizable surfactants) 
could be very important for transfection. A high CMC would be essential for having a 
high concentration of monomers for DNA complexation; however, a low CMC may 
increase the stability of the complex due to micellar aggregation that could keep the 
complex together during the delivery process. In our studies with gemini compounds in 
the 12-n-12 series having short spacers (n=3-10), lower CMCs were associated with 
lower transfection rates (Table VII.7). However, at n=12-16 transfection efficiency 
gradually increased with decreasing CMC. The highest transfection efficiency was 
observed with the 18:1-3-18:1, which has the lowest CMC among all gemini compounds 
investigated in this study (0.023 mM). Since a lower CMC is advantageous for 
maintaining DNA complex stability, controlling the formation of the complex by the 
formulation procedure is important. We found that DNA complex formation was 
dependent upon the order of addition of complex forming excipients, such as the gemini 
compounds and DOPE. The addition of gemini surfactant first to the plasmid (to create 
high clocal / αc) followed by addition of preformed DOPE vesicles was crucial to form the 
complex. Adding the gemini surfactants to DOPE first, and then combining with the 
plasmid did not form suitable complexes for transfection (results not shown). 
 Analysis of the CD spectra, namely the decrease in the positive peak at 290 nm 
(Figure VII.8B), correlated with transfection efficiency. The PG complexes and the 
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 plasmid–DOPE mixtures exhibited a blue shift, but neither the gemini surfactant nor the 
DOPE alone, were able to depress the peak. They were able to induce only very low or 
no cell transfection in PAM 212 cells. In the PG complexes of the 12-n-12 series, the 
changes induced in the DNA structure (degree of depression at 260 nm) indicated 
significant correlation with the fluorescence quenching properties (Pearson correlation 
0.838, with a p=0.019 level of significance). The PGL systems showed correlation with 
the in vitro transfection efficiency (Pearson correlation of 0.814 at p=0.026 level of 
significance). A higher degree of depression of the 260 nm peak correlated with higher 
transfection efficiency in the murine kerationocytes. CD measurements showed that the 
gemini surfactants and DOPE induced changes similar to those described in the 
literature, namely the formation of Ψ– DNA, a left handed highly organized structure 
[131], as evidenced by the decreased positive peak at 290 nm and shift of the 260 nm 
peak to negative values. 
 SAXS spectra of the PG complexes showed a single sharp peak, and lacked any 
indication of polymorphic arrangements. The relative position of the peak in the 12-n-12 
series correlated with the transfection efficiency (Pearson correlation 0.937 at p<0.002 
level of significance), a shift of the main peak to smaller values of q being associated 
with higher transfection efficiency. The PGL systems showed increased structural 
complexity, with lamellar and other possible phases present.  
 In summary, in this work it has been demonstrated that no single characteristic of 
the gemini surfactants is responsible for in vitro transfection efficiency. Although it has 
been recognized in the literature that size, ζ-potential, electrostatic interactions and 
phase behaviour are important properties in determination of transfection efficiency of 
cationic lipid-based delivery systems, a combined evaluation of these factors is 
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 necessary to select optimal delivery systems. Factors that play an important role in the 
ability of the gemini cationic surfactants to deliver genetic material are: (1) size of 
complexes of 100-200 nm, (2) positive ζ-potential, (3) ability to compact DNA, (4) 
presence of helper lipid, (5) polymorphic structure that increases the delivery of the 
DNA into the cell and facilitates the release in the cytoplasm, and (6) charge density that 
exceeds a critical value. An optimal combination of these features contributes to the high 
transfection efficiency of these delivery systems. 
VII.3.4 Conclusion 
 Our results demonstrate that novel cationic gemini surfactants are able to 
transfect PAM 212 keratinocytes in vitro. The transfection efficiency is dependent on 
both spacer and tail length; however, the transfection efficiency of these compounds was 
generally lower than that of the commercial agent, but was better tolerated by the cells, 
i.e., lower cytotoxicity. We have evaluated the physicochemical characteristics of PG 
surfactant complexes and PGL systems and evaluated the possibility of predicting the in 
vitro transfection efficiency of gemini cationic surfactants. Considering the transfection 
efficiency of the PG and PGL systems and the physicochemical properties of the gemini 
surfactants, we can draw the following conclusions: 
 1. The DNA must be compacted through neutralization of the negative charges 
by the cationic gemini surfactants. This is evident from AFM images. The 12-3-12 and 
12-4-12 surfactants yield somewhat smaller particles of 145-155 nm compared to the 
other formulations (average about 175 nm), but there was no significant difference 
among the PGL systems. The gemini surfactants with short (C3) or long (C16) spacers 
protect the DNA from dye intercalation causing 10-20% more fluorescent quenching 
160 
 than species with intermediate spacers (C4-C10). Comparing the helical pitch of the B-
DNA (3.4 Å) with the calculated distance between the two positively charged atoms in 
the headgroup of the surfactant (5.1 Å for the 12-3-12, 6.5 Å for the 12-4-12 and average 
of 6.55 Å for all other spacers obtained from the energy-minimized structures calculated 
(using Chem 3D Pro v. 8.0), we might expect no significant differences in the ionic 
interactions. Yet, fluorescence-quenching measurements show differently, indicating 
that other conformational criteria might be more important than a perfect electrostatic fit.  
 2. Structural alteration of the DNA, shown in the CD spectra, is crucial for 
delivery of plasmid into cells. The structure of the native DNA is altered by the gemini 
surfactants causing a shift of the 260 nm peak into the negative region, indicating an 
increase in the interhelical interactions. Since the transfection efficiency of the PG 
complexes was very low or nil, additional structural changes are necessary. The 
presence of the helper lipid in the PGL systems causes a shift of the positive 260 nm 
peak into the negative region and flattening of the 290 nm peak. For efficient 
transfection, both flattening the 290nm peak and depression of the 260nm peak may be 
required. The degree of depression of the 260 nm peak correlates with the transfection 
efficiency, a deeper depression being associated with higher transgene expression.  
 3. SAXS analysis of the PG complexes and PGL systems demonstrated 
correlation of the structure of the PG complexes with the transfection efficiency. 
Analysis of scattering vector (q) positions showed that a shift of the main scattering peak 
relates to the size of the headgroup, and reflects differences associated with the packing 
of the PG complex. The complexity of the structural elements increases by introducing a 
helper lipid in the system. Lamellar and possibly cubic Pn3m phases appear in the 
system, characterized by 1:2:3:4 and √2: √3:√4:√6 periodicity. This heterogeneity 
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 influences the transfection efficiency of the delivery systems. The size of the headgroup 
is a determining factor in the overall structure of the complex, and is directly implicated 
in the in vitro transfection ability. The helper lipid contributes to the stabilization of the 
DNA–lipid complexes. Felgner et al. [186] indicate that the phosphate group of the 
DOPE interacts with the cationic lipid, forming a heterodimer, a unit responsible for the 
high transfection efficiency. Compared to other phospholipids having two C14, C16 or 
C18 saturated acyl chains or one saturated and one unsaturated chain, DOPE was a 
better helper lipid, transfecting cells more efficiently. A high degree of chain saturation 
conferes rigidity to the molecule and stiffness to the lipid bilayer, influencing negatively 
the transfection efficiency [186].  Due to its fusogenic properties, DOPE also helps DNA 
escape from the endosomes [62].  In a study of DNA–cationic lipid–phospholipid 
systems both DOPE and DOPC mixed equally with plasma membranes; however, only 
DOPE was able to transfect cells efficiently. Of the two lipids, only DOPE caused 
hemolysis of red blood cells, by membrane disruption. The authors concluded that 
important feature of the helper lipid DOPE is not its ability to intermix with biological 
membranes, but the ability to perturb the structure of the membrane [325]. 
 It has been demonstrated that gemini surfactants are capable of compacting the 
plasmid DNA. We found that the transfection efficiency correlated with changes 
induced by the gemini surfactants in the CD spectrum of the DNA, the scattering 
patterns of the complexes and the surface area occupied by a molecule at the air/water 
interface (a). The correlations indicate that predictions on the transfection efficiency of 
new compounds can be made by analyzing the PG complexes and measuring their 
physicochemical properties, such as surface area and CMC. 
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  Hydration behaviour of the gemini surfactants might also play an important role 
in their ability to interact with biological membranes and consequently deliver DNA. A 
study of 16-n-16 and 18:1-n-18:1 surfactants (n=2, 3 and 6) [116] demonstrated that all 
cetyl derivatives and the 18:1-2-18:1 showed lamellar structure and the 18:1-6-16:1 was 
of micellar conformation. These compounds in our case showed lower transfection 
efficiency compared to the 18:1-3-18:1, the most efficient agent. This surfactant presents 
lamellar structure in water and micellar conformation in high ionic strength medium 
[116]. We can speculate that the ability of polymorphic transition of the gemini 
surfactants and increased structural complexity conferred by the helper lipid are key 
requirements for efficient gene delivery. In a recent publication by Fisicaro et al. [119], 
the importance of the interaction of alkyl-cationic gemini surfactants with DNA was also 
described. The biological activity of these compounds increases with increasing chain 
length, similar to our observations (12-3-12 < 16-3-16 < 18:1-3-18:1).  
VII.4  In vivo evaluation of various topical DNA delivery systems containing gemini 
surfactants 
VII.4.1 Topical application of nanoparticle (NP) and nanoemulsion (NE) 
formulations using novel gemini surfactants: optimization of formulations and 
treatment regimen in normal CD1 mice 
VII.4.1.a Formulation selection for topical application 
 In order to evaluate topical delivery of plasmid DNA, nanoparticle and 
nanoemulsion DNA formulations were compared to the blank formulations. The level of 
expressed protein was measured in the treated skin. Additionally IFN-γ levels were 
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 measured in both lymph nodes and blood in order to evaluate possible cytokine 
trafficking pathways. The 18:1-3-18:1 gemini surfactant, which showed the highest in 
vitro transfection efficiency, was incorporated in all formulations. Protein expression 
was higher in the skin of animals treated with the nanoparticle formulation (178±220 
pg/cm2) compared to the nanoemulsion formulation (80±56 pg/cm2) (Figure VII.18A). 
The blank formulations also showed relatively high background IFN-γ levels. IFN-γ 
levels in the lymph nodes of the formulation-treated animals were low, with the 
exception of the NP18-DNA formulation (44±30 pg/animal) almost undetectable (Figure 
VII.18B). No significant differences were observed among treatment groups. 
 The nanoparticle formulation was selected from the previous experiment, and the 
18:1-3-18:1 gemini surfactant was replaced with either the 12-3-12 or the 16-3-16 
surfactant. The purpose of this experiment was to correlate the in vitro transfection 
efficiency to the in vivo delivery. Contrary to the in vitro findings, where the 18:1-3-18:1 
surfactant showed the best efficiency (see Figure VII.15B), the highest IFN-γ levels in 
the skin (359±239 pg/cm2) were generated by the nanoparticle formulation prepared 
with the 16-3-16 surfactant (p<0.05 compared to the blank formulation) (Figure 
VII.19A). Formulation prepared with the cationic cholesterol derivative, Dc-chol, was 
used as a comparison, and showed lower efficiency than the gemini 16-3-16 surfactant 
(82±74 pg IFN-γ /cm2). As in the previous experiment, the IFN-γ in the lymph nodes 
was generally lower than in the skin, with the exception of the animals treated with the 
nanoparticle 16-3-16 formulation (443±456 pg/animal) (Figure VII.19B).    
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Figure VII.18.  IFN-γ expression measured by ELISA in the skin and lymph nodes 
of CD1 mice. 
A – IFN-γ expression in skin in the CD1 mice treated with the pGTmCMV.IFN-GFP 
plasmid and the 18:1-3-18:1 gemini surfactant in various formulations.  
B – IFN-γ expression in lymph nodes in the CD1 mice treated with the pGTmCMV.IFN-
GFP plasmid and the 18:1-3-18:1 gemini surfactant in various formulations. 
Results were standardized by subtracting the average IFN-γ levels measured in skin and 
lymph nodes of the control animals (Background values were 683±61 pg/cm2 for the 
skin and 208±37 pg/animal for the lymph nodes, n=5).  
• NP18-DNA-t (n=10) – topically treated with pGTmCMV.IFN-GFP in gemini 
18:1-3-18:1 nanoparticle formulation 25 µg in 50 µL for three days (total dose 75 
µg); 
• NE18-DNA-t (n=5) – topically treated with pGTmCMV.IFN-GFP in gemini 
18:1-3-18:1 nanoemulsion formulation 25 µg in 50 µL for three days (total dose 
75 µg);  
• NP18-t (n=3) – topically treated with blank gemini 18:1-3-18:1 nanoparticle 
formulation for three days;  
• NE18-t (n=3) – topically treated with blank gemini 18:1-3-18:1 nanoemulsion 
formulation for three days. 
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Figure VII.19.  IFN-γ expression in CD1 mice treated with the pGTmCMV.IFN-
GFP plasmid and various gemini surfactants in nanoparticle formulations. 
A – IFN-γ expression in skin.  
B – IFN-γ expression in lymph nodes. 
Results were standardized by subtracting the background values obtained in the control 
animals. (Background values were 152±50 pg/cm2 for the skin and 233±89 pg/animal 
for the lymph nodes, n=5)  
Significant differences were observed at the p<0.05 level (ANOVA). 
• NP12-DNA-t (n=5) – topically treated with pGTmCMV.IFN-GFP in gemini 12-
3-12 nanoparticle formulation 25 µg in 50 µL for three days (total dose 75 µg); 
• NP16-DNA-t (n=14) – topically treated with pGTmCMV.IFN-GFP in gemini 
16-3-16 nanoparticle formulation 25 µg in 50 µL for three days (total dose 75 
µg); 
• NP18-DNA-t (n=10) – topically treated with pGTmCMV.IFN-GFP in gemini 
18:1-3-18:1 liposomalnanoparticle formulation 25 µg in 50 µL for three days 
(total dose 75 µg);  
• NPDc-DNA-t (n=5) – topically treated with pGTmCMV.IFN-GFP in Dc-Chol 
nanoparticle formulation 25 µg in 50 µL for three days (total dose 75 µg);  
• NP16-t (n=10) – topically treated with blank gemini 16-3-16 
liposomalnanoparticle formulation for three days. 
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 VII.4.1.b Topical treatment of CD1 mice with various selected formulations 
 Four experiments were carried out using 25-40 CD1 mice/ experiment to 
optimize formulations and treatment regimen. Generally, topical treatment of mice with 
pGTmCMV.IFN-GFP plasmid in nanoparticle or nanoemulsion lipid formulations 
resulted in high levels of IFN-γ expression in the skin (Figure VII.20A) and lymph 
nodes (Figure VII.20B). The highest levels of gene expression were detected in the skin 
of the animals treated topically with nanoparticle and nanoemulsion formulation 
(359±239 and 607±411 pg/cm2). Both formulations lead to significantly higher IFN-γ 
expression in the skin than topical naked DNA and blank nanoparticle formulation 
(359±239 and 607±411, respectively, compared to 136±125 and 106±103 pg/cm2). 
Interestingly, IFN-γ levels in the skin after topical application of DNA-NE16 
nanoemulsion formulations were higher compared to the NP16-DNA (607±411 vs. 
359±239 pg/cm2), whereas in formulations prepared with the 18:1-3-18:1 gemini 
surfactant the nanoparticle formulation led to higher gene expression (Figure VII.18A). 
The IFN-γ levels in the skin of animals treated topically with naked DNA (136±125 pg 
/cm2) or Dc-chol formulation (82±74 pg/cm2) were not statistically different from the 
control group treated with placebo nanoparticles (106±103 pg/cm2). Based on the 
number of cells transfected in vitro and the amount of protein generated in 24h, we 
estimate that approximately 1x103 cells/cm2 were expressing IFN-γ after topical 
administration. We selected Dc-chol as a comparison for the in vivo studies because 
laboratory [326, 327] and clinical trials [328] showed its ability to deliver plasmid DNA 
in vivo in various tissues, although this is the first time it was used on the skin. The use 
of Lipofectamine Plus for the animal experiments was not feasible due to the high 
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 plasmid concentration in the topical formulations. IFN-γ expression in the lymph nodes 
was the highest in the animals treated topically with gemini nanoparticles, at 
significantly higher levels compared to the control gemini nanoparticles (443± 456 vs. 
36±66 pg/animal) (p<0.05). Application of the 16-3-16 gemini nanoparticle formulation 
induced four fold higher levels of IFN-γ than the Dc-chol formulation in the lymph 
nodes. The IFN-γ expression after intradermal injection of nanoparticle formulation of 
the plasmid in gemini nanoparticles (2.5 µg/10µL) was approximately three times higher 
than intradermal injection of naked DNA solution (same dose) in both skin and lymph 
nodes. In the animals injected intradermally with naked DNA at a dose of 5 µg/10µL 
and 2.5 µg/10 µL, respectively, protein expression was proportional with the dose, both 
in the skin (256±130 pg/cm2 vs. 127±100 pg/cm2) and the lymph nodes (281±173 
pg/animal vs. 115±124 pg/animal). No IFN-γ could be detected in the sera obtained from 
animals in any of the groups. 
In addition to IFN-γ quantification, GFP expression was detected in the skin 
treated with nanoparticle formulation in the epidermis (Figure VII.21, Panels A1-D1) 
and around the injection site in skin injected with 2.5 µg DNA/site (Figure VII.21, Panel 
E1). No GFP fluorescence was observed in the skin of animals treated with control (no 
DNA) nanoparticle formulation (Figure VII.21, Panel F1 shows the autofluorescence of 
a hair shaft in the GFP band and Panel 2 in Rhodamine band).  
Autofluorescence was ruled out by comparing the images to those taken in the 
rhodamine emission band (Figure VII.21 Panels A2-F2).
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 Figure VII.20.  IFN-γ expression in CD1 mice treated with the pGTmCMV.IFN-
GFP plasmid and gemini lipid 16-3-16 in various formulations. 
A – IFN-γ expression in skin. Results are expressed as amount of IFN-γ/cm2 treated skin 
for the topical treatment (circles) and as amount of IFN-γ/animal for the injected groups 
(diamonds).  
B – IFN-γ expression in lymph nodes. Results are expressed as amount of IFN-γ/animal 
for all groups.  
Results were combined from four experiments and standardized by subtracting the 
background values obtained in the naïve animals in each experiment from the other 
groups. (Background values ranged 100-300 pg/cm2 with an average of 239±127 pg/cm2 
for the skin and 150-800 pg/animal with an average of 490±289 pg/animal for the lymph 
nodes).  
Circles – topical treatment; diamonds – intradermal injection 
Significant differences were observed at the p<0.05 level (ANOVA). 
• DNA-s-t (n=15) – topically treated with pGTmCMV.IFN-GFP 25 µg in 50 µL in 
aqueous solution for three days (total dose 75 µg);  
• NP16-DNA-t (n=14) – topically treated with pGTmCMV.IFN-GFP in cationic 
gemini nanoparticle formulation 25 µg in 50 µL for three days (total dose 75 µg); 
• NE16-DNA-t (n=4) – topically treated with pGTmCMV.IFN-GFP in cationic 
gemini nanoemulsion formulation 25 µg in 50 µL for three days (total dose 75 
µg);  
• NPDc-DNA-t (n=5) – topically treated with pGTmCMV.IFN-GFP in Dc-chol 
nanoparticle formulation 25 µg in 50 µL for three days (total dose 75 µg);  
• NP16-t (n=10) – topically treated with 50 µL blank cationic gemini nanoparticle 
formulation for three days;  
• NP16-DNA-i (n=4) – intradermally injected with pGTmCMV.IFN-GFP in 
cationic gemini nanoparticle formulation 5 µg in 10 µL (total dose 15 µg) for one 
day;  
• DNA-s-h-i (n=4) – intradermally injected with pGTmCMV.IFN-GFP in aqueous 
solution (5 µg in 10 µL, total dose 15 µg) for one day;  
• DNA-s-l-i (n=10) – intradermally injected with pGTmCMV.IFN-GFP in 
aqueous solution (2.5 µg in 10 µL, total dose 7.5 µg) for one day;  
• PBS-i (n=3) – intradermally injected with 10 µL PBS for one day.  
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Figure VII.21.  Fluorescence microscopic evaluation of the GFP expression in skin 
of mice treated with the pGTmCMV.IFN-GFP plasmid and gemini lipid 16-3-16 in 
various formulations.   
Phase contrast micrographs were overlaid on fluorescent micrographs of 7 µm thick skin 
sections. Panels A1-F1 represent the GFP fluorescence and Panels A2-F2 are taken in 
the rhodamine emission band. 
• Panels A-D – NP16-DNA-t (n=14) – animals topically treated with 
pGTmCMV.IFN-GFP in cationic gemini nanoparticle formulation 25 µg in 50 
µL for three days (total dose 75 µg); 
• Panel E – DNA-s-l-i (n=10) – animals intradermally injected with 
pGTmCMV.IFN-GFP in aqueous solution (2.5 µg in 10 µL, total dose 7.5 µg) for 
one day; 
• Panel F – NP16-t (n=10) – animals topically treated with 50 µL blank cationic 
gemini nanoparticle formulation for three days. Autofluorescence of a hair shaft 
is shown. 
 
  Quantification of plasmid delivery was carried out by nested PCR in the skin of 
the animals treated intradermally and topically with the gemini cationic nanoparticle 
formulation (Table VII.8). Approximately 20 x106 copies/cm2 skin were detected after 
topical treatment with 3x25 µg DNA in gemini nanoparticles (NP16-DNA-t) (a single 
treatment resulted in 15x106 copies/cm2 skin; results not shown). When gemini cationic 
nanoparticle formulation of 5 µg DNA/site was injected intradermally (NP16-DNA-i), 
about 130 x106 copies of DNA/cm2 skin were detected. Low plasmid levels were 
detected in the skin of the gemini nanoemulsion treated group (2.5x106 copies/cm2). 
Plasmid was not present in either the skin of animals injected with 5 µg DNA 
solution/site (DNA-s-h-i) or in the control group (PBS-i).  
 
VII.4.2 Conclusion 
Two different types of formulations were selected for in vivo screening in CD1 
mice: nanoparticles and nanoemulsion. Initially, the 18:1-3-18:1 surfactant, showing the 
highest in vitro transfection efficiency of all eleven tested surfactants, was incorporated 
in the formulations. The results show that in the skin, the IFN-γ levels were higher after 
topical application of the nanoparticle DNA formulation (178 pg/cm2) compared to the 
nanoemulsion (80 pg/cm2). Both blank formulations showed relatively high background, 
a normal response to physical manipulation of the skin. Protein levels in the lymph 
nodes were low, with the exception of the NP18-DNA formulation.  
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Table VII.8.  Nested PCR for pGTmCMV.IFN-GFP plasmid detection in the skin. 
Treatment Number of copies of  
pGTmCMV.IFN-GFP/cm2 skin 
NP16-DNA-t (n=4) 
20 million 
 
NE16-DNA-t (n=4) 
2 million 
 
NP16-DNA-i (n=3) 
130 million 
 
DNA-s-h-i (n=4) 
0 
 
PBS-i (n=3) 
0 
 
 
The ethidium bromide-stained bands were quantified based on standard dilutions of the 
same plasmid. 
173 
 In order to correlate the in vitro transfection efficiency and in vivo cutaneous 
delivery, the nanoparticle formulation was prepared with the three gemini surfactants of 
the m-3-m series (showing better overall transfection efficiency than the 12-n-12 
compounds). All three formulations demonstrated transgene expression, but only the 
NP16-DNA formulation yielded significantly higher IFN-γ levels than background (the 
blank NP16 formulation).   
For further experiments, the highest transfection efficiency nanoparticle 16-3-16 
formulation (NP16-DNA-t) was compared to topically applied nanoemulsion 
formulation (DNA-NE16-t) and naked DNA solution (DNA-s-t). Positive control groups 
included intradermally injected plasmid solution (2.5 and 5 µg doses) and topical 
formulation (5 µg doses). The topical blank formulation and intradermally injected PBS 
represented negative controls. Protein quantification indicated that topical application of 
nanoparticle DNA formulation generated 359 pg IFN-γ/cm2, whereas the nanoemulsion 
formulation produced 607 pg/cm2. These levels were 2.6-fold and 4.5-fold higher than 
for the naked DNA treatment. Furthermore, IFN-γ levels in the skin of animals treated 
with gemini nanoparticle formulation were approximately 3.5-fold higher than in the 
skin treated with the Dc-chol-based formulation. From this level of expression, one 
could assume potential for using the topical non-invasive gemini surfactant based 
delivery systems to generate IFN-γ levels within the skin, sufficient to induce biological 
changes leading to reduction of excessive collagen synthesis. In the lymph nodes, topical 
gemini nanoparticle formulations induced a 12-fold increase of protein compared to 
blank formulation and a 3.6-fold increase in the gemini nanoemulsion treated animals. 
The nanoemulsion formulation leads to higher levels of IFN-γ in the skin and lower 
levels in the lymph nodes compared to the nanoparticle formulation with 16-3-16 and 
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 18:1-3-18:1 gemini surfactants. The difference in the expression pattern could be further 
evaluated in the context of penetration pathways. Evaluation of the distribution of IFN-γ 
and its involvement in immunological processes such as cellular trafficking (e.g. 
drainage into lymp nodes) and Th1/Th2 balance are worth pursuing in further studies. 
Correlating the expression of the two genes, IFN-γ and GFP, with the detection of the 
plasmid in the skin, one could conclude at the time of sample collection, 24 hours post-
treatment, that high levels of IFN-γ detected in the skin of the animals treated with 
nanoparticle DNA formulation were associated with the presence of GFP and plasmid 
DNA. In the skin of the animals treated with the nanoemulsion formulation, the IFN-γ 
levels were higher, compared to the nanoparticle formulation, but 10-fold less plasmid 
was present. The rate of DNA-penetration into the skin, uptake and transgene expression 
are different for the two types of delivery systems.  In the animals injected with DNA 
solution, the IFN-γ levels were lower (short half-life) compared to the topical 
application, but the GFP fluorescence was strong. All the naked plasmid injected into the 
skin was destroyed in the 24-hour interval, while the nanoparticle formulation conferred 
protection against degradation, reflected in the highest amount of DNA in the skin.  
 It is difficult to compare different gene delivery systems presented in the 
literature. The differences in carrier vectors, inserted genes, delivery mechanisms, and 
pretreatments are factors contributing to the diversity of results. We compared the extent 
of expression of IFN-γ gene to cytokines described in the literature and found them to 
have comparable half-lives. For example, application of 10 µg plasmid coding for 
human IFNα2 in a nanoemulsion formulation in mice for four days generated 
approximately 100 pg protein/cm2 skin [211] while topical application of 2x350 µg 
plasmid DNA (coding for human IL-1ra) for three days resulted in approximately 165 
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 pg/cm2 protein in hamster ears [213]. IL-12 levels of 266±27.8 pg in the epidermal layer 
were measured in mouse skin after introduction of plasmid DNA coding for IL-12 into 
the skin with the aid of a gene gun. This protein level was sufficient to exert a biological 
effect, causing tumour regression in mice [214]. We could detect comparable, even 
higher levels of protein in the CD1 mice treated with nanoparticle formulation (359.9 
pg/cm2). The present data suggest that topical application of IFN-γ coding plasmid DNA 
using gemini cationic delivery vehicles significantly enhances cutaneous IFN-γ levels 
after application to intact skin and appears to be several-fold more efficient than other 
delivery systems tested in vivo. PCR results confirmed the successful delivery of the 
plasmid into the skin.  
 Although the IFN-γ levels in the skin of NP16-DNA formulation-treated animals 
was lower compared to the DNA-NE16 nanoemulsion formulation, the nanoparticle 
formulation was selected for further experiments due to the high variability in transgene 
expression in the nanoemulsion formulation.  
VII.5 Study of the extent of gene expression in IFN-γ-deficient mice  
 From the results of studies of CD1 mice, the topical nanoparticle formulation 
with the 16-3-16 surfactant was selected for gene delivery in IFN-γ-deficient mice [329]. 
This strain was created by homozygous targeted mutation. These animals are unable to 
synthesize IFN-γ, appear normal in a clean environment, but cannot mount immune 
response to external stimuli. This model was selected for evaluation of in vivo gene 
delivery in order to distinguish between the exogenous IFN-γ and transgene expression. 
In normal CD1 mice, IFN-γ secretion can be triggered by physical injury (scratching, 
shaving or injection) or chemical irritation. The “background” IFN-γ levels of the IFN-γ-
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 deficient strain are minimal (30 pg/cm2), thus the measured protein levels are a 
reflection solely of transgene expression. In the IFN-γ-deficient mice, topical treatment 
with the pGTmCMV.IFN-GFP in 16-3-16 nanoparticle formulations resulted in the 
highest levels of IFN-γ expression in the skin (278 pg/cm2) (Figure VII.22). These levels 
were only about 30% lower than in the CD1 mice, indicating that topical application of 
the plasmid in nanoparticle 16-3-16 formulation induces minimal endogenous IFN-γ 
secretion in normal mice. The protein expression in animals treated topically with both 
nanoparticle formulations (NP16-DNA and NPDc-DNA) was significantly higher 
compared to the untreated animals (p<0.001). IFN-γ levels in the skin of DNA solution-
treated animals were significantly lower (p<0.05) than in the 16-3-16 formulation-
treated animals (157 pg/cm2 vs. 278 pg/cm2). Interestingly, the nanoparticle Dc-chol 
formulation led to protein expression levels similar to the nanoparticle 16-3-16 
formulation in the IFN-γ-deficient strain, but significantly lower levels in the CD1 
animals. This difference might be due to differences between the two strains. No IFN-γ 
was detected in the sera of the mice.  
 In conclusion, the pattern of protein expression in the IFN-γ-deficient mice was 
similar to the normal CD1 animals, with generally lower levels (due to complete lack of 
endogeneous IFN-γ). By using an IFN-γ-deficient strain, the transgene expression could 
be measured without the interference of endogenous IFN-γ. However, due to 
obtainability of very similar data, we conclude that the normal CD1 mice are appropriate 
for formulation screening, due to their ready availability and lower cost (US$5 vs. 
US$60/animal).
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Figure VII.22.  IFN-γ expression in the skin of IFN-γ-deficient mice treated with 
the pGTmCMV.IFN-GFP in solution and nanoparticle formulations.  
Significant differences were observed at the p<0.05 level (ANOVA). 
• DNA-s-t (n=4) – topically treated with pGTmCMV.IFN-GFP 25 µg in 50 µL in 
aqueous solution for four days (total dose 100 µg);  
• NP16-DNA-t (n=4) – topically treated with pGTmCMV.IFN-GFP in cationic 
gemini 16-3-16 nanoparticle formulation 25 µg in 50 µL for four days (total dose 
100 µg);  
• NPDc-DNA-t (n=4) – topically treated with pGTmCMV.IFN-GFP in Dc-chol 
nanoparticle formulation 25 µg in 50 µL for four days (total dose 100 µg). 
• Control (n=4) – no treatment. 
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 VII.6. Topical application of gemini nanoparticle formulation in Tsk mice: study of the 
biological effect 
The Tsk strain was generated by a spontaneous mutation of the fibrillin-1 gene 
causing excessive collagen synthesis and deposition in the skin [236]. The mice present 
tight skin, similar to patients suffering from localized scleroderma. The Tsk mice were 
chosen for in vivo evaluation of the effect of the transgene IFN-γ on collagen synthesis. 
Gene delivery into the tight skin, IFN-γ expression and biological effect was used as a 
model for gene delivery into scleroderma patients. Since significant differences between 
topical DNA solution and nanoparticle formulations were demonstrated in CD1 and 
IFN-γ-deficient mice, the treatment of the Tsk mice with topical nanoparticle 
formulations was compared to intradermal injection (used as a positive control). Two 
different treatment regimens were tested: a 4-day and 20-day application. The 4-day 
regimen consisted of four topical applications of 50 µg plasmid in NP16 nanoparticle 
formulation at 24-hour intervals and a single injection.  The 20-day treatment consisted 
of five topical applications of 100 µg plasmid in NP16-PDM formulation per week at 
24-hour intervals (no treatment on weekends), and two intradermal injections weekly for 
four weeks. 
VII.6.1 Protein expression measured by ELISA and confocal microscopy 
Protein levels (IFN-γ and GFP) as well as biological effect (mRNA levels of 
procollagen and ICAM-1) were measured. Both topical and intradermal treatments 
increased IFN-γ expression in the skin of Tsk mice (Figure VII.23). Short term, topical 
treatment was equivalent to intradermal injection (472±171 and 559 pg/cm2). These 
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 protein levels were similar to those measured in the skin of CD1 animals treated 
topically with NP16-DNA formulation (359±239 pg/cm2) and intradermal injection 
(256±130 pg/cm2) (Figure VII.20). After a month of treatment, intradermal injections 
appeared to produce higher transgene expression (1069±612 pg/cm2), although, 
statistically it was not different from topical treatment (345±275 pg/cm2).   
In addition to IFN-γ expression, the GFP was also monitored by confocal 
microscopy in the DNA nanoparticle formulation-treated Tsk mice (Figure VII.24, 
Panels A to D), intradermally injected Tsk animals (Figure VII.24, Panels E and F) and 
non-treated Tsk animals (Figure VII.24, Panels G and H). In the intradermally injected 
animals, the fluorescence was strong around the injection site but was confined to a 
smaller area. In the skin of animals treated topically, the fluorescence was weaker, but 
distributed across the entire examined area. No GFP fluorescence was detected in the 
skin of control animals.  
In conclusion, IFN-γ expression was at high levels in the skin of Tsk mice after 
4-day and 20-day treatments. Topical application led to protein levels similar to 
intradermal injection, thus the topical non-invasive delivery route using the gemini 
cationic surfactant delivery system is a feasible alternative for gene delivery. 
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Figure VII.23.  IFN-γ levels in the skin of Tsk mice treated topically with 
pGTmCMV.IFN-GFP in nanoparticle formulations or injected intradermally with 
DNA solution.  
The 4-day regimen (diamonds) consisted of four topical applications of 50 µg plasmid in 
NP16 nanoparticle formulation at 24-hour intervals and a single injection.  The 20-day 
treatment (circles) consisted of five topical applications of 100 µg plasmid in NP16-
PDM formulation per week at 24-hour intervals (no treatment on weekends), and two 
intradermal injections weekly for four weeks. 
• NP-DNA-t – Tsk mice topically treated with pGTmCMV.IFN-GFP in cationic 
gemini 16-3-16 nanoparticle formulations.  
• DNA-s-i – Tsk mice intradermally injected with pGTmCMV.IFN-GFP 2.5 µg in 
10 µL in aqueous solution;  
• Control – untreated animals. 
 
  
181 
    
 
Figure VII.24.  Confocal one-photon images of GFP expression in the skin of the 
Tsk mice. 
Panels A-D: treated topically with plasmid nanoparticle formulation. 
Panels E-F: injected intradermally with DNA solution. 
Panels G-H: untreated.  
The images were recorded 15-30 µm deep in the skin.   
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 VII.6.2 Biological effect of the transgene IFN-γ on molecular and cellular 
markers of scleroderma: collagen and ICAM-1 mRNA measurements 
 Keratinocytes in the skin can act as a “bioreactor” and participate in immune 
processes [177], hence secreted IFN-γ can upregulate surface expression of ICAM-1 on 
keratinocytes (Figure I.4). Diffusion of the IFN-γ secreted by the keratinocytes in the 
epidermis into the dermis can reduce collagen synthesis by the fibroblasts directly, by 
interfering with the YB1 pathway, and indirectly by the Jak/STAT1 signaling pathway 
(Figure I.7). In order to evaluate the biological effect of the in situ generated IFN-γ, 
markers of the gene expression such as the murine procollagen type Iα1 mRNA and 
ICAM-1 mRNA were determined quantitatively by real-time PCR (Table VII.9). Both 4-
day and 20-day treatments reduced the procollagen type I α1 mRNA levels for the 
topical and injected treatments. The 20-day treatment was about 6% more efficient 
compared to the 4-day treatment in the topically treated animals and 14% more efficient 
in the intradermally injected groups. Both treatments (topical and intradermal) induced a 
significant decrease in the collagen level compared to the untreated animals (p<0.01). 
The highest degree of reduction of approximately 70% was caused by the IFN-γ 
generated by 20-day injection regimen of pGTmCMV.IFN-GFP solution, correlating 
with the highest level of transgene expression (1069 pg/cm2; Figure VII.23). ICAM-1 
was upregulated by 50% in both topically treated and injected animals after 20-day 
treatment, but no effect of the IFN-γ was observed after 4-day treatment in the 
nanoparticle formulation-treated animals.  
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 Table VII.9.  Procollagen and ICAM-1 mRNA levels quantified by real-time PCR in Tsk 
mice treated with topical and injected nanoparticle formulations.  
Procollagen type Iα1 ICAM-1 Treatment 
4-day 20-day 4-day 20-day 
Control 100% 100% 100% 100% 
NP-DNA-t 36±29%↓ 30±19%↓* 103±40% 154±65%↑ 
DNA-s-i 42↓ 28±10%↓* N/D 142±81%↑ 
Arrows indicate increase (↑) or decrease (↓) compared to the control animals (n=4 for all 
groups except DNA-s-i for 4-day regimen n=2). 
*Indicates significant differences compared to the control animals (ANOVA, p<0.01) 
N/D – not determined 
Mean value for four samples ± standard deviation. 
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  Evidence for reduced collagen synthesis in the skin was also obtained by 
evaluating the dermal thickness in histologic sections (Figure VII.25). Tsk mice develop 
hypertrophy of the connective tissue, bone and cartilage. The structure of the skin is 
different from the homozygous siblings in regards to tensile properties and histology. 
Normal skin presents differences in the longitudinal and transversal tensile properties 
due to the organization of collagen fibres, thus puncure wounds show eliptical pattern. 
Tsk skin, on the other hand, presents nearly round puncture wounds, indication of 
disorganized and densely packed collagen, also evidenced by histological staining [237]. 
Histologic examination of skin sections stained with hematoxylin-eosine reveals a 
thicker dermis of the Tsk mice compared to the normal animals, with excessive 
deposition of collagen fibers extending into the underlaying adipose tissue [244]. In the 
skin of animals treated topically with NP-PDM-DNA formulation (Figure VII.25, Panel 
A), or injected with DNA solution (Figure VII.25, Panel B), the thickness of the dermal 
layer (indicated by arrows) is reduced compared to the untreated animals (Figure VII.25, 
Panel C).  The homozygous littermates of the Tsk animals, without the tight-skin 
mutation (Figure VII.25, Panel D), showed similar dermal thickness to the Tsk animals 
treated with nanoparticle formulation and intradermal injection, indicating that in 
addition to the collagen reduction, the clinical manifestation of the disease could also be 
reduced. McGaha et al. indicated that a two-fold decrease in the skin thickness after 
intraperitoneal injection of halofuginone for 60 days was associated with reduced 
collagen synthesis, evidenced in fibroblast cell culture exposed to halofuginone. 
Collagen α2I mRNA levels were significantly reduced 8 hours after treatment and 
completely inhibited after 12 h. Additionally, collagen levels were also reduced in 
fibroblast cultures derived from Tsk animals [330].  
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Figure VII.25.  Light microscopy images of the skin of the Tsk mice, treated 
topically with plasmid nanoparticle formulation (A), injected intradermally with 
DNA solution (B) and untreated (C), compared to homozygous littermates without 
the tight-skin mutation (D) and images of Tsk mice (E) and homozygous siblings 
(F).  
Paraffin-embedded sections (7 µm) were stained with hematoxylin-eosin. Arrows 
indicate the thickness of the dermis. Two sections of 1cm x 1cm biopsies were evaluated 
from each animal. The images are representative for each treatment (n=4 for Tsk 
animals and n=3 for the homozygous siblings). Bar represents 100 µm. 
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 VII.6.3. Conclusions 
Early clinical studies demonstrated that intramuscular injections of increasing 
doses of IFN-γ (10-100 µg) could improve the clinical signs of the scleroderma, such as 
skin score, range of motion, oral opening and dysphagia [331]. Similarly, 
subcutaneously injected IFN-γ (50 µg dose three times per week) caused significant 
improvement of skin score and lung function in scleroderma patients with pulmonary 
and skin involvement [332].  Later clinical trials using subcutaneously injected IFN-γ 
described modest results and common flu-like side effects [333, 334]. Here, we have 
demonstrated that in situ generated IFN-γ from injected plasmid DNA can significantly 
reduce collagen levels in a Tsk mouse model and cause decrease of the dermal thickness 
in the Tsk mice. 
Moreover, topical application of the plasmid DNA coding for the IFN-γ in 
cationic gemini nanoparticle formulations can induce similar changes in the collagen 
synthesis and skin thickness. The absence of IFN-γ in the serum might suggest minimal 
systemic exposure to the protein, hence side effects observed in the clinical trials can be 
avoided by the topical administration of plasmid DNA in nanoparticle delivery systems. 
The present data suggest that topical application of IFN-γ coding plasmid DNA using 
gemini cationic delivery vehicles significantly enhances cutaneous IFN-γ levels after 
application to intact skin and appears to be comparable or more efficient than other non-
viral delivery systems tested in vivo [211, 213, 214]. In addition, its effect on collagen 
synthesis and reduction of dermal thickness indicate the feasibility of this application in 
the treatment of cutaneous involvement of scleroderma.  
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 VIII. OVERALL CONCLUSIONS 
 In the present study, two dimensions of research into improved therapy of 
localized scleroderma were probed. The first was the design, construction and 
characterization of a cationic, non-viral gemini surfactant-based delivery system for an 
IFN-γ coding plasmid suitable for cutaneous gene therapy. The second was the 
evaluation of this novel therapeutic approach in a Tsk (tight-skin scleroderma) mouse 
model to determine its clinical feasibility.  
VIII.1 Plasmid vectors and in vitro delivery 
 The first key element in efficient transgene expression is the design of a plasmid 
carrier of the targeted gene, suitable for gene therapy. The ability of the plasmid to 
express the reporter gene at high levels in mammalian cells is the foremost requirement 
in gene delivery. An important feature of the plasmid should be transient gene 
expression, since continuous generation of a foreign protein after alleviation of clinical 
signs of the disease could cause imbalance in the body. Important features of the 
pGTmCMV carrier vector, specifically designed for gene therapy were: absence of CpG 
motifs, lack of ability to induce an immune response, presence of a murine CMV 
promoter, and the GFP gene for easy qualitative evaluation of protein expression (Figure 
VII.1). The therapeutic gene of IFN-γ was inserted into the multiple-cloning site with the 
GFP in a bicistronic format. It was demonstrated that these considerations were 
important, since the level of IFN-γ expression was 20 times higher using the 
pGTmCMV.IFN-GFP compared to the pIRES.IFN-GFP plasmid. Replacement of the 
human CMV promoter with murine CMV promoter increased gene expression; the IFN-
 γ levels in the supernatant of cells transfected with the pGTmCMV.IFN-GFP plasmid 
were 20% higher compared to the pGT.IFN-GFP (Figure VII.2).  
VIII.2 Cationic gemini surfactant based formulation development and in vitro 
assessment of the delivery efficiency  
 Physicochemical characterization of the gemini surfactant-based transfection 
agents revealed that these compounds in conjunction with DOPE can induce changes in 
the structure of the plasmid DNA and assume morphological conformations suitable to 
efficient gene delivery in PAM 212 kerationocytes. All gemini surfactants studied were 
found to bind the DNA and induce changes of the B-DNA into a highly compacted Ψ– 
DNA, and the degree of this change was dependent on the spacer length and nature of 
the tails. Addition of the helper lipid, DOPE to the PG complexes caused additional 
structural changes (Figure VII.8). 
 The ability of the gemini surfactants to bind the DNA by electrostatic interaction 
was demonstrated by dye exclusion measurements (Figure VII.9). Study of the lipid 
organization in the PG complexes and PGL systems indicated increasing structural 
complexity caused by the addition of the helper lipid. In the PGL systems, the presence 
of lamellar structure was detected by SAXS measurements, with additional, probably 
cubic phases, being present (Figure VII.10). Generally, the PG complexes exhibited low 
or no transfection in the PAM 212 keratinocytes. The presence of DOPE significantly 
increased transgene expression. The efficiency of the PGL systems was dependent on 
the spacer-length, showing a hyperbolic profile (Figure VII.15). Gene expression was 
the highest for the n=3 spacers, lowest for n=8, after which it gradually increased to 
n=16. The transfection efficiency correlated with changes induced in DNA structure, 
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 with a higher degree of compaction leading to higher transgene expression. 
Morphological requirements for successful transfection included the presence of 
polymorphic phases, present in the PGL systems, but absent in the PG complexes. 
Physicochemical properties of the gemini surfactants such as surface area of the head-
group and CMC also influenced cell transfection.  
 One of the limitations of the non-viral delivery systems is that it is still less 
efficient compared to viral vectors. In an attempt to increase transfection efficiency of 
the non-viral vectors at the cellular level, modifications in the map of the plasmid and 
improvements in the delivery system have been pursued by several research groups. 
Several approaches such as use of cationic lipids, neutral fusogenic lipids, pH sensitive 
polymers, targeting peptides, and nuclear localization signals have been tested. These 
agents have been used individually or in combination. Combination of various delivery 
agents increased transgene expression to levels high enough to trigger immune reactions, 
but to date the therapeutic success has been minimal, as demonstrated by the reduced 
number of current clinical trials involving gene delivery for therapeutic purposes. In 
order to achieve higher levels of gene expression, more complex systems need to be 
built by a stepwise combination of several components. In this project, a gemini 
surfactant-based delivery system was developed as shown in Figure VIII.1A. The DNA 
is complexed by a mixture of lipids; cationic lipids causing neutralization and 
compaction of DNA, which is necessary to penetrate into the cell and fusogenic lipids 
that perturb the cellular membrane, temporarily increasing its permeability. Further 
possibilities for improvement may include the addition of pH-sensitive polymers to 
facilitate endosomal escape of the DNA. The targeting peptides attached to the surface 
of particles to specifically anchor the DNA onto the surface of target cells, thus directing 
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 gene expression to the affected tissue. This multicomponent modular design might 
increase cellular delivery and gene expression at therapeutic levels (Figure VIII.1B and 
C). 
VIII.3 In vivo evaluation of gene delivery and potential for gene therapy 
 The delivery of plasmids through intact skin has been a challenging task. 
Typically, many of the studies have demonstrated delivery after the skin was damaged in 
some way with depilatory lotion, scraping, stripping or micromechanical disruption 
[166, 202-204]. Topical delivery of the DNA molecules through intact skin of mice was 
demonstrated using novel lipid-based delivery systems such as liposomes [107], biphasic 
vesicles [209], cationic nanoparticles [104], ethanol-in-fluorocarbon microemulsion 
[208] or water-in-oil nanoemulsion [211].  
 Using gemini cationic surfactant based topical delivery systems, we have 
demonstrated the feasibility of delivery of plasmid DNA into the skin through intact 
stratum corneum, gene expression and its biological effect. The choice of the topical 
delivery system was based on several criteria: (1) the ability of the cationic component 
to bind and compact DNA, (2) presence of structural polymorphism that contributes to 
efficient cellular transfection, and (3) ability of the delivery system to perturb the lipid 
organization of the stratum corneum and facilitate partitioning of the DNA into the 
viable layers of the epidermis. 
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igure VIII.1.  Future possibilities: schematic representation of the building of an 
improved delivery system.  
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   In normal CD1 mice, three topical applications of nanoparticle DNA formulation 
(3 x 25 µg total dose) generated 359.4 ± 238.9 pg IFN-γ/cm2, whereas the nanoemulsion 
formulation produced 607.24 ± 411.34 pg IFN-γ/cm2 (Figure VII.20). These levels are 
2.6-fold and 4.5-fold higher than for the naked DNA treatment. Interestingly, plasmid 
DNA was detected in the nanoparticle formulation-treated skin at 10-fold higher levels 
compared to the nanoemulsion. This difference might be due to differences in 
partitioning of the DNA into the skin from the two delivery systems. Furthermore, IFN-γ 
levels in the skin of CD1 animals treated with gemini nanoparticle formulation were 
approximately 3.5-fold higher than in the skin treated with the Dc-chol-based 
formulation. Topical treatment with both gemini nanoparticle and gemini nanoemulsion 
formulation generated higher levels of protein in the skin than a single intradermal 
injection of 15 µg DNA (359.4 ± 238.9 and 607.24 ± 411.34 vs. 255.68 ± 130.3 pg, 
respectively) (Figure VII.20). These levels of protein are 3.5-6 fold higher compared to 
results reported in the literature for huIFN α2 [211], and 3-5 times higher than levels 
reported for IL-12, calculated per cm2 [213]. From this level of expression, it can be 
assumed that there is a potential for using the topical non-invasive gemini surfactant 
based delivery systems to generate IFN-γ levels within the skin, sufficient to induce 
biological changes leading to blockage of excessive collagen synthesis.  In the lymph 
nodes, topical gemini nanoparticle formulations induced a 12-fold increase of protein 
compared to blank formulation and a 3.6-fold increase in animals treated by the gemini 
nanoemulsion (Figure VII.20). The present data suggest that topical application of IFN-γ 
coding plasmid DNA using gemini cationic delivery systems significantly enhances 
cutaneous IFN-γ levels after application to intact skin and appear to be several-fold more 
efficient than other delivery systems tested in vivo. The nanoemulsion formulation leads 
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 to higher levels of IFN-γ in the skin and lower levels in the lymph nodes compared to 
the nanoparticle formulation, suggesting that the two delivery systems may have 
different penetration pathways (Figure VII.20). Additionally, the presence of plasmid 
DNA in the skin of animals treated topically with nanoparticle and nanoemulsion 
formulations has been detected (Table VII.8).  
 Studies of the delivery of genetic material into the skin performed by Khavari et 
al. [9] demonstrated that immune response could be elicited by applying naked DNA on 
the skin. However, the same group recognized that for treatment of skin diseases higher 
transfection efficiency would be necessary [200]. Although some success was 
demonstrated after delivery of plasmid DNA into the skin by semi-invasive methods 
such as gene gun, electroporation or microneedles [204, 207, 219, 335-337], ultimately 
improved non-invasive, topically applied non-viral delivery systems could be the most 
appropriate therapeutic products.  
 Here, we have demonstrated significant improvements in topical delivery of 
plasmid DNA using gemini cationic nanoparticle formulations. Significant increases in 
pGTmCMV.IFN-GFP plasmid delivery and IFN-γ expression in the skin and lymph 
nodes compared to naked DNA and Dc-chol based complex are evident. These systems 
show potential for use in the treatment of localized scleroderma.  
 Evaluation of the gene delivery into the skin of IFN-γ-deficient animals treated 
with nanoparticle formulation showed a significantly higher level of gene expression 
compared to naked DNA (Figure VII.22). The protein levels were about 20% lower 
compared to the CD1 mice, indicating higher endogenous IFN-γ levels in CD1 mice, 
caused by the manipulation of the animals preceding and during the treatment (clipping, 
shaving and cleaning of the skin).   
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  The therapeutic effect of the transgene IFN-γ was evaluated in vivo in Tsk mice, 
an animal model for scleroderma. It was shown that skin collagen levels were slightly 
decreased after a 3-day treatment in both intradermally injected and topically treated 
animals, and showed significant decrease after a 20-day treatment regimen, compared to 
the untreated animals (Table VII.9). Skin thickness was also visibly reduced by day 20 
of the treatment (Figure VII.25). The 4-day treatment had no effect on the ICAM-1 
expression on the surface of keratinocytes in the skin, but was upregulated 50% after the 
20-day treatment. This indicated that skin lesions in scleroderma patients would require 
a 20-day or longer treatment regimen, which would not be unreasonable. Current 
treatment options also involve drug administration for several weeks to months. A case 
study of topical treatment of localized scleroderma with imiquimod (a cytokine inducer 
compound) cream showed that skin lesions were significantly improved at the 6-week 
follow-up visit, and some cleared completely by 8 months [262]. To date, no topical 
IFN-γ gene applications have been described in the literature. Injectable treatment varied 
from intramuscular injections for 18 weeks [270, 333] or subcutaneous injections for 1 
year [334]. The modest improvements observed in these treatments could be due to the 
short half-life of the IFN-γ and the relatively low local concentrations in the skin lesions 
that are achieved by the subcutaneous and intramuscular injections. At the same time, 
the presence of side effects could be attributed to the systemic exposure to the drug.  
 By using a genetic approach, namely generating IFN-γ in situ by the cells in the 
epidermis (mostly keratinocytes), the half-life of the protein can be extended. The 
topical transfection could create high local concentrations of therapeutic protein with 
minimal systemic exposure. The length of the treatment could be evaluated based on the 
clinical improvement, since overexposure to IFN-γ in the skin could cause undesired 
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 reactions in the skin. Such symptoms could include redness, flaky skin, hair loss and 
depigmentation, and growth retardation described in transgenic (but otherwise normal) 
mice overexpressing IFN-γ by keratinocytes in the skin [338].  
 Here, it has been demonstrated that cationic gemini surfactant-based delivery 
systems are able to transfect epidermal cells in vivo, and the transgene IFN-γ expression 
is sufficient to cause significant reduction of collagen in the animal model of 
scleroderma. It has been shown for the first time that topical IFN-γ gene therapy could 
be a feasible approach for the modulation of excessive collagen synthesis in 
scleroderma-affected skin.  
 The debate whether viral or non-viral approaches are the future of gene delivery 
still continues to be vigorous. After an initial success, the use of viral vectors for genetic 
diseases (ornitine transcarbamylase deficiency and X-linked severe combined 
immunodeficiency), has declined due to the severe toxicity caused by the viral carriers. 
Yet, the role of the viral vectors in cancer treatment (67% worldwide) and vaccine 
delivery (6.7%) is significant, as demonstrated by the fact that the majority of clinical 
trials worldwide [http://www.wiley.co.uk/genmed/clinical/ ] implicate viral vectors 
(over 70%).  Due to the high toxicity of viral vectors, their role in genetic reconstitution 
is limited. In my opinion, non-viral gene delivery will gain more and more importance in 
this area, focusing on monogenetic, cutaneous and cardiovascular diseases.  By 
combination of appropriate carrier vectors and delivery systems, high levels of transgene 
expression could be achieved.  
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 VIII.4 Future research directions 
 The next steps for the development of the gemini-based gene delivery system 
could be in the following areas: 
VIII.4.1 Testing in human skin   
 Experiments should include testing in human skin, which could be done in vitro 
using a viable skin model. Such system was developed in our laboratory by a previous 
graduate student (P. Asavapichayont). Alternatively, a miniature swine (Hanford 
minipig) could be used, which is a particularly suitable model for human skin. These 
experiments will contribute to the characterization of delivery and expression of the 
IFN-γ gene in human or a close model skin.   
VIII.4.2 Optimization of the plasmid vector and formulation 
 Further optimization of the plasmid could improve transgene expression. It has 
been shown that murine skin transfected via gene gun with plasmid DNA containing the 
CMV promoter induced gene expression in the epidermis and dermis, while keratin14 
promoter allowed protein expression only in the epidermis [339]. By using keratin14 
promoter, gene expression could be targeted to the epidermis and exposure to the 
transgene limited to the skin. Insertion of an episomal replication sequence, such as a 
scaffold/matrix attachment region (S/MAR) in the plasmid can allow extrachromosomal 
replication of the plasmid and perpetuate gene expression in the cell proliferation 
process [340]. It has been shown that this system facilitated episomal plasmid replication 
in a once-per-cell cycle manner, preserving the gene expression without overpowering 
the cells. It is especially important to perpetuate the plasmid in epidermal transfection by 
cellular division, since skin renewal can lead to loss of plasmid in the tissue. 
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  The formulation improvement could include evaluation of cationic gemini 
surfactants with substituted head groups that increase the in vitro and in vivo transfection 
efficiency. Parameters such as DNA compaction, interaction with biological membranes, 
and release of the genetic material in the cell could be addressed. New helper lipids 
could be added to the formulations, and their ability to induce polymorphic phase 
behaviour could be evaluated. The multicomponent modular approach including 
permeation enhancers, targeting moieties and polymers could also be evaluated. 
Addition of pH-sensitive polymers to facilitate endosomal escape of the DNA, targeting 
peptides attached to the surface of particles to specifically anchor the DNA onto the 
surface of target cells, and nuclear targeting moieties to increase nuclar uptake could be 
explored.  
VIII.4.3 Study of the mechanism 
 The understanding of the mechanism of topical delivery and interaction of the 
topical formulations with stratum corneum lipids, uptake of the DNA by various cells in 
the skin (keratinocytes, dendritic cells and fibroblasts), and trafficking of the generated 
IFN-γ will be important. 
VIII.4.4 Toxicology studies 
 Animal experiments should focus on the optimization of the treatment regimen: 
the dose, dosage frequency and length of the treatment. Kinetic studies are necessary to 
establish the pharmacological profile of the DNA drug. Prior to any clinical trials, 
evaluation of safety and efficacy must be performed. 
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